
<html lang="en"     class="pb-page"  data-request-id="62cadc8b-5621-4395-a3e8-96c4bf4a3147"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.9b00687;issue:issue:10.1021/jmcmar.2019.62.issue-17;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase" /></meta><meta name="dc.Creator" content="Yunhang  Guo" /></meta><meta name="dc.Creator" content="Ye  Liu" /></meta><meta name="dc.Creator" content="Nan  Hu" /></meta><meta name="dc.Creator" content="Desheng  Yu" /></meta><meta name="dc.Creator" content="Changyou  Zhou" /></meta><meta name="dc.Creator" content="Gongyin  Shi" /></meta><meta name="dc.Creator" content="Bo  Zhang" /></meta><meta name="dc.Creator" content="Min  Wei" /></meta><meta name="dc.Creator" content="Junhua  Liu" /></meta><meta name="dc.Creator" content="Lusong  Luo" /></meta><meta name="dc.Creator" content="Zhiyu  Tang" /></meta><meta name="dc.Creator" content="Huipeng  Song" /></meta><meta name="dc.Creator" content="Yin  Guo" /></meta><meta name="dc.Creator" content="Xuesong  Liu" /></meta><meta name="dc.Creator" content="Dan  Su" /></meta><meta name="dc.Creator" content="Shuo  Zhang" /></meta><meta name="dc.Creator" content="Xiaomin  Song" /></meta><meta name="dc.Creator" content="Xing  Zhou" /></meta><meta name="dc.Creator" content="Yuan  Hong" /></meta><meta name="dc.Creator" content="Shuaishuai  Chen" /></meta><meta name="dc.Creator" content="Zhenzhen  Cheng" /></meta><meta name="dc.Creator" content="Steve  Young" /></meta><meta name="dc.Creator" content="Qiang  Wei" /></meta><meta name="dc.Creator" content="Haisheng  Wang" /></meta><meta name="dc.Creator" content="Qiuwen  Wang" /></meta><meta name="dc.Creator" content="Lei  Lv" /></meta><meta name="dc.Creator" content="Fan  Wang" /></meta><meta name="dc.Creator" content="Haipeng  Xu" /></meta><meta name="dc.Creator" content="Hanzi  Sun" /></meta><meta name="dc.Creator" content="Haimei  Xing" /></meta><meta name="dc.Creator" content="Na  Li" /></meta><meta name="dc.Creator" content="Wei  Zhang" /></meta><meta name="dc.Creator" content="Zhongbo  Wang" /></meta><meta name="dc.Creator" content="Guodong  Liu" /></meta><meta name="dc.Creator" content="Zhijian  Sun" /></meta><meta name="dc.Creator" content="Dongping  Zhou" /></meta><meta name="dc.Creator" content="Wei  Li" /></meta><meta name="dc.Creator" content="Libin  Liu" /></meta><meta name="dc.Creator" content="Lai  Wang" /></meta><meta name="dc.Creator" content="Zhiwei  Wang" /></meta><meta name="dc.Description" content="Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological mali..." /></meta><meta name="Description" content="Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological mali..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 5, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00687" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00687" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00687" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00687" /></link>
        
    
    

<title>Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00687" /></meta><meta property="og:title" content="Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0019.jpeg" /></meta><meta property="og:description" content="Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00687"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00687">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00687&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00687&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00687&amp;href=/doi/10.1021/acs.jmedchem.9b00687" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7923-7940</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00686" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00698" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yunhang Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunhang Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunhang++Guo">Yunhang Guo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3980-0673" title="Orcid link">http://orcid.org/0000-0003-3980-0673</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ye Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ye Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ye++Liu">Ye Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nan Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nan Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nan++Hu">Nan Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Desheng Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Desheng Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Desheng++Yu">Desheng Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Changyou Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Changyou Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Changyou++Zhou">Changyou Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gongyin Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gongyin Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gongyin++Shi">Gongyin Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bo Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Zhang">Bo Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Wei">Min Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Junhua Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junhua Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junhua++Liu">Junhua Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lusong Luo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lusong Luo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lusong++Luo">Lusong Luo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiyu Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyu Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyu++Tang">Zhiyu Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huipeng Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huipeng Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huipeng++Song">Huipeng Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yin Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yin Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yin++Guo">Yin Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuesong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuesong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuesong++Liu">Xuesong Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dan Su</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dan Su</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of DMPK, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Su">Dan Su</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuo Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuo Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuo++Zhang">Shuo Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaomin Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaomin Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaomin++Song">Xiaomin Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xing Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xing Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xing++Zhou">Xing Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuan Hong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuan Hong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Hong">Yuan Hong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuaishuai Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuaishuai Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuaishuai++Chen">Shuaishuai Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenzhen Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenzhen Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenzhen++Cheng">Zhenzhen Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steve Young</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steve Young</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steve++Young">Steve Young</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiang Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiang Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiang++Wei">Qiang Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haisheng Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haisheng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haisheng++Wang">Haisheng Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiuwen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiuwen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiuwen++Wang">Qiuwen Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Lv</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Lv</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Lv">Lei Lv</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fan Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of DMPK, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fan++Wang">Fan Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haipeng Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haipeng Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haipeng++Xu">Haipeng Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hanzi Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hanzi Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hanzi++Sun">Hanzi Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haimei Xing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haimei Xing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haimei++Xing">Haimei Xing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Na Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Na Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Na++Li">Na Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zhang">Wei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhongbo Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhongbo Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhongbo++Wang">Zhongbo Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guodong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guodong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guodong++Liu">Guodong Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhijian Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhijian Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhijian++Sun">Zhijian Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongping Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongping Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Biology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongping++Zhou">Dongping Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Li">Wei Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Libin Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Libin Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Libin++Liu">Libin Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lai Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lai Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of In Vivo Pharmacology, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lai++Wang">Lai Wang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zhiwei Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiwei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, BeiGene (Beijing) Co., Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping District, Beijing 102206, P.R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 86-10-58958102. Fax: 86-10-58958088. E-mail: <a href="/cdn-cgi/l/email-protection#90eaf8f9e7f5f9bee7f1fef7d0f2f5f9f7f5fef5bef3fffd"><span class="__cf_email__" data-cfemail="1e647677697b7730697f70795e7c7b77797b707b307d7173">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiwei++Wang">Zhiwei Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8792-9573" title="Orcid link">http://orcid.org/0000-0001-8792-9573</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00687&amp;href=/doi/10.1021%2Facs.jmedchem.9b00687" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7923–7940</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 5, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 April 2019</li><li><span class="item_label"><b>Published</b> online</span>5 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 September 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00687" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00687</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7923%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYunhang%2BGuo%252C%2BYe%2BLiu%252C%2BNan%2BHu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D17%26contentID%3Dacs.jmedchem.9b00687%26title%3DDiscovery%2Bof%2BZanubrutinib%2B%2528BGB-3111%2529%252C%2Ba%2BNovel%252C%2BPotent%252C%2Band%2BSelective%2BCovalent%2BInhibitor%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7940%26publicationDate%3DSeptember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00687"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6317</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">61</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00687" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yunhang&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Ye&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Nan&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Desheng&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Changyou&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Gongyin&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Junhua&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Lusong&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Zhiyu&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Huipeng&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Yin&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Xuesong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Shuo&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Xiaomin&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Xing&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Shuaishuai&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Zhenzhen&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Steve&quot;,&quot;last_name&quot;:&quot;Young&quot;},{&quot;first_name&quot;:&quot;Qiang&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Haisheng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Qiuwen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Lv&quot;},{&quot;first_name&quot;:&quot;Fan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Haipeng&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Hanzi&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Haimei&quot;,&quot;last_name&quot;:&quot;Xing&quot;},{&quot;first_name&quot;:&quot;Na&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhongbo&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Guodong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Zhijian&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Dongping&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Libin&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Lai&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhiwei&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7923-7940&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00687&quot;},&quot;abstract&quot;:&quot;Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00687&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00687" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00687&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00687" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00687&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00687" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00687&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00687&amp;href=/doi/10.1021/acs.jmedchem.9b00687" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00687" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00687" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00687%26sid%3Dliteratum%253Aachs%26pmid%3D31381333%26genre%3Darticle%26aulast%3DGuo%26date%3D2019%26atitle%3DDiscovery%2Bof%2BZanubrutinib%2B%2528BGB-3111%2529%252C%2Ba%2BNovel%252C%2BPotent%252C%2Band%2BSelective%2BCovalent%2BInhibitor%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D17%26spage%3D7923%26epage%3D7940%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/jmcmar.2019.62.issue-17/20190912/jmcmar.2019.62.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Aberrant activation of Bruton’s tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound <b>BGB-3111</b> (<b>31a</b>, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) belongs to the TEC family of cytoplasmic tyrosine kinases, which is the second largest family of nonreceptor kinases in humans.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is expressed in all cell lineages of the hematopoietic system, except for T cells, that are localized in bone marrow, spleen, and lymph node tissue.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Inactivating mutations in the gene encoding BTK cause X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (XID) in mice.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> These diseases are characterized by dramatic defects in B cell development and function, suggesting the essential role of BTK for B cell development and function. In addition, constitutive activation of BTK in B cells results in the accumulation of autoreactive plasma cells.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> BTK is activated by upstream Src-family kinases in the BCR signaling pathway. Once activated, BTK in turn phosphorylates phospholipase-Cγ (PLCγ), leading to Ca<sup>2+</sup> mobilization and activation of NF-κB and MAP kinase pathways. These proximal signaling events promote expression of genes involved in proliferation and survival.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition to its essential regulatory role as downstream of BCR, BTK activity also plays a critical role in Fc receptors (FcR) signaling. Signaling via FcγR associated receptors also promotes BTK-dependent proinflammatory cytokine production by cells such as macrophages.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> BTK has been an important target due to its proximal location in the BCR and FcR signaling pathways. Aberrant activation of BTK plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">The first clinically effective covalent BTK inhibitor, Ibrutinib<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> (<b>1a</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was approved by the U.S. FDA for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM,) and chronic graft versus host disease (cGVHD). From the time we initiated our work, and recently, several other covalent inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), including Acalabrutinib (<b>1b</b>, ACP-196),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Tirabrutinib (<b>1c</b>, ONO/GS-4059),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Spebrutinib (<b>2</b>, CC-292, AVL-292),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and Branebrutinib (<b>3</b>, BMS-986195)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> have been developed and are in clinical trials. Acalabrutinib was approved by the U.S. FDA for the treatment of MCL in 2017. Even though Ibrutinib has excellent efficacy and general tolerability, adverse events like bleeding, rash, and diarrhea have been reported.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> These Ibrutinib related adverse effects are thought to be partly associated with the inhibition of off-target kinases such as wild-type (wt) EGFR, TEC, JAK3, and Src family member (such as Src, Lyn, Fyn, and Lck) etc. Targeting wt EGFR is well-known to induce dramatic cutaneous toxicity and gastrointestinal adverse effects because the EGFR-signaling cascade is involved in biology of the skin and gastrointestinal system.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Both BTK and TEC belong to the TEC family kinases. Platelets express BTK and TEC, which serve as downstream of glycoprotein VI (GPVI) signaling. TEC compensates for the absence of BTK in signaling downstream of GPVI in murine platelets.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Inhibition of TEC kinase by Ibrutinib interferes with platelet aggregation and may contribute to the observed bleeding,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> while a recent report suggested BTK inhibition is the primary driver for inhibition of platelet aggregation after comparison of different BTK inhibitors’ activities in collagen-induced platelet activation.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Src family kinases such as Src, Lyn, Fyn, and Lck were also reported to cause hemostatic dysfunction associated with increased bleeding risk.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Although it has not been established if the clinical antitumor efficacy of Ibrutinib was associated with the off-target effect or not, the discovery of more selective on-target inhibitors was desirable.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known irreversible BTK inhibitors in the clinic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For traditional reversible inhibitors, a drug candidate target profile in terms of pharmacokinetics would have high oral bioavailability, low clearance, and reasonable half-life, while a covalent inhibitor can persist in vivo PD even after it has disappeared.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> For example, CC-292 has target inhibition on BTK protein for >12 h after it is cleared.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> For Ibrutinib, a high dose (560 mg daily) is required to achieve effective BTK target occupancy, likely due to its low oral bioavailability in human (3.9% in the fasting state to 8.4% under fed condition).<a onclick="showRef(event, 'cit22a cit22b'); return false;" href="javascript:void(0);" class="ref cit22a cit22b">(22a,b)</a> Thus, a balance between fast absorption/high exposure and fast elimination could bring rapid target inhibition and reduce the potential risk of off-target issues or drug–drug interactions, respectively, which could ultimately realize once or twice a day dosage is sufficient to maintain the desired effect, considering the turnover rate of BTK is around 24–48 h.<a onclick="showRef(event, 'ref11 cit22c'); return false;" href="javascript:void(0);" class="ref ref11 cit22c">(11,22c)</a></div><div class="NLM_p last">Herein, we describe our work that led to the identification of a novel, potent and more selective BTK inhibitor <b>BGB-3111</b> (<b>31a</b>, Zanubrutinib), having improved oral absorption and better target occupancy, which was given breakthrough therapy designation in MCL and fast track designation in WM by the US FDA.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Establishing Early Leads</h3><div class="NLM_p">Well known fragments pyrrolopyrimidine, pyrazolopyrimidine, and purine (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) are commonly used in kinase inhibitor design.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> Mimicking the pyrimidinone ring through intramolecular hydrogen bond was also an attractive strategy which is often used in the drug design.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> As outlined in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, first, a pseudo pyrimidinone series I were synthesized<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and these compounds showed good BTK potency (for example, <b>I</b>-<b>2</b>: 0.17 and 1.0 nM vs enzyme and BTK pY223, respectively; see <a class="ref internalNav" href="#notes-1" aria-label="p S3 in Supporting Information">p S3 in Supporting Information</a>). To illuminate the binding mode of early lead series I, the binding mode of <b>I</b>-<b>2</b> without warhead was established and aligned to that of <b>B43</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> see <a class="ref internalNav" href="#notes-1" aria-label="p S3 in Supporting Information">p S3 in Supporting Information</a>). Compound <b>I</b>-<b>2</b> without warhead in series I showed deserved binding mode and one additional hydrogen bond formed with hinge residue Met477 compared to that of <b>B43</b>. Alignment between these two binding poses showed good 3D shape match and similar interaction mode with surrounding residues. A novel series II through the ring-merging approach were reported herein and found to have unexpectedly high BTK potency and high selectivity against other kinases.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of new series of compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> In Vitro and in Vivo SAR</h3><div class="NLM_p">Generally, two series (tricyclic compounds and bicyclic compounds) of fused-ring compounds were synthesized and the inhibitory activities were evaluated using a well-established TR-FRET biochemical assay at <i>K</i><sub>m</sub> ATP and a HTRF-based BTK pY223 cellular assay in Ramos cells. Initially, we synthesized tricyclic <b>5</b>, which is a reversible inhibitor with an IC<sub>50</sub> of 17 nM for BTK (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). We then introduced an acrylamino group as the warhead (<b>6</b>) which dramatically lowered the IC<sub>50</sub> to 0.32 nM. This result indicated there may be an irreversible covalent bond with the BTK Cys481 residue. Although <b>6</b> demonstrated promising cellular activity (2.8 nM in our BTK-pY223 cellular assay), poor physicochemical properties, and concomitant low oral bioavailability were observed in rats (data not shown). By moving the acrylamide group to the adjacent position, low biochemical activity was observed (<b>7</b>, 14 nM). Considering the high rigidity of tricyclic aromatic core, one of the aromatic rings was replaced with an aliphatic ring to give <b>8</b>, <b>9</b>, <b>10</b>, <b>11</b>, and <b>12</b>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <b>8</b>, <b>9</b>, <b>10</b>, <b>11</b>, and <b>12</b> all showed similar enzyme potency to <b>6</b> and all potently inhibited BTK Tyr223 phosphorylation in vitro. Unfortunately, all compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> showed no selectivity against EGFR except <b>6</b> with approximately 7-fold selectivity. Possibly due to the rigidity of the tricyclic core, the pharmacokinetics (PK) properties of <b>8</b>, <b>9</b>, and <b>11</b> in rat were consistently poor, which led to poor pharmacodynamic (PD) effects of <b>8</b> and <b>11</b> in mouse (22% and 40% occupancy in splenocytes at 4 h after a single dose of 10 mg/kg for <b>8</b> and <b>11</b>, respectively; see <a class="ref internalNav" href="#notes-1" aria-label="p S5 in Supporting Information">p S5 in Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and Selected Properties of <b>5</b>–<b>12</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0012.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><b>5</b></th><th class="colsep0 rowsep0" align="center" char="."><b>6</b></th><th class="colsep0 rowsep0" align="center"><b>7</b></th><th class="colsep0 rowsep0" align="center" char="."><b>8</b></th><th class="colsep0 rowsep0" align="center" char="."><b>9</b></th><th class="colsep0 rowsep0" align="center" char="."><b>10</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11</b></th><th class="colsep0 rowsep0" align="center" char="."><b>12</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char="."><0.25</td><td class="colsep0 rowsep0" align="char" char="."><0.25</td><td class="colsep0 rowsep0" align="char" char="."><0.25</td><td class="colsep0 rowsep0" align="char" char="."><0.25</td><td class="colsep0 rowsep0" align="char" char="."><0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK pY223 IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="char" char=".">322.2</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="char" char="."><0.5</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">number of determinations = 1.</p></div></div></div><div class="NLM_p">As we reasoned the rigid conformation of the tricycle core led to the poor pharmacokinetics (PK) property, a new series of compounds bearing a bicyclic aromatic core was synthesized. Initially, compounds with an imidazopyrazole core were prepared giving <b>13</b>–<b>16</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compared to <b>14</b> (150 nM) and <b>15</b> (34 nM), <b>13</b> and <b>16</b> showed exceptionally improved IC<sub>50</sub> values at 2.7 and 0.13 nM in the biochemical assay, respectively. This improved potency suggested that the warhead acryl groups in these compounds were well positioned to react with BTK Cys481 residue (covalent bond formation with Cys481 was further confirmed using serine mutant assay and fast dilution experiment, see <a class="ref internalNav" href="#notes-1" aria-label="p S6 in Supporting Information">p S6 in Supporting Information</a>). Although <b>13</b> surprisingly demonstrated good EGFR selectivity (77-fold), it was not as potent as <b>16</b> in both biochemical and cellular assays. Unfortunately, <b>16</b> showed low pharmacodynamic (PD) activity in mouse (56% occupancy in splenocytes at 4 h after a single dose of 10 mg/kg, see <a class="ref internalNav" href="#notes-1" aria-label="p S5 in Supporting Information">p S5 in Supporting Information</a>) due to its poor pharmacokinetics (PK) property.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and Selected Properties of <b>13</b>–<b>16</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0013.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">BTK (IC<sub>50</sub>, nM)</th><th class="colsep0 rowsep0" align="center">EGFR (IC<sub>50</sub>, nM)</th><th class="colsep0 rowsep0" align="center">BTK pY223 (IC<sub>50</sub>, nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">2.7</td><td class="colsep0 rowsep0" align="center">208</td><td class="colsep0 rowsep0" align="center">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">150</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">0.13</td><td class="colsep0 rowsep0" align="center"><0.25</td><td class="colsep0 rowsep0" align="center">0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">number of determinations = 1.</p></div></div></div><div class="NLM_p">In light of the poor PK profile of <b>16</b>, a compound with pyrazolopyrimidine core (<b>17</b>) was investigated and it showed an IC<sub>50</sub> value at 860 nM (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). To further break the aromatic character and coplanarity of the bicyclic core, the pyrimidine ring of <b>17</b> was reduced to give <b>18</b> (IC<sub>50</sub> 2.6 nM), resulting in more than 300-fold improvement in biochemical activity. After chiral separation, <b>18a</b> (2.2 and 2.0 nM vs enzyme and BTK pY223, respectively) was slightly more potent than its opposite enantiomer <b>18b</b> (2.7 and 8.7 nM vs enzyme and BTK pY223, respectively) in cellular assay, and both compounds retained the selectivity over wt EGFR (>60-fold) in the biochemical assay. Shifting the Michael acceptor to the para position (<b>19</b>) resulted in a reduction in potency, whereas placing the Michael acceptor in the ortho position (<b>20</b>) led to an approximately 4-fold potency increase compared to <b>18</b>. Surprisingly, <b>20a</b> (0.38 nM) was >300-fold more potent than its opposite enantiomer <b>20b</b> (130 nM) in the biochemical assay and showed the best cellular potency (3.0 nM) in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The wt EGFR selectivity of <b>20a</b> was dramatically reduced compared to compounds with substituents at the meta position (<b>18a</b> and <b>18b</b>) and para position (<b>19</b>). The steric environment and warhead position were also essential for the binding and the formation of covalent bond with BTK respectively, starting from <b>20</b>, introduction of a methyl group into <b>21</b> reduced overall potency (<i>Note</i>: To exclude the possibility that the aforementioned compounds without warheads are potent on their own, IC<sub>50</sub> values of <b>20</b> and <b>21</b> without warheads were evaluated on biochemical assay as 200 and 1000 nM, respectively, see <a class="ref internalNav" href="#notes-1" aria-label="p S9 in Supporting Information">p S9 in Supporting Information</a>). Although <b>18a</b>, <b>18b</b>, and <b>20a</b> demonstrated promising cellular activity, they all showed poor oral absorption (data not shown for <b>18a</b>, <b>18b</b>, and AUC 21.3 h·ng/mL for <b>20a</b> in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, respectively), and low oral bioavailability (data not shown for <b>18a</b>, <b>18b</b>, and 1.7% for <b>20a</b> in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, respectively) in rat. This series of compounds were not pursued further.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures and Selected Properties of <b>17</b>–<b>21</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0014.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>17</b></th><th class="colsep0 rowsep0" align="center"><b>18</b></th><th class="colsep0 rowsep0" align="center"><b>18a</b> (<i>S</i> or <i>R</i>)</th><th class="colsep0 rowsep0" align="center"><b>18b</b> (<i>R</i> or <i>S</i>)</th><th class="colsep0 rowsep0" align="center"><b>19</b></th><th class="colsep0 rowsep0" align="center"><b>20</b></th><th class="colsep0 rowsep0" align="center"><b>20a</b> (<i>S</i> or <i>R</i>)</th><th class="colsep0 rowsep0" align="center"><b>20b</b> (<i>R</i> or <i>S</i>)</th><th class="colsep0 rowsep0" align="center"><b>21</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="center">860</td><td class="colsep0 rowsep0" align="center">2.6</td><td class="colsep0 rowsep0" align="center">2.2</td><td class="colsep0 rowsep0" align="center">2.7</td><td class="colsep0 rowsep0" align="center">9.5</td><td class="colsep0 rowsep0" align="center">0.62</td><td class="colsep0 rowsep0" align="center">0.38</td><td class="colsep0 rowsep0" align="center">130</td><td class="colsep0 rowsep0" align="center">4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">141</td><td class="colsep0 rowsep0" align="center">334</td><td class="colsep0 rowsep0" align="center">169</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><0.25</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK pY223 IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">8.7</td><td class="colsep0 rowsep0" align="center">43.4</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.0</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">232.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Number of determinations = 1.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vivo Pharmacokinetics (PK) Parameters of Selected Compounds in Rat</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">iv (1 mg·kg<sup>–1</sup>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po (5 mg·kg<sup>–1</sup>)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (h·ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b> (<i>S</i> or <i>R</i>)</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="char" char=".">65.3</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">29.5</td><td class="colsep0 rowsep0" align="char" char=".">21.3</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b> (<i>S</i> or <i>R</i>)</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">1.01</td><td class="colsep0 rowsep0" align="char" char=".">82.3</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">202</td><td class="colsep0 rowsep0" align="char" char=".">344</td><td class="colsep0 rowsep0" align="char" char=".">34.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b> (<i>S</i> or <i>R</i>)</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.83</td><td class="colsep0 rowsep0" align="char" char=".">77.7</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">217</td><td class="colsep0 rowsep0" align="char" char=".">268</td><td class="colsep0 rowsep0" align="char" char=".">24.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29a</b> (<i>S</i> or <i>R</i>)</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">1.41</td><td class="colsep0 rowsep0" align="char" char=".">80.6</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">242</td><td class="colsep0 rowsep0" align="char" char=".">326</td><td class="colsep0 rowsep0" align="char" char=".">30.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Dosed using 1 mg/kg solution.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Dosed using 5 mg/kg of methylcellulose suspension.</p></div></div></div><div class="NLM_p">Upon the basis of the above findings, we retained the warhead group at the ortho-position and a series of substituents were introduced to replace the top phenoxyl group to improve oral bioavailability. Absorption is a critical factor impacting compounds’ oral bioavailability.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Reducing a molecule’s overall lipophilicity is a useful approach for improving oral absorption. One widely employed approach is replacing bulky lipophilic substituents (i.e., phenyl or benzyl) with smaller groups (ethyl, propyl, cyclopropyl, or halogens) known to lower lipophilicity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, replacing the top phenoxyl functionality was generally tolerated, including not only large (<b>22</b>–<b>23</b>) but small moieties (<b>24</b>–<b>30</b>) as well. All of these compounds showed activities within a range of subnanomolar to single nanomolar potency. Replacement of the phenoxyl of <b>20a</b> with a less lipophilic cyclopropylmethoxyl (<b>23a</b>, 1.2 and 2.5 nM vs enzyme and BTK pY223, respectively), methoxyl (<b>25a</b>, 1.0 and 2.5 nM vs enzyme and BTK pY223, respectively), or chloride (<b>29a</b>, 0.64 and 4.2 nM vs enzyme and BTK pY223, respectively) has no impact on the pharmacological activity. In vitro data showed that <b>23a</b>, <b>25a</b>, and <b>29a</b> had better solubility and liver microsomes stability compared with <b>20a</b> (kinetic solubility (μM at pH = 7.4): <b>20a</b>/<b>23a</b>/<b>25a</b>/<b>29a</b> = 33.6/74.7/97.5/83.7; for liver microsomes stability data, see <a class="ref internalNav" href="#notes-1" aria-label="p S10 in Supporting Information">p S10 in Supporting Information</a>). Three aforementioned compounds had dramatically improved oral exposure and bioavailability in rat (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compared to <b>20a</b>, <b>23a</b>, <b>25a</b>, and <b>29a</b> have higher plasma clearance but improved oral bioavailability, likely due to an improved solubility profile that leads to better absorption. In the meanwhile, <b>23a</b>, <b>25a</b>, and <b>29a</b> also showed good PD due to high cellular potency and good PK properties or high free drug fraction (81%, 77%, 82% occupancy in splenocytes at 4 h after a single dose of 10 mg/kg for <b>23a</b>, <b>25a</b>, and <b>29a</b>, respectively, see <a class="ref internalNav" href="#notes-1" aria-label="p S5 in Supporting Information">p S5 in Supporting Information</a>; 3.95, 28.3, and 16.5 of free fraction percentages (%) in mouse for <b>23a</b>, <b>25a</b>, and <b>29a</b>, respectively, see <a class="ref internalNav" href="#notes-1" aria-label="p S10 in Supporting Information">p S10 in Supporting Information</a>). Unfortunately, all compounds in this series also showed strong wt EGFR inhibitory activities. This poor selectivity for EGFR could result in dose limiting toxicities such as skin rash and diarrhea, and these compounds were not pursued further.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Structures and Selected Properties of <b>22</b>–<b>30</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0016.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">number of determinations = 1.</p></div></div><div></div></div><div class="NLM_p">To increase selectivity over wt EGFR and improve the oral absorption, a strategy of replacing the aromatic rings with aliphatic moieties of varying size, geometry, and substitution pattern was pursued, and a new series of compounds derived from <b>20</b> were synthesized. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, aliphatic amine linkers were used, and among them, racemic <b>31</b> (IC<sub>50</sub> of 0.63 nM), <b>32</b> (IC<sub>50</sub> of 0.53 nM), and <b>33</b> (IC<sub>50</sub> of 0.90 nM) had similar biochemical activity to <b>20</b> (IC<sub>50</sub> of 0.62 nM). However, <b>34</b> and <b>35</b> had IC<sub>50</sub> values of 3.5 and 41 nM, respectively, nearly 6-fold and 70-fold less potent, indicating the cyclopropyl and <i>gem</i>-methyl group were too bulky for this position. Encouraged by the observation that racemic <b>31</b>, <b>32</b>, and <b>33</b> had good inhibitory activity, the enantiomeric pairs were also prepared. Among these targets, <b>31a/31b</b>, <b>32a</b>/<b>32b</b>, and <b>33a</b>/<b>33b</b> did show preference for one enantiomer (<b>31a</b>, IC<sub>50</sub> of 0.30 nM; <b>32a</b>, IC<sub>50</sub> of 0.58 nM; <b>33a</b>, IC<sub>50</sub> of 0.24 nM). <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> values were determined for <b>31a</b>, <b>31b</b>, and Ibrutinib (see <a class="ref internalNav" href="#notes-1" aria-label="p S11 in Supporting Information">p S11 in Supporting Information</a>). The ranking of <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> values of three compounds is consistent with IC<sub>50</sub> values (<b>31a</b> ≈ Ibrutinib > <b>31b</b>, see <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Tables <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">9</a>). We further evaluated <b>31a</b>, <b>32a</b>, and <b>33a</b> in our BTK pY223 cellular assay and Rec-1 cell viability assays. Compounds <b>31a</b>, <b>32a</b>, and <b>33a</b> with high biochemical activities potently inhibited BTK Tyr223 phosphorylation, exhibiting IC<sub>50</sub> values of 1.8, 1.6, and 5.3 nM, respectively. Cell viability assays further confirmed the phosphorylation results. Three compounds displayed subnanomolar to single-digit nanomolar potency in Rec-1 cells, which are dependent on BTK activity for survival. To exclude the possibility that the antiproliferative activity was due to the general cell toxicity, <b>31a</b> was further evaluated in HEK293 and Ramos cells in which cell survival was not BTK-dependent and showed to be nontoxic in these cells (see <a class="ref internalNav" href="#notes-1" aria-label="p S12 in Supporting Information">p S12 in Supporting Information</a>). Compound <b>31a</b> was further evaluated in BTK dependent OCI-LY10 cell viability assay (IC<sub>50</sub> = 0.35 nM), and it showed similar potency to Ibrutinib (IC<sub>50</sub> = 0.30 nM). Moreover, <b>31a</b> was evaluated for inhibition of EGFR activity in a p-EGFR HTRF cellular assay. According to the cellular data in <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">10</a></a>, <b>31a</b> demonstrated a large margin of selectivity against wt EGFR (337-fold).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Structures and Selected Properties of <b>31</b>–<b>35</b><a class="ref internalNav" href="#t6fn1" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0017.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0018.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup><sup>a</sup></sup><p class="last"><i>n</i> = 3; where unspecified <i>n</i> = 1.</p></div><div class="footnote" id="t6fn1"><sup><sup>b</sup></sup><p class="last"><i>n</i>: number of determinations</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> X-ray Crystal Structure of <b>31a</b> in the Active Site of Human BTK</h3><div class="NLM_p">Fast dilution and protein precipitation experiments suggested that <b>31a</b> forms a covalent bond with human BTK, see <a class="ref internalNav" href="#notes-1" aria-label="p S7 in Supporting Information">p S7 in Supporting Information</a>. To confirm the <b>31a</b> form of covalent bond to Cys481, we determined the cocrystal structure of human BTK<sup>393–659</sup> with <b>31a</b> at 1.25 Å [PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a>]. The statistics of data collection and refinement are shown in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information, p S13">Supporting Information, p S13</a>. In the active site of BTK<sup>393–659</sup>, electron density corresponding to <b>31a</b> and Cys481 showed that <b>31a</b> formed a covalent adduct with Cys481 and the absolute configuration of <b>31a</b> was determined as <i>S</i> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which was further confirmed by single-crystal X-ray diffraction analyses (see <a class="ref internalNav" href="#notes-1" aria-label="p S15 in Supporting Information">p S15 in Supporting Information</a>). In addition, we compared the structure of <b>31a</b> and Ibrutinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>) with BTK (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Although <b>31a</b> has a similar piperidinyl linker as Ibrutinib, it adopts a different binding mode with BTK compared with Ibrutinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c). Three critical hydrogen bonds with hinge residues Glu475 and Met477 were observed in the <b>31a</b> cocrystal structure with BTK. Compared to the cocrystal structure of Ibrutinib with BTK, one more hydrogen bond was formed between the backbone carbonyl moiety of Met477 with <b>31a</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a,b). In addition, we observed a T-shape π–π stacking between terminal phenyl group and Phe540 and a water bridge between nitrogen atom of the pyrazolyl ring and Lys430 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a,b). Moreover, classic intramolecular H-bonds are actually formed in the single crystal of <b>31a</b> (see <a class="ref internalNav" href="#notes-1" aria-label="p S15 in Supporting Information">p S15 in Supporting Information</a>), which further confirmed our initial strategy to mimic the pyrimidinone ring.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Electron density map corresponding to <b>31a</b> and Cys481 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a>). <b>31a</b> is shown as sticks and colored in magenta. The key residues of human BTK around the compound are shown as sticks and colored in green. Water molecules are shown as spheres. The density map of <b>31a</b> and Cys481 is shown as mesh in gray. The <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> electron-density map for <b>31a</b> was contoured at 3.0σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode comparison between <b>31a</b> and Ibrutinib. (a) Binding mode of Ibrutinib and BTK from cocrystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>). (b) Binding mode of <b>31a</b> and BTK from cocrystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a>). (c) Alignment between Ibrutinib and <b>31a</b>. BTK is shown as ribbon and colored in orange. Ibrutinib, <b>31a</b>, and the amino acid residues of BTK interacting with compound are shown as stick and are colored in green, magenta, and gray, respectively. Water molecules are shown as spheres. The figure is generated using Schrödinger software (Maestro 11.2 in Schrödinger Suite 2017-2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Pharmacokinetic Properties of <b>31a</b>, <b>32a</b>, and <b>33a</b></h3><div class="NLM_p">From the results of in vitro assays, <b>31a</b>, <b>32a</b>, and <b>33a</b> showed excellent biochemical activity and promising cellular activity. Therefore, they were selected for further pharmacokinetic study in rats following intravenous (1 mg/kg) and oral (5 mg/kg) administration. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, <b>31a</b>, <b>32a</b>, and <b>33a</b> have moderate volumes of distribution. However, <b>31a</b> showed relatively lower clearance rate (76.8 mL/min/kg), higher exposure <i>C</i><sub>max</sub> (235 ng/mL), AUC (257 h·ng/mL), and bioavailability (23.6%) in rat than <b>32a</b> and <b>33a</b>. For this reason, <b>31a</b> was further profiled in preclinical in vitro studies by evaluating the plasma protein binding, liver microsomes stability, and cytochrome P450 inhibition. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, the mean free fraction percentages (%) of <b>31a</b> were 5.8, 6.7, 3.3, and 5.1 in human, dog, rat, and mouse plasma, respectively. No significant species difference was observed. Microsomal in vitro clearance was species dependent. Compound <b>31a</b> showed high clearance in human and rat and moderate clearance in dog and mouse. Compound <b>31a</b> showed weak or no inhibition of cytochrome P450 isoforms. Because of favorable PK properties, <b>31a</b> was selected for in vivo PD and efficacy study using xenograft model.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vivo PK Parameters of <b>31a</b>, <b>32a</b>, and <b>33a</b> in Rat</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><b>31a</b></th><th class="colsep0 rowsep0" align="center" char="."><b>32a</b></th><th class="colsep0 rowsep0" align="center" char="."><b>33a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv (1 mg·kg<sup>–1</sup>)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.53</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">76.8</td><td class="colsep0 rowsep0" align="char" char=".">169</td><td class="colsep0 rowsep0" align="char" char=".">93.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">2.32</td><td class="colsep0 rowsep0" align="char" char=".">2.85</td><td class="colsep0 rowsep0" align="char" char=".">1.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po (5 mg·kg<sup>–1</sup>)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">2.33</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">235</td><td class="colsep0 rowsep0" align="char" char=".">10.4</td><td class="colsep0 rowsep0" align="char" char=".">19.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC (h·ng/mL)</td><td class="colsep0 rowsep0" align="char" char=".">257</td><td class="colsep0 rowsep0" align="char" char=".">50.3</td><td class="colsep0 rowsep0" align="char" char=".">51.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">23.6</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Dosed using 1 mg/kg solution.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Dosed using 5 mg/kg of methylcellulose suspension.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Plasma Protein Binding, Liver Microsomes Stability, and in Vitro Cytochrome P450 Inhibition of <b>31a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center"><b>31a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding free fraction (<i>f</i><sub>u</sub>, %)</td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsomal intrinsic clearance (μL·min<sup>–1</sup>·mg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">109</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">25.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">148</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">67.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP, IC<sub>50</sub> (μM)</td><td class="colsep0 rowsep0" align="left">3A4</td><td class="colsep0 rowsep0" align="left">14.3<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> or 60.6<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2C9</td><td class="colsep0 rowsep0" align="left">5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2C8</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2C19</td><td class="colsep0 rowsep0" align="left">7.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1A2, 2B6, 2D6</td><td class="colsep0 rowsep0" align="left">>30</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Used midazolam as the probe substrate.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Used testosterone as the probe substrate.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Pharmacodynamic Characterization of <b>31a</b> in Mice</h3><div class="NLM_p">After single oral administration of <b>31a</b> at 14.5 mg/kg, BTK protein in both PBMC and spleen was quickly occupied by <b>31a</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Maximal BTK occupancy was achieved at 0.5 h in both PBMC and spleen, which coincided well with its <i>C</i><sub>max</sub>. The <i>C</i><sub>max</sub> of <b>31a</b> at 14.5 mg/kg in plasma was 4.8 μM. Its plasma drug concentration quickly decreased to 0.47 and 0.09 μM at 2 and 4 h after dosing, respectively, and dropped below detection limit after 12 h. Furthermore, the pharmacodynamic activity of <b>31a</b> and Ibrutinib were compared in ICR mice at different dose levels 4 h after dosing. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B, treatment with <b>31a</b> or Ibrutinib resulted in a dose dependent BTK occupancy in PBMC and spleen. <b>31a</b> achieved above 70% target engagement at doses higher than 1.4 and 2.9 mg/kg in PBMC and spleen, respectively, while Ibrutinib achieved above 70% target inhibition at doses higher than 4.4 and 8.9 mg/kg in PBMC and spleen, respectively. Compound <b>31a</b> was around 3-fold more potent than Ibrutinib at the same dose level in both target organs. Additionally, the plasma concentration of both <b>31a</b> and Ibrutinib were dose proportional at 0.5 h. The plasma concentration of <b>31a</b> was roughly 3-fold higher than Ibrutinib at the same dose level, consistent with their pharmacodynamic activities (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Taken together, <b>31a</b> was about 3-fold more potent than Ibrutinib in mouse PD assays, which correlated very well with its higher exposure compared to Ibrutinib. Clinical studies further confirmed that <b>31a</b> with excellent pharmacokinetic properties could lead to complete and continuous occupancy in both PBMC and lymph nodes (LN).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) ICR mice were treated with 14.5 mg/kg of <b>31a</b> and euthanized at different time points after dosing as indicated. PBMC and spleens were collected for BTK occupancy assay. Plasma drug concentration of <b>31a</b> was also determined at different time points. (B) ICR mice were treated with different dose levels of <b>31a</b> or Ibrutinib and euthanized 4 h after dosing. PBMC and spleens were collected from euthanized mice, and protein lysates were prepared for BTK occupancy assay. (C) Plasma drug concentration of <b>31a</b> or Ibrutinib was measured at 0.5 h after dosing. Data are presented as mean ± SEM of four animals in each group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Tumor Growth Inhibition of <b>31a</b> in the OCI-LY10 Xenograft Model</h3><div class="NLM_p">To test the effect in vivo, NCG mice with OCI-LY10 DLBCL tumor xenografts was treated with <b>31a</b> or Ibrutinib at 2.5 and 7.5 mg/kg BID. While Ibrutinib at 2.5 and 7.5 mg/kg induced significant tumor inhibition with the TGI of 61% and 77% on day 28, <b>31a</b> achieved better antitumor activities with 76% and 88% of TGI on day 28, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). All treatment groups had no significant impact on animal body weight throughout the study (data not shown). Drug exposure of <b>31a</b> and Ibrutinib (AUC<sub>0–8h</sub> and <i>C</i><sub>max</sub>) at steady state increased dose dependently from 2.5 to 7.5 mg/kg. Compound <b>31a</b>’s AUC<sub>0–8h</sub> and <i>C</i><sub>max</sub> were higher than Ibrutinib at the same dose level.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) OCI-LY10 tumor cells (5 × 10<sup>6</sup>) were implanted subcutaneously in female NCG mice. When the tumors were palpable, mice were randomly divided into five groups and treated for 28 days as indicated. Data are presented as mean tumor volume ± SEM of 12 animals in each group. (B) Plasma drug concentration of <b>31a</b> and Ibrutinib was measured at the indicated time points after dosing. Data are presented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vitro Selectivity Profile of <b>31a</b></h3><div class="NLM_p">To gain an understanding of the overall kinase selectivity, <b>31a</b> was evaluated in kinase panel (Reaction Biology Corp.) that tested the inhibitory activity of the compound at 1 μM against 342 human kinases. It displayed less than 70% inhibition against 329 kinases and greater than 70% inhibition against 13 kinases, including BTK (see <a class="ref internalNav" href="#notes-1" aria-label="p S18 in Supporting Information">p S18 in Supporting Information</a>). IC<sub>50</sub> of <b>31a</b> for these 13 kinases were determined except MEK2 (see <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">9</a></a>). Out of these 10 kinases which have a comparable cysteine residue in analogous location, <b>31a</b> demonstrated selectivity of 187-fold against ITK, 1933-fold against JAK3, and 1800-fold against HER2, respectively, this is likely attributed to both the intrinsic structural selectivity of the compound and the microenvironment impact of the cysteine of these kinases on the covalent binding. Moreover, <b>31a</b> showed low inhibition in Src family kinases such as SRC (29% inhibition), LYN (35% inhibition), FYN (50% inhibition), and LCK (73% inhibition, IC<sub>50</sub> = 187 nM) which were reported to be critical in platelet activation associated with increased bleeding risk.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> The BTK potency of <b>31a</b> more depends on chemical reactivity rate (<i>k</i><sub>inact</sub>) compared to Ibrutinib with higher reversible binding capability may contribute to the greater selectivity of <b>31a</b>. Compared to Ibrutinib, <b>31a</b> has much higher IC<sub>50</sub> or no inhibition on kinase activities of ITK, JAK3, HER2, FGR, LCK, CSK, FYN, HCK, LYN, SRC, YES, and FRK.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Biochemical Kinase Selectivity of <b>31a</b> and Ibrutinib<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM) of <b>31a</b></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM) of Ibrutinib</th><th class="colsep0 rowsep0" align="center">selectivity of <b>31a</b></th><th class="colsep0 rowsep0" align="center">selectivity of Ibrutinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK<a class="ref internalNav" href="#t10fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.30 ± 0.06<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.18 ± 0.04<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK<a class="ref internalNav" href="#t10fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">56 ± 12<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">3.0 ± 0.7<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">187</td><td class="colsep0 rowsep0" align="left">17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC<a class="ref internalNav" href="#t10fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2.0 ± 0.8<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.57 ± 0.18<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3<a class="ref internalNav" href="#t10fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">580 ± 21<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">10 ± 2<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1933</td><td class="colsep0 rowsep0" align="left">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR<a class="ref internalNav" href="#t10fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">2.6 ± 1.0</td><td class="colsep0 rowsep0" align="left">0.75 ± 0.14</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2<a class="ref internalNav" href="#t10fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">530 ± 273<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">19 ± 7<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1800</td><td class="colsep0 rowsep0" align="left">106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BLK<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1.13</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.62</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRK<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER4<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1.58</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGR<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">155</td><td class="colsep0 rowsep0" align="left">1.82</td><td class="colsep0 rowsep0" align="left">168</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FRK/PTK5<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">379</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left">412</td><td class="colsep0 rowsep0" align="left">172</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LCK<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">187</td><td class="colsep0 rowsep0" align="left">2.85</td><td class="colsep0 rowsep0" align="left">203</td><td class="colsep0 rowsep0" align="left">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK<a class="ref internalNav" href="#t10fn5" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">2.95</td><td class="colsep0 rowsep0" align="left">2.89</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">6.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last"><i>n</i>: number of determinations.</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 3; where unspecified <i>n</i> = 1.</p></div><div class="footnote" id="t10fn4"><sup><sup>c</sup></sup><p class="last">Note: IC<sub>50</sub> values of compounds were measured at <i>K</i><sub>m</sub> of ATP for the kinases and with 1 h preincubation at BeiGene by using a TR-FRET assay.</p></div><div class="footnote" id="t10fn5"><sup><sup>d</sup></sup><p class="last">Data were generated at Reaction Biology Corp. using <sup>33</sup>P-ATP and filter-binding assay. IC<sub>50</sub> values of compounds were measured at 1 μM ATP and with 1 h preincubation. Selectivity for these kinases was calculated based on IC<sub>50</sub> of BTK generated in Reaction Biology Corp. for <b>31a</b> (0.92 nM) and Ibrutinib (0.46 nM).</p></div></div></div><div class="NLM_p">To further assess the compound’s selective property, we examined the EGFR, ITK, and TEC inhibitory activity of Ibrutinib and <b>31a</b> in cells. <b>31a</b> was confirmed to be more selective than Ibrutinib over EGFR, ITK, and TEC (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">10</a></a>). In EGFR, ITK, and TEC phosphorylation cellular assay, the selectivity of <b>31a</b> was 337-fold, 1932-fold, and 114-fold, respectively. While the selectivity of Ibrutinib was 29-fold, 22-fold, and 13-fold, respectively. In conclusion, <b>31a</b> was more selective than Ibrutinib over EGFR, ITK, and TEC.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Cellular Selectivity against ITK, EGFR, and TEC</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">targets</th><th class="colsep0 rowsep0" align="center">assays</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM) of <b>31a</b></th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM) of Ibrutinib</th><th class="colsep0 rowsep0" align="center" char=".">selectivity of <b>31a</b></th><th class="colsep0 rowsep0" align="center" char=".">selectivity of Ibrutinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">BTKpY223 assay</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.2<a class="ref internalNav" href="#t11fn2" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 1.9<a class="ref internalNav" href="#t11fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">p-EGFR HTRF assay</td><td class="colsep0 rowsep0" align="char" char="±">606 ± 49<a class="ref internalNav" href="#t11fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">101 ± 38<a class="ref internalNav" href="#t11fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">337</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK</td><td class="colsep0 rowsep0" align="left">p-PLCγ1 assay</td><td class="colsep0 rowsep0" align="char" char="±">3477 ± 218<a class="ref internalNav" href="#t11fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">76.9 ± 3.3<a class="ref internalNav" href="#t11fn4" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">1932</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC</td><td class="colsep0 rowsep0" align="left">p-TEC MSD assay</td><td class="colsep0 rowsep0" align="char" char="±">204.7 ± 1.6<a class="ref internalNav" href="#t11fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">46.7 ± 3.1<a class="ref internalNav" href="#t11fn3" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">114</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><p class="first last"><i>n</i>: number of determinations.</p></div><div class="footnote" id="t11fn2"><sup><sup>a</sup></sup><p class="last"><i>n</i> = 3.</p></div><div class="footnote" id="t11fn3"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 5.</p></div><div class="footnote" id="t11fn4"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 2.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65752" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65752" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Synthesis of Tricyclic Compounds</h3><div class="NLM_p">Tricyclic compounds <b>5</b>, <b>6</b>, <b>7</b>, and <b>10</b> were synthesized first (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Hydrazine intermediates <b>36a</b>–<b>c</b> reacted with 2-(methoxy(4-phenoxyphenyl)methylene)malononitrile to generate substituted-pyrazole <b>37a</b>–<b>c</b>. Hydrolization of the cyano group and cyclization by copper catalyst generated <b>39a</b>–<b>c</b>. Starting from <b>39a</b>,<b>b</b>, the nitro groups were reduced by zinc powder and the resulting anilines were acylated by reacting with acryloyl chloride to generate <b>6</b> and <b>7</b> with moderate yield. Compound <b>39c</b> reacted with benzyl bromide, and the corresponding six-member ring was reduced to give <b>41</b>. The protecting group was removed, and the warhead group was attached to generate <b>10</b>.</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of <b>5</b>, <b>6</b>, <b>7</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EtOH, 2-(methoxy(4-phenoxyphenyl)methylene)malononitrile, 70 °C; (ii) phosphorous acid (85% in H<sub>2</sub>O), 100 °C; (iii) DMF, CuI, <i>N</i><sub>1</sub>,<i>N</i><sub>2</sub>-dimethylethane-1,2-diamine, K<sub>3</sub>PO<sub>4</sub>, 60 °C; (iv) HOAc, Zn, rt; (v) DCM, acryloyl chloride, TEA, 0 °C to rt; (vi) THF, benzyl bromide, 65 °C, then MeOH, NaBH<sub>4</sub>, rt; (vii) MeOH, Pd/C (10%), H<sub>2</sub> (1 atm), rt.</p></p></figure><div class="NLM_p">However, tricyclic core <b>8</b>, <b>9</b>, <b>11</b>, and <b>12</b> were prepared by using different strategies compared to their analogues. As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, bromo <b>43a</b>–<b>b</b> reacted with 5-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazole-4-carbonitrile to generate <b>44a</b>–<b>c</b>, respectively. Cleavage of the Boc protecting group, hydrolysis of nitrile group in one pot, and acryloylation with acryloyl chloride or 4-(dimethylamino) but-2-enoic acid hydrochloride to generate final <b>8</b>, <b>9</b>, <b>11</b>, and <b>12</b>.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of <b>8</b>, <b>9</b>, <b>11</b>, and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 5-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazole-4-carbonitrile, DMF, K<sub>2</sub>CO<sub>3</sub>, 80 °C; (ii) H<sub>3</sub>PO<sub>4</sub> (85% in H<sub>2</sub>O), 100 °C; (iii) DCM, acryloyl chloride, TEA, 0 °C to rt or 4-(dimethylamino)but-2-enoic acid hydrochloride, HATU, TEA, DCM, rt.</p></p></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of Bicyclic Compounds</h3><div class="NLM_p">The synthetic route for <b>13</b>–<b>16</b> was outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The cyano group of 5-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazole-4-carbonitrile (<b>46</b>) was hydrolyzed first, and the resulting product was cyclized to give <b>48a</b>–<b>d</b>. The nitro group was reduced or the protecting groups were cleaved to afford <b>49a</b>–<b>d</b>, then the warhead group was installed to generate final <b>13</b>–<b>16</b>.</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthesis of <b>13</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) H<sub>3</sub>PO<sub>4</sub> (85% in water), 120 °C; (ii) EtOH, haloketone, 80 °C; (iii) MeOH/DCM, Pd/C (10%), H<sub>2</sub> (balloon), rt; (iv) HCl, MeOH, rt; (v) DCM, TEA, acryloyl chloride, rt.</p></p></figure><div class="NLM_p">Tetrahydropyrazolopyrimidine core <b>18</b>–<b>20</b> and <b>25</b>–<b>35</b> were synthesized as outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. 5-Amino-3-phenyl-1<i>H</i>-pyrazole-4-carbonitrile analogues reacted with 3-dimethylamino-1-(aryl, heteroaryl, or alkyl)-2-propen-1-one to generate intermediates bearing pyrazolopyrimidine core. Cleavage of the protecting groups or reduction of the nitro group yielded <b>57</b>–<b>70</b>. Then the pyrimidine rings were reduced by using NaBH<sub>4</sub>, and the resulting product were hydrolyzed by H<sub>2</sub>O<sub>2</sub> in the presence of NaOH to generate <b>71</b>–<b>84</b> with moderate yields. Acryloylation of <b>71</b>–<b>84</b> resulted in <b>18</b>−<b>20</b> and <b>25</b>−<b>35</b> with warhead groups and the racemic <b>25</b>, <b>29</b>, <b>31</b>–<b>33</b> were further separated by Chiral-HPLC to deliver final pure enantiomers <b>25a</b>/<b>25b</b>, <b>29a</b>/<b>29b</b>, <b>31a</b>/<b>31b</b>, <b>32a</b>/<b>32b</b>, and <b>33a</b>/<b>33b</b>. For the synthesis of <b>18a</b>/<b>18b</b> and <b>20a</b>/<b>20b</b>, we separated anilines <b>71</b> and <b>73</b> first to obtain two enantiomers <b>85</b>/<b>87</b> and <b>86</b>/<b>88</b> and then installed the warhead to obtain final targets.</div><figure id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. General Synthesis of <b>18</b>–<b>20</b> and <b>25</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3-dimethylamino-1-(aryl, heteroaryl, or alkyl)-2-propen-1-one; acetic acid, reflux; (ii) EtOH or MeOH, HCl (conc), 75 or 60 °C, or hydrazine hydrate, MeOH/dioxane, 60 °C, or Pd/C (10%), MeOH/DCM, rt, H<sub>2</sub>; (iii) EtOH, NaBH<sub>4</sub>, 60 °C; (iv) DMSO/EtOH (v:v = 1:1), 5 N NaOH, H<sub>2</sub>O<sub>2</sub> (30%), 60 °C; (v) chiral separation; (vi) DCM, pyridine or Et<sub>3</sub>N, acryloyl chloride, rt.</p></p></figure><div class="NLM_p">Compounds <b>22</b>–<b>24</b> were synthesized by use of chemistry similar to that described above (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Nitro group and pyrimidine ring of <b>89</b> were reduced by using palladium/carbon, and in the meanwhile, the benzyl group was removed in one pot. The hydroxyl group was alkylated, the cyano group was hydrolyzed, and the warhead was installed to give final <b>22</b>, <b>23</b>, and <b>24</b>. Enantiomers <b>23a</b>/<b>23b</b> were obtained by chiral separation.</div><figure id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. General Synthesis of <b>22</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) MeOH/DCM, Pd/C (10%), H<sub>2</sub> (3 atm), rt; (ii) acetone, R<sub>1</sub>Br, K<sub>2</sub>CO<sub>3</sub>, rt or reflux; (iii) DMSO/EtOH (v:v = 1:1), NaOH (1N), H<sub>2</sub>O<sub>2</sub> (30%), 60 °C; (iv) DCM, Et<sub>3</sub>N, acryloyl chloride, rt; (v) chiral separation.</p></p></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01511" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01511" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we used a structure–activity relationship driven drug design strategy and selected candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic (PD) for prioritizing compounds. Starting from a series of pseudo pyrimidinone compounds, we designed and synthesized two series (tricyclic and bicyclic) of new compounds. Among them, <b>31a</b> was shown to be a potent, highly specific, and irreversible BTK inhibitor. It has great selectivity against other TEC, EGFR, and Src-family kinases, good ADME, excellent in vivo PD in mice, and efficacy in OCI-LY10 DLBCL xenograft models. This compound, <b>31a</b> is currently being tested in numerous clinical trials. Toxicology, pharmacokinetics, and detailed results from clinical trials will be reported in other publications.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Experimental Procedures</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General</h3><div class="NLM_p last">All solvents and chemical used were reagent grade. Unless indicated otherwise, the reactions set forth below were performed under a positive pressure of nitrogen or argon or with a drying tube in anhydrous solvents, the reaction flasks were fitted with rubber septa for the introduction of substrates and reagents via syringe, and glassware was oven-dried and/or heat dried. <sup>1</sup>H NMR spectra were recorded on an operating at 400 MHz and <sup>13</sup>C at 100 MHz on a Bruker spectrometer. <sup>1</sup>H NMR spectra were obtained using CDCl<sub>3</sub>, CD<sub>3</sub>OD, D<sub>2</sub>O, DMSO-<i>d</i><sub><i>6</i></sub> as solvent, and tetramethylsilane (0.00 ppm) or residual solvent (CDCl<sub>3</sub>, 7.25 ppm; CD<sub>3</sub>OD, 3.31 ppm; D<sub>2</sub>O, 4.79 ppm; DMSO-<i>d</i><sub>6</sub>, 2.50 ppm) as the reference standard. Coupling constants, when given, are reported in hertz (Hz). Preparative HPLC was conducted on a column (150 mm × 21.2 mm ID, 5 μm, Gemini NX-C18) at a flow rate of 20 mL/min, injection volume 2 mL, at room temperature, and UV detection at 214 and 254 nm. The purities of all final compounds were determined to be above 95% by high-performance liquid chromatography (HPLC) or LC-MS. HPLC conditions were as follows: Gemini C18 column at room temperature, 4.6 cm × 150 cm, 5 μm, 10–90% acetonitrile (0.05% TFA)/water (0.05% TFA), 10 min run; flow rate, 1 mL/min; UV detection λ = 214 nm, 254, and 280 nm. LC-MS spectrometer (Agilent 1260), detector MWD (190–400 nm), mass detector 6120 SQ. Mobile phase: A, acetonitrile with 0.1% formic acid; B, water with 0.1% formic acid; column, Poroshell 120 EC-C18, 4.6 mm × 50 mm, 2.7 μm. Gradient method: 5–95% B in 1.5 min; 95% B, 0.5 min; 95%–5% B, 2.0–2.1 min; 5% B, 2.1–3.0 min; flow rate, 1.8 mL/min. Accurate mass was determined by analysis of samples on a calibrated Waters Acquity UPLC Xevo G2 QToF-MS.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis of <b>6</b>–<b>35</b></h3><div class="NLM_p">General method 1: TEA (0.35 mmol) or pyridine (0.20 mL) was added to a solution of appropriate amine (0.11 mmol) in DCM (10 mL), then a solution of acryloyl chloride (0.12 mmol) in DCM (2.0 mL) was added dropwise. The reaction mixture was stirred until TLC and LC-MS showed that most of starting material was consumed. The mixture was then partitioned between water (50 mL) and DCM (20 mL), the aqueous phase was extracted with DCM (20 mL), and the combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified by pre-TLC (MeOH:DCM = 1:20) or by pre-HPLC and or by silica gel column chromatography to afford the desired amide. General method 2: HATU (1.6 mmol) and TEA (3.2 mmol) were added to a mixture of appropriate acid (0.88 mmol) in DCM (50 mL). The mixture was stirred at RT for about 2 h, then appropriate amine (0.80 mmol) was added. The mixture was stirred at RT for overnight. TLC and LCMS analysis showed that starting material was consumed. Water (100 mL) and DCM (50 mL) were added to the reaction, the aqueous phase was extracted with DCM (50 mL), and the combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the crude product which was purified by column chromatography on silica gel (DCM:MeOH = 20:1 to 10:1) to afford the desired amide.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 7-Amino-2-(4-phenoxyphenyl)-4<i>H</i>-benzo[4,5]imidazo[1,2-<i>b</i>]pyrazole-3-carboxamide (<b>5</b>)</h4><div class="NLM_p last">To a solution of <b>39a</b> (0.022 mol) in acetic acid (3.0 mL) was added zinc powder (0.22 mol), the mixture was stirred at RT for about 20 min. LCMS analysis showed that most of starting material was consumed, the solid was filtered off, the filtrate was concentrated, the residual was suspended in EA (10 mL) and filtered, and the filtrate was concentrated to afford the desired product as white solid in 50% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.63 (s, 1H), 7.83–7.79 (m, 2H), 7.54–7.47 (m, 2H), 7.28–7.22 (m, 2H), 7.20–7.12 (m, 4H), 7.02 (d, <i>J</i> = 2.0 Hz, 1H), 6.68 (dd, <i>J</i> = 2.2, 8.6 Hz, 1H), 5.21 (br s, 2 H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.20, 157.02, 156.41, 153.49, 144.87, 144.09, 130.94, 130.19, 129.02, 126.17, 125.79, 123.82, 119.07, 118.09, 113.04, 111.62, 94.51, 91.53. HRMS: calcd for C<sub>22</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 384.1460, found 384.1467.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 7-Acrylamido-2-(4-phenoxyphenyl)-4<i>H</i>-benzo[4,5]imidazo[1,2-<i>b</i>]pyrazole-3-carboxamide (<b>6</b>)</h4><div class="NLM_p last">Synthesized from <b>5</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.06 (s, 1H), 10.34 (s, 1H), 8.41 (s, 1H), 7.77–7.72 (m, 2H), 7.46–7.35 (m, 2H), 7.19–7.13 (m, 1H), 7.11–7.03 (m, 2H), 6.44 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.26 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 5.74 (dd, <i>J</i> = 2.0, 10.0 Hz, 1H). HRMS: calcd for C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 438.1566, found 438.1562.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 6-Acrylamido-2-(4-phenoxyphenyl)-4<i>H</i>-benzo[4,5]imidazo[1,2-<i>b</i>]pyrazole-3-carboxamide (<b>7</b>)</h4><div class="NLM_p last">Synthesized from <b>40</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.14 (s, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.8 Hz, 2H), 7.38–7.24 (m, 3H), 7.12–6.94 (m, 5H), 6.46–6.25 (m, 2H), 5.71 (dd, <i>J</i> = 2.0, 9.6 Hz, 1H). HRMS: calcd for C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 438.1566, found 438.1559.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 7-Acryloyl-2-(4-phenoxyphenyl)-5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[5′,1′:2,3]imidazo[4,5-<i>c</i>]pyridine-3-carboxamide (<b>8</b>)</h4><div class="NLM_p last">Synthesized from <b>45a</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub> at 80 °C) δ 11.55 (s, 1H), 7.71 (d, <i>J</i> = 8.6 Hz, 2H), 7.43 (d, <i>J</i> = 7.6 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.18 (t, <i>J</i> = 7.6 Hz, 1H), 7.10–7.05 (m, 4H), 6.88 (dd, <i>J</i> = 10.6, 17.1 Hz, 1H), 6.24 (s, 2H), 6.15 (d, <i>J</i> = 17.1 Hz, 1H), 5.74 (d, <i>J</i> = 10.6 Hz, 1H), 4.78 (s, 2H), 3.94–3.91 (m, 2H), 2.80–2.76 (m, 2H). HRMS: calcd for C<sub>24</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 428.1723, found 428.1720.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 7-(4-(Dimethylamino)but-2-enoyl)-2-(4-phenoxyphenyl)-5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[5′,1′:2,3]imidazo[4,5-<i>c</i>]pyridine-3-carboxamide (<b>9</b>)</h4><div class="NLM_p last">Synthesized from <b>45a</b> and 4-(dimethylamino)but-2-enoic acid hydrochloride according to general method 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub> at 80 °C) δ 11.52 (s, 1H), 7.69 (d, <i>J</i> = 8.6 Hz, 2H), 7.42 (d, <i>J</i> = 7.6 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.16 (t, <i>J</i> = 7.6 Hz, 1H), 7.12–6.99 (m, 4H), 6.78–6.56 (m, 2H), 6.22 (s, 2H), 4.75 (s, 2H), 3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.12 (d, <i>J</i> = 5.6 Hz, 2H), 2.80–2.72 (m, 2H), 2.22 (s, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.28, 164.14, 156.81, 156.46, 152.07, 142.52, 141.11, 130.94, 130.17, 129.24, 124.89, 123.76, 122.52, 119.00, 118.10, 111.92, 109.58, 91.67, 59.91, 45.06, 42.72, 37.40, 23.01. HRMS: calcd for C<sub>27</sub>H<sub>28</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 485.2301, found 485.2311.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 6-Acryloyl-2-(4-phenoxyphenyl)-5,6,7,8-tetrahydro-4<i>H</i>-pyrazolo[1′,5′:1,2]imidazo[4,5-<i>c</i>]pyridine-3-carboxamide (<b>10</b>)</h4><div class="NLM_p last">Synthesized from <b>42</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.72 (s, 1H), 7.66 (d, <i>J</i> = 8.4 Hz, 2H), 7.45–7.38 (m, 2H), 7.21–7.15 (m, 1H), 7.12–7.03 (m, 4H), 6.95 (dd, <i>J</i> = 10.2, 16.2 Hz, 1H), 6.17 (dd, <i>J</i> = 2.0, 16.2 Hz, 1H), 5.76 (dd, <i>J</i> = 2.0, 10.2 Hz, 1H), 4.69–4.63 (m, 2 H), 3.96–3.89 (m, 2H), 2.88–2.76 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.41, 164.23, 156.84, 156.45, 151.80, 141.27, 130.91, 130.16, 129.24, 128.42, 128.02, 127.84, 123.76, 123.36, 118.99, 118.18, 113.23, 91.79, 42.53, 20.76. HRMS: calcd for C<sub>24</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 428.1723, found 428.1725.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 7-Acryloyl-2-(4-phenoxyphenyl)-4,5,6,7,8,9-hexahydropyrazolo[1′,5′:1,2]imidazo[4,5-<i>d</i>]azepine-3-carboxamide (<b>11</b>)</h4><div class="NLM_p last">Synthesized from <b>45b</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.64–7.60 (m, 2H), 7.43–7.37 (m, 2H), 7.19–7.14 (m, 1H), 7.12–7.05 (m, 4H), 6.97–6.85 (m, 1H), 6.32 (dd, <i>J</i> = 2.0, 16.8 Hz, 1H), 5.81 (dd, <i>J</i> = 2.0, 8.4 Hz, 1H), 4.04–3.91 (m, 4H), 3.17–3.09 (m, 2H), 3.07–3.01 (m, 2H). HRMS: calcd for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 442.1879, found 442.1790.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 8-Acryloyl-2-(4-phenoxyphenyl)-4,5,6,7,8,9-hexahydropyrazolo[5′,1′:2,3]imidazo[4,5-<i>c</i>]azepine-3-carboxamide (<b>12</b>)</h4><div class="NLM_p last">Synthesized from <b>45c</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.61 (dd, <i>J</i> = 2.4, 8.8 Hz, 2H), 7.41–7.33 (m, 2H), 7.14 (t, <i>J</i> = 8.0 Hz, 1H), 7.11–7.02 (m, 4H), 6.82 (dd, <i>J</i> = 10.6, 16.8 Hz, 1H), 6.19 (dd, <i>J</i> = 1.8, 16.8 Hz, 1H), 5.74 (dd, <i>J</i> = 1.8, 10.6 Hz, 1H), 4.98 (d, <i>J</i> = 12.4 Hz, 2H), 4.06–3.80 (m, 2H), 2.96–2.89 (m, 2H), 2.12–1.93 (m, 2H). HRMS: calcd for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 442.1879, found 442.1877.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3-(3-Acrylamidophenyl)-6-(4-phenoxyphenyl)-1<i>H</i>-imidazo[1,2-<i>b</i>]pyrazole-7-carboxamide (<b>13</b>)</h4><div class="NLM_p last">Synthesized from <b>49a</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.18 (d, <i>J</i> = 2.4 Hz, 1H), 10.31 (s, 1H), 8.38 (s, 1H), 7.85 (d, <i>J</i> = 8.0 Hz, 1H), 7.80–7.73 (m, 4H), 7.46–7.40 (m, 3H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 7.13–7.07 (m, 4H), 6.50 (dd, <i>J</i> = 10.2, 17.0 Hz, 1H), 6.27 (d, <i>J</i> = 17.0 Hz, 1H), 5.76 (d, <i>J</i> = 10.2 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.05, 163.34, 156.95, 156.49, 153.07, 142.03, 139.32, 131.94, 131.18, 130.18, 129.26, 129.23, 128.95, 126.99, 123.77, 120.40, 119.85, 118.99, 118.57, 118.17, 115.56, 115.39, 91.73. HRMS: calcd for C<sub>27</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 464.1723, found 464.1730.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(3-Acrylamidophenyl)-6-(4-phenoxyphenyl)-1<i>H</i>-imidazo[1,2-<i>b</i>]pyrazole-7-carboxamide (<b>14</b>)</h4><div class="NLM_p last">Synthesized from <b>49b</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.06 (s, 1H), 7.83 (s, 1H), 7.64 (d, <i>J</i> = 8.4 Hz, 1H), 7.52–7.38 (m, 5H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 7.09–7.05 (m, 4H), 6.49–6.37 (m, 2H) and 5.80 (dd, <i>J</i> = 4.0, 8.8 Hz, 1H). HRMS: calcd for C<sub>27</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 464.1723, found 464.1722.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(1-Acryloylpyrrolidin-3-yl)-6-(4-phenoxyphenyl)-1<i>H</i>-imidazo[1,2-<i>b</i>]pyrazole-7-carboxamide (<b>15</b>)</h4><div class="NLM_p last">Synthesized from <b>49c</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.76 (s, 1H), 7.67 (d, <i>J</i> = 8.0 Hz, 2H), 7.56 (s, 1H), 7.47–7.38 (m, 2H), 7.17 (t, <i>J</i> = 7.6 Hz, 1H), 7.11 (d, <i>J</i> = 7.6 Hz, 2H), 7.04 (d, <i>J</i> = 8.0 Hz, 2H), 6.60 (dd, <i>J</i> = 10.3, 16.6 Hz, 1H), 6.16 (dd, <i>J</i> = 2.2, 16.6 Hz, 1H), 5.69 (dd, <i>J</i> = 2.2, 10.3 Hz, 1H), 4.09–3.95 (m, 1H), 3.94–3.73 (m, 1H), 3.70–3.37 (m, 3H), 2.42–2.24 (m, 1H), 2.21–2.01 (m, 1H). HRMS: calcd for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 442.1879, found 442.1872.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-(1-Acryloylpiperidin-4-yl)-6-(4-phenoxyphenyl)-1<i>H</i>-imidazo[1,2-<i>b</i>]pyrazole-7-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Synthesized from <b>49d</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.53 (s, 1H), 7.64 (d, <i>J</i> = 8.4 Hz, 2H), 7.40 (d, <i>J</i> = 7.6 Hz, 1H), 7.38 (d, <i>J</i> = 7.6 Hz, 1H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 7.05 (d, <i>J</i> = 8.0 Hz, 2H), 7.02 (d, <i>J</i> = 8.0 Hz, 2H), 6.96 (s, 1H), 6.80 (dd, <i>J</i> = 10.1, 16.8, Hz, 1H), 6.40 (brs, 2H), 6.07 (dd, <i>J</i> = 2.0, 16.8, Hz, 1H), 5.64 (dd, <i>J</i> = 2.0, 10.1, Hz, 1H), 4.46 (d, <i>J</i> = 12.8 Hz, 1H), 4.10 (d, <i>J</i> = 12.8 Hz, 1H), 3.24–3.04 (m, 2H), 2.80 (t, <i>J</i> = 12.8 Hz, 1H), 2.20–2.05 (m, 2H), 1.64–1.46 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.24, 164.10, 156.74, 156.53, 152.99, 141.24, 131.04, 130.15, 129.43, 128.57, 127.13, 123.92, 123.69, 118.89, 118.13, 113.17, 91.32, 44.96, 41.31, 31.40, 30.37, 29.32. HRMS: calcd for C<sub>26</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 456.2036, found 456.2028.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 7-(3-Acrylamidophenyl)-2-(4-phenoxyphenyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>17</b>)</h4><div class="NLM_p last">Synthesized from <b>71</b> according to active MnO<sub>2</sub> oxidation and general method 1. Procedure of active MnO<sub>2</sub> oxidation: To a solution of <b>71</b> (4.0 mg, 0.01 mmol) in DCE (2.0 mL) was added active MnO<sub>2</sub> (100 mg, 1.15 mmol), and the mixture was stirred at 75 °C for 2 h. The mixture was cooled to RT and filtered, and the filtrate was purified by Pre-TLC (DCM:CH<sub>3</sub>OH = 10:1) to afford 7-(3-aminophenyl)-2-(4-phenoxyphenyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (2.0 mg) as yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD and CDCl<sub>3</sub>) δ 8.62 (d, <i>J</i> = 4.4 Hz, 1H), 7.88 (d, <i>J</i> = 8.8 Hz, 2H), 7.41–7.39 (m, 2H), 7.31–7.26 (m, 3H), 7.11 (d, <i>J</i> = 4.4 Hz, 1H), 7.10–7.04 (m, 1H), 7.01–6.97 (m, 4H), 6.90–6.86 (m, 1H). <b>17</b> was then synthesized from 7-(3-aminophenyl)-2-(4-phenoxyphenyl)pyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.42 (s, 1H), 8.80 (d, <i>J</i> = 4.4 Hz, 1H), 8.47 (s, 1H), 8.07 (s, 1H), 7.95 (d, <i>J</i> = 8.8 Hz, 2H), 7.89 (d, <i>J</i> = 8.4 Hz, 1H), 7.81 (d, <i>J</i> = 8.0 Hz, 1H), 7.56 (t, <i>J</i> = 8.0 Hz, 1H), 7.47 (br s, 1H), 7.42–7.37 (m, 3H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 7.06 (d, <i>J</i> = 8.0 Hz, 2H), 7.01 (d, <i>J</i> = 8.8 Hz, 2H), 6.44 (dd, <i>J</i> = 10.1, 16.9 Hz, 1H), 6.26 (dd, <i>J</i> = 1.6, 16.9 Hz, 1H), 5.76 (dd, <i>J</i> = 1.6, 10.1 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.53, 163.33, 157.61, 156.22, 155.77, 151.49, 148.50, 146.37, 139.32, 131.89, 131.75, 130.52, 130.19, 129.25, 127.59, 127.39, 124.80, 123.91, 122.17, 120.30, 119.17, 117.43, 109.47, 101.98. HRMS: calcd for C<sub>28</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 476.1723, found 476.1722.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 7-(3-Acrylamidophenyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>18</b>)</h4><div class="NLM_p last">Synthesized from <b>71</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.58 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 8.8 Hz, 2H), 7.34–7.26 (m, 4H), 7.10 (t, <i>J</i> = 7.6 Hz, 1H), 7.04–6.95 (m, 4H), 6.84 (d, <i>J</i> = 7.6 Hz, 1H), 6.39–6.25 (m, 2H), 5.69 (dd, <i>J</i> = 2.4, 9.6 Hz, 1H), 5.47–5.44 (m, 1H), 3.38–3.31 (m, 1H), 3.22–3.12 (m, 1H), 2.52–2.42 (m, 1H), 2.23–2.17 (m, 1H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 480.2. <b>18a</b> (peak 1, <i>R</i> or <i>S</i>, retention time at 4.45 min) and <b>18b</b> (peak 2, <i>R</i> or <i>S</i>, retention time at 7.41 min) were synthesized from <b>86</b> and <b>88</b> according to general method 1, <b>86</b> and <b>88</b> were obtained through chiral separation of <b>71</b>. The chiral separation and analysis conditions are shown in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Data of <b>18a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.73, 163.22, 156.88, 156.39, 149.58, 147.96, 142.89, 139.20, 131.87, 130.54, 130.14, 128.94, 128.81, 126.96, 123.76, 121.49, 118.96, 118.38, 117.07, 93.16, 57.34, 34.65, 29.74. HRMS: calcd for C<sub>28</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 480.2036, found 480.2043.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 7-(4-Acrylamidophenyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>19</b>)</h4><div class="NLM_p last">Synthesized from <b>72</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.14 (s, 1H), 7.60 (d, <i>J</i> = 8.4 Hz, 2H), 7.46 (d, <i>J</i> = 8.8 Hz, 2H), 7.40–7.32 (m, 2H), 7.12 (t, <i>J</i> = 7.6 Hz, 1H), 6.94–7.06 (m, 6H), 6.75 (s, 1H), 6.39 (dd, <i>J</i> = 10.1, 17.0 Hz, 1H), 6.21 (dd, <i>J</i> = 1.8, 17.0 Hz, 1H), 5.71 (dd, <i>J</i> = 1.8, 10.1 Hz, 1H), 5.41–5.36 (m, 1H), 3.27–3.22 (m, 1H), 3.07–2.97 (m, 1H), 2.37–2.24 (m, 1H), 2.08–1.95 (m, 1H). HRMS: calcd for C<sub>28</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 480.2036, found 480.2045.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 7-(2-Acrylamidophenyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>20</b>)</h4><div class="NLM_p last">Synthesized from <b>73</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1H), 7.50–7.32 (m, 5H), 7.26 (td, <i>J</i> = 1.2, 7.6 Hz, 1H), 7.21–7.08 (m, 2H), 7.04–6.98 (m, 4H), 6.79 (s, 1H), 6.60 (dd, <i>J</i> = 1.2, 7.6 Hz, 1H), 6.50 (dd, <i>J</i> = 10.2, 17.0 Hz, 1H), 6.24 (dd, <i>J</i> = 1.9, 17.0 Hz, 1H), 5.77–5.74 (m, 2H), 3.26–3.22 (m, 1H), 2.98–2.92 (m, 1H), 2.32–2.25 (m, 1H), 1.96–1.93 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.68, 164.08, 156.90, 156.36, 149.89, 148.07, 136.27, 134.00, 131.52, 130.45, 130.16, 128.69, 127.69, 127.17, 127.06, 126.73, 125.99, 123.79, 119.00, 118.33, 93.18, 53.55, 34.48, 27.35. HRMS: calcd for C<sub>28</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 480.2036, found 480.2042. <b>20a</b> (peak 1, <i>R</i> or <i>S</i>, retention time at 4.02 min) and <b>20b</b> (peak 2, <i>R</i> or <i>S</i>, retention time at 6.68 min) were synthesized from <b>85</b> and <b>87</b> according to general method 1 and , <b>85</b> and <b>87</b> were obtained through chiral separation of <b>73</b>. The chiral separation and analysis conditions are shown in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 7-(2-(<i>N</i>-Methylacrylamido)phenyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>21</b>)</h4><div class="NLM_p last">Synthesized from 7-(2-(methylamino)phenyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.45–7.37 (m, 6H), 7.29–7.24 (m, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 7.06–7.00 (m, 5H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 6.25–6.16 (m, 2H), 5.94–5.87 (m, 1H), 5.63–5.51 (m, 1H), 5.41–5.35 (m, 1H), 3.41–3.22 (m, 5H), 2.41–2.23 (m, 1H), 2.22–1.97 (m, 1H). HRMS: calcd for C<sub>29</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 494.2192, found 494.2188.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 7-(2-Acrylamidophenyl)-2-(4-(cyclopentyloxy)phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>22</b>)</h4><div class="NLM_p last">Synthesized from <b>92a</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.83 (s, 1H), 7.45 (d, <i>J</i> = 7.6 Hz, 1H), 7.37 (d, <i>J</i> = 8.8 Hz, 2H) 7.29 (t, <i>J</i> = 7.6 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.8 Hz, 2H), 6.81 (s, 1H), 6.64 (d, <i>J</i> = 7.6 Hz, 1H), 6.53 (dd, <i>J</i> = 10.2, 17.0 Hz, 1H), 6.27 (d, <i>J</i> = 17.0 Hz, 1H), 5.80–5.77 (m, 2H), 4.86–4.79 (m, 1H), 3.27–3.23 (m, 1H), 3.03–2.94 (m, 1H), 2.36–2.25 (m, 1H), 1.99–1.91 (m, 3H), 1.75–1.53 (m, 6H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 471.9. <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.73, 164.06, 157.80, 149.88, 148.48, 136.27, 134.00, 131.51, 130.02, 127.66, 127.12, 127.03, 126.74, 125.96, 125.49, 115.34, 93.01, 78.7653.46, 34.47, 32.33, 32.32, 27.35, 23.67. HRMS: calcd for C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 472.2349, found 472.2351.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 7-(2-Acrylamidophenyl)-2-(4-(cyclopropylmethoxy)phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>23</b>)</h4><div class="NLM_p last">Synthesized from <b>92b</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.83 (s, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 6.96 (d, <i>J</i> = 8.4 Hz, 2H), 6.81 (s, 1H), 6.64 (d, <i>J</i> = 8.0 Hz, 1H), 6.53 (dd, <i>J</i> = 10.2, 16.7 Hz, 1H), 6.27 (d, <i>J</i> = 16.7 Hz, 1H), 5.80–5.77 (m, 2H), 3.83 (d, <i>J</i> = 7.2 Hz, 2H), 3.27–3.23 (m, 1H), 3.03–2.93 (m, 1H), 2.36–2.25 (m, 1H), 2.02–1.91 (m, 1H), 1.23–1.14 (m, 1H), 0.59–0.53 (m, 2H), 0.34–0.29 (m, 2H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 457.9. <b>23a</b> (peak 1, <i>R</i> or <i>S</i>, retention time at 3.03 min in chiral analysis) and <b>23b</b> (peak 2, <i>S</i> or <i>R</i>, retention time at 3.82 min in chiral analysis) were obtained through chiral separation of <b>23</b>. The chiral separation and analysis conditions are shown in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Data of <b>23a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.73, 164.07, 158.79, 149.88, 148.48, 136.29, 134.00, 131.52, 130.04, 127.67, 127.15, 127.05, 126.74, 125.97, 125.70, 114.49, 93.03, 72.11, 53.46, 34.44, 27.33, 10.18, 3.15. HRMS: calcd for C<sub>26</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 458.2192, found 458.2196.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 7-(2-Acrylamidophenyl)-2-(4-(2-methoxyethoxy)phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>24</b>)</h4><div class="NLM_p last">Synthesized from <b>92c</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.83 (s, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.6, 2H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.6 Hz, 2H), 6.82 (s, 1H), 6.64 (d, <i>J</i> = 8.0 Hz, 1H), 6.53 (dd, <i>J</i> = 10.5, 17.0 Hz, 1H), 6.27 (dd, <i>J</i> = 1.7, 17.0 Hz, 1H), 5.80–5.77 (m, 2H), 4.11 (t, <i>J</i> = 4.4 Hz, 2H), 3.66 (t, <i>J</i> = 4.4 Hz, 2H), 3.30 (s, 3H), 3.27–3.23 (m, 1H), 3.03–2.94 (m, 1H), 2.36–2.25 (m, 1H), 2.01–1.95 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.57, 167.36, 160.93, 15177, 151.33, 137.75, 134.75, 131.68, 131.34, 129.21, 129.06, 128.14, 127.99, 127.95, 126.20, 115.77, 93.92, 71.94, 68.31, 59.05, 55.27, 35.48, 28.57. HRMS: calcd for C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup> 462.2141, found 462.2146.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 7-(2-Acrylamidophenyl)-2-(4-methoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Synthesized from <b>74</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (s, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.8 Hz, 2H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 6.98 (d, <i>J</i> = 8.8 Hz, 2H), 6.82 (s, 1H), 6.64 (d, <i>J</i> = 8.0 Hz, 1H), 6.53 (dd, <i>J</i> = 10.2, 17.0 Hz, 1H), 6.27 (dd, <i>J</i> = 1.8, 17.0 Hz, 1H), 5.82–5.74 (m, 2H), 3.77 (s, 3H), 3.31–3.19 (m, 1H), 3.03–2.91 (m, 1H), 2.38–2.24 (m, 1H), 2.02–1.92 (m, 1H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 417.9. <b>25a</b> (peak 1, <i>S</i> or <i>R</i>) and <b>25b</b> (peak 2, <i>R</i> or <i>S</i>) were obtained through chiral separation of <b>25</b>. Data of <b>25a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.74, 164.08, 159.39, 149.88, 148.46, 136.29, 134.00, 131.52, 130.07, 127.68, 127.15, 127.06, 126.74, 125.98, 125.88, 113.99, 93.04, 55.21, 53.47, 34.44, 27.33. HRMS: calcd for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 418.1879, found 418.1883.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 7-(2-Acrylamidophenyl)-2-(4-(trifluoromethoxy)phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Synthesized from <b>75</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (s, 1H), 7.65–7.60 (m, 2H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 2H), 7.33–7.27 (m, 1H), 7.23–7.18 (m, 1H), 6.79 (br s, 1H), 6.53 (dd, <i>J</i> = 10.0, 16.8 Hz, 1H), 6.27 (dd, <i>J</i> = 1.8, 16.8 Hz, 1H), 5.83–5.76 (m, 2H), 3.30–3.23 (m, 1H), 3.02–2.93 (m, 1H), 2.37–2.26 (m, 1H), 2.02–1.94 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.59, 164.10, 149.72, 148.20, 147.36, 136.21, 133.99, 132.98, 131.51, 130.50, 127.73, 127.07, 126.70, 126.01, 121.41, 120.84, 118.86, 93.58, 53.71, 34.49, 27.30. HRMS: calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 472.1596, found 472.1600.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 7-(2-Acrylamidophenyl)-2-(<i>p</i>-tolyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Synthesized from <b>76</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (s, 1H), 7.45 (d, <i>J</i> = 7.6 Hz, 1H), 7.36 (d, <i>J</i> = 8.0 Hz, 2H), 7.33–7.27 (m, 1H), 7.26–7.18 (m, 3H), 6.83 (s, 1H), 6.64 (d, <i>J</i> = 7.6 Hz, 1H), 6.53 (dd, <i>J</i> = 10.4, 16.8 Hz, 1H), 6.27 (dd, <i>J</i> = 1.8, 16.8 Hz, 1H), 5.81–5.76 (m, 2H), 3.31–3.24 (m, 1H), 3.02–2.93 (m, 1H), 2.36–2.26 (m, 1H), 2.33 (s, 3H), 2.02–1.94 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.66, 164.07, 149.89, 148.65, 137.82, 136.27, 13398, 131.52, 130.83, 129.13, 128.68, 127.68, 127.16, 127.04, 126.72, 125.98, 93.09, 53.50, 34.42, 27.31, 20.90. HRMS: calcd for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 402.1930, found 402.1928.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 7-(2-Acrylamidophenyl)-2-(4-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>28</b>)</h4><div class="NLM_p last">Synthesized from <b>77</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.86 (s, 1H), 7.76–7.70 (m, 4H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.34–7.28 (m, 1H), 7.24–7.18 (m, 1H), 6.79 (br s, 1H), 6.63 (dd, <i>J</i> = 0.8, 7.6 Hz, 1H), 6.53 (dd, <i>J</i> = 10.2, 17.0 Hz, 1H), 6.28 (dd, <i>J</i> = 2.0, 17.0 Hz, 1H), 5.84–5.76 (m, 2H), 3.32–3.23 (m, 1H), 3.02–2.93 (m, 1H), 2.37–2.26 (m, 1H), 2.02–1.94 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.53, 164.11, 149.70, 147.30, 137.79, 136.21, 133.98, 131.50, 129.22, 128.44, 128.12, 127.75, 127.26, 127.08, 126.68, 126.03, 125.17, 125.13, 93.81, 53.80, 34.47, 27.26. HRMS: calcd for C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 456.1647, found 456.1650.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 7-(2-Acrylamidophenyl)-2-(4-chlorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>29</b>)</h4><div class="NLM_p last">Synthesized from <b>78</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.83 (s, 1H), 7.48 (d, <i>J</i> = 8.6 Hz, 2H), 7.45–7.38 (m, 3H), 7.27 (t, <i>J</i> = 7.2 Hz, 1H), 7.17 (t, <i>J</i> = 7.2 Hz, 1H), 6.79 (s, 1H), 6.59 (d, <i>J</i> = 7.2 Hz, 1H), 6.50 (dd, <i>J</i> = 10.2, 17.0 Hz, 1H), 6.24 (dd, <i>J</i> = 1.8, 17.0 Hz, 1H), 5.79–5.67 (m, 2H), 3.26–3.18 (m, 1H), 2.99–2.89 (m, 1H), 2.35–2.20 (m, 1H), 1.99–1.88 (m, 1H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 421.8, 423.8. Compound <b>29</b> was separated into two enantiomeric stereoisomers <b>29a</b> (peak 1, <i>S</i> or <i>R</i>, retention time at 4.15 min in chiral analysis) and <b>29b</b> (peak 2, <i>R</i> or <i>S</i>, retention time at 10.52 min in chiral analysis) by chiral prep-HPLC (instrument, Agilent 1260 HPLC; column, CHIRALPAK AD-H; column size, 0.46 cm I.D. × 15 cm L, 5 μm; mobile phase, <i>n</i>-hexane/EtOH (0.1% triethyl amine) = 70/30 (v/v); column temperature, 35 °C; flow rate, 1.0 mL/min). Data of <b>29a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.59, 164.10, 149.77, 147.50, 136.24, 133.98, 132.90, 132.53, 131.50, 130.39, 128.41, 127.72, 127.22, 127.07, 126.70, 126.02, 93.45, 53.66, 34.46, 27.29. HRMS: calcd for C<sub>22</sub>H<sub>20</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 422.1384, found 422.1382.</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 7-(2-Acrylamidophenyl)-2-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>30</b>)</h4><div class="NLM_p last">Synthesized from <b>79</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.83 (s, 1H), 7.55–7.49 (m, 2H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.33–7.27 (m, 1H), 7.26–7.18 (m, 3H), 6.80 (br s, 1H), 6.64 (dd, <i>J</i> = 1.0, 8.0 Hz, 1H), 6.53 (dd, <i>J</i> = 10.0, 17.2 Hz, 1H), 6.27 (dd, <i>J</i> = 2.0, 17.2 Hz, 1H), 5.81–5.76 (m, 2H), 3.32–3.23 (m, 1H), 3.03–2.94 (m, 1H), 2.36–2.25 (m, 1H), 2.02–1.94 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.62, 164.09, 163.35, 160.92, 149.79, 147.71, 136.25, 134.00, 131.51, 130.82 and 130.74, 130.10 and 130.07, 127.70, 127.19 and 127.06, 126.72, 126.00, 115.44 and 115.23, 93.36, 53.59, 34.47, 27.32. HRMS: calcd for C<sub>22</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 406.1679, found 406.1682.</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>31</b>)</h4><div class="NLM_p last">Synthesized from <b>80</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50 (d, <i>J</i> = 8.8 Hz, 2H), 7.46–7.38 (m, 2H), 7.17 (t, <i>J</i> = 7.6 Hz, 1H), 7.08 (d, <i>J</i> = 7.6 Hz, 2H), 7.05 (d, <i>J</i> = 8.8 Hz, 2H), 6.83–6.76 (m, 1H), 6.68 (br s, 1H), 6.07 (d, <i>J</i> = 18.4 Hz, 1H), 5.64 (d, <i>J</i> = 10.4 Hz, 1H), 4.52–4.42 (m, 1H), 4.11–3.98 (m, 2H), 3.33–3.24 (m, 2H), 3.04–2.94 (m, 1H), 2.67–2.55 (m, 1H), 2.33–2.25 (m, 1H), 2.01–1.93 (m, 2H), 1.78–1.66 (m, 1H), 1.61–1.50 (m, 1H), 1.30–1.18 (m, 2H). HRMS: calcd for C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 472.2349, found 472.2346. Compound <b>31</b> was separated into two enantiomeric stereoisomers, <b>31a</b> (peak 1, <i>S</i>, retention time at 6.49 min in chiral analysis) and <b>31b</b> (peak 2, <i>R</i>, retention time at 8.03 min in chiral analysis), by chiral prep-HPLC (column, CHIRALPAK IC; column size, 2 cm × 25 cm; mobile phase, MeOH/ACN = 60/40; flow rate, 15 mL/min; wavelength, UV 254 nm). Data of <b>31a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.69, 164.12, 156.86, 156.40, 149.03 and 148.91, 147.10, 130.56, 130.15, 129.00, 128.63, 126.91, 123.77, 118.98, 118.41, 93.27, 57.56, 45.18, 41.68 and 41.48, 38.81, 36.36 and 36.14, 29.77 and 28.44, 27.67 and 26.72, 22.65, and 22.56. HRMS: calcd for C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 472.2349, found 472.2355.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 7-(1-Acryloylazetidin-3-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>32</b>)</h4><div class="NLM_p last">Synthesized from <b>81</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.44–7.40 (m, 2H), 7.20–7.15 (m, 1H), 7.10–7.04 (m, 4H), 6.69 (br s, 1H), 6.37–6.26 (m, 1H), 6.12–6.04 (m, 1H), 5.68–560 (m, 1H), 4.43–4.25 (m, 2H), 4.18–4.08 (m, 1H), 4.04–3.96 (m, 1H), 3.86–3.80 (m, 1H), 3.32–3.26 (m, 2H), 3.02–2.92 (m, 1H), 2.14–2.06 (m, 1H), 1.79–1.70 (m, 1H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 444.0. Compound <b>32</b> was separated into two enantiomeric stereoisomers, <b>32a</b> (peak 1, <i>R</i> or <i>S</i>, retention time at 10.54 min in chiral analysis) and <b>32b</b> (peak 2, <i>S</i> or <i>R</i>, retention time at 13.98 min in chiral analysis), by chiral prep-HPLC. The chiral separation conditions are shown in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Data of <b>32a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.60, 164.58, 156.95 and 156.88, 156.38 and 156.34, 148.72 and 148.60, 147.52 and 147.50, 130.51 and 130.43, 130.16, 128.85, 127.11 and 126.96, 126.30 and 126.25, 123.82 and 123.77, 119.06 and 118.99, 118.39 and 118.34, 93.36 and 93.31, 56.36 and 56.00, 54.36 and 51.80, 51.69 and 49.49, 36.23 and 36.16, 33.09 and 32.95, 24.23, and 24.12. HRMS: calcd for C<sub>25</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 444.2036, found 444.2035.</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 7-(Acrylamidomethyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">Synthesized from <b>82</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (t, <i>J</i> = 6.0 Hz, 1H), 7.52 (d, <i>J</i> = 8.8 Hz, 2H), 7.45–7.39 (m, 2H), 7.17 (t, <i>J</i> = 7.6 Hz, 1H), 7.11–7.03 (m, 4H), 6.69 (s, 1H), 6.63 (d, <i>J</i> = 7.2 Hz, 1H), 6.26 (dd, <i>J</i> = 10.1, 17.0 Hz, 1H), 6.11 (dd, <i>J</i> = 1.9, 17.0 Hz, 1H), 5.62 (dd, <i>J</i> = 1.9, 10.1 Hz, 1H), 4.22–4.12 (m, 1H), 3.95–3.76 (m, 1H), 3.45–3.25 (m, 3H), 2.07–1.87 (m, 2H). MS (ESI) <i>m</i>/<i>e</i> [M + H]<sup>+</sup> 417.9. Compound <b>33</b> was separated into two enantiomeric stereoisomers, <b>33a</b> (peak 1, <i>R</i> or <i>S</i>, retention time at 6.04 min in chiral analysis) and <b>33b</b> (peak 2, <i>S</i> or <i>R</i>, retention time at 8.87 min in chiral analysis), by chiral prep-HPLC. The chiral separation conditions are shown in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Data of <b>33a</b>: <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 165.62, 165.09, 156.94, 156.38, 148.98, 147.69, 131.60, 130.17, 128.88, 125.63, 123.81, 119.04, 118.35, 93.47, 53.29, 41.43, 35.53, 23.68. HRMS: calcd for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 418.1879, found 418.1875.</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 7-(1-Acrylamidocyclopropyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>34</b>)</h4><div class="NLM_p last">Synthesized from <b>83</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 2H), 7.46–7.38 (m, 2H), 7.21–7.15 (m, 1H), 7.11–7.04 (m, 4H), 6.75 (s, 1H), 6.21 (dd, <i>J</i> = 9.9, 17.1 Hz, 1H), 6.09 (dd, <i>J</i> = 2.4, 17.1 Hz, 1H), 5.58 (dd, <i>J</i> = 2.4, 9.9 Hz, 1H), 4.36–4.30 (m, 1H), 3.44–3.35 (m, 2H), 2.31–2.19 (m, 1H), 1.96–1.82 (m, 1H), 1.08–1.00 (m, 1H), 0.81–0.73 (m, 1H), 0.72–0.59 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.68, 165.44, 156.91, 156.38, 149.06, 147.48, 131.80, 130.58, 130.16, 128.88, 125.64, 123.80, 119.02, 118.36, 92.66, 56.03, 35.43, 34.00, 23.51, 11.20, 10.46. HRMS: calcd for C<sub>25</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 444.2036, found 444.2027.</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 7-(2-Acrylamidopropan-2-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide (<b>35</b>)</h4><div class="NLM_p last">Synthesized from <b>84</b> according to general method 1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06 (s, 1H), 7.53 (d, <i>J</i> = 8.6 Hz, 2H), 7.46–7.37 (m, 2H), 7.17 (t, <i>J</i> = 8.0 Hz, 1H), 7.08 (d, <i>J</i> = 8.0 Hz, 2H), 7.06 (d, <i>J</i> = 8.6 Hz, 2H), 6.78 (s, 1H), 6.28 (dd, <i>J</i> = 10.1, 17.1 Hz, 1H), 6.06 (dd, <i>J</i> = 1.6, 17.1 Hz, 1H), 5.56 (dd, <i>J</i> = 1.6, 10.1 Hz, 1H), 4.80 (t, <i>J</i> = 5.4 Hz, 1H), 3.32–3.26 (m, 2H), 2.11–1.82 (m, 2H), 1.49 (s, 3H), 1.19 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.76, 164.39, 156.92, 156.37, 149.97, 147.19, 132.64, 130.51, 130.16, 128.85, 124.87, 123.80, 119.03, 118.36, 92.79, 57.95, 56.94, 36.63, 25.43, 23.58, 22.83. HRMS: calcd for C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 446.2192, found 446.2180.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Biology</h3><div id="sec6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Protein Expression and Purification of BTK</h4><div class="NLM_p last">The gene encoding residues 393–659 of human BTK was cloned into the baculovirus expression vector pFastBac1 with His tag fused to its N terminus. High-titer virus stocks were used for protein expression in Sf9 cells. After 2 days post-transfection, the cells were harvested and lysed by sonication. After centrifugation, the supernatant was purified with Ni-NTA resin, and the His tag was removed by TEV protease. The cleaved protein was then passed through Ni–NTA resin, and the flow-through was collected and applied onto a HiLoad 16/600 Superdex 200 pg gel-filtration column (GE Healthcare) in buffer containing 25 mM Tris–HCl pH 7.5, 150 mM NaCl. The peak fraction was collected and concentrated to 8 mg/mL for cocrystallization.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Experimental Protocols for Biochemical Kinase Selectivity of <b>31a</b></h4><div id="sec6_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <sup>33</sup>P-ATP and Filter-Binding Assay</h5><div class="NLM_p last">The percentage inhibition of <b>31a</b> on a full-panel of 342 kinases and the IC<sub>50</sub> values of <b>31a</b> against some related kinases were determined by Reaction Biology Corp. using <sup>33</sup>P-ATP and filter-binding assay. Briefly, specific kinase/substrate pairs along with required cofactors were prepared in reaction buffer. Compounds were delivered into the reaction, followed 15–20 min (60 min for IC<sub>50</sub> determination) later by addition of a mixture of ATP (Sigma, St. Louis MO) and <sup>33</sup>P ATP (PerkinElmer, Waltham MA) to a final concentration of 1 μM. Reactions were carried out at room temperature for 120 min, followed by spotting of the reactions onto P81 ion exchange filter paper (Whatman Inc., Piscataway, NJ). Unbound phosphate was removed by extensive washing of filters in 0.75% phosphoric acid. After subtraction of background derived from control reactions containing inactive enzyme, kinase activity data was expressed as the percent of remaining kinase activity in test samples compared to vehicle (dimethyl sulfoxide) reactions. IC<sub>50</sub> values and curve fits were obtained using Prism (GraphPad Software).</div></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> BTK Biochemical Assay</h5><div class="NLM_p last">Recombinant BTK was preincubated with the compounds at room temperature for 1 h in an assay buffer containing 50 mM Tris pH 7.4, 10 mM MgCl<sub>2</sub>, 2 mM MnCl<sub>2</sub>, 0.1 mM EDTA, 1 mM DTT, 20 nM SEB, 0.1% BSA, 0.005% tween-20. The reactions were initiated by the addition of ATP (at the concentration of ATP Km) and peptide substrate (Biotin-AVLESEEELYSSARQ-NH<sub>2</sub>). After incubating at room temperature for 1 h, an equal volume of stop solution containing 50 mM HEPES pH 7.0, 800 mM KF, 20 mM EDTA, 0.1% BSA, Eu cryptate-conjugated p-Tyr66 antibody, and streptavidin-labeled XL665 was added to stop the reaction. Plates were further incubated at room temperature for 1 h, and then the TR-FRET signals were read on BMG PHERAstar FS instrument.</div></div><div id="sec6_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> ITK/TEC/JAK3/EGFR/HER2 Biochemical Assay</h5><div class="NLM_p last">These enzymatic assays were all carried out in the time-resolved fluorescence resonance energy transfer method similar to BTK biochemical assay.</div></div><div id="sec6_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> BTK pY223 Cellular Assay</h5><div class="NLM_p last">BTK pY223 cellular assay was an HTRF-based assay (Cisbio) conducted in Ramos cells to quantitatively determine the inhibition of phosphorylation at BTK Tyr-223. The phosphorylation is necessary for full activation of BTK. Briefly, Ramos cells were serum starved for overnight following the compound treatment at various concentrations for 3 h. After the treatment, cells were stimulated with 1 mM pervanadate (PV) or Na<sub>3</sub>VO<sub>4</sub> (OV) for 20 min, then lysed. Then 18 μL of each cell lysate was mixed with 2 μL of 1× antibody mixture prepared by diluting anti-BTK-d2 and anti-pBTK-K in detection buffer. After mixing gently and spinning briefly, the plate was sealed up and kept in the dark overnight. The fluorescence emission was measured at two different wavelengths (665 and 620 nm) on a compatible HTRF reader (PHERAstar FS, BMG). The potency of compounds was calculated based on the inhibition ratio between signal intensities at 665 and 620 nm.</div></div><div id="sec6_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Rec-1 and OCI-LY10 Cell Viability Assay</h5><div class="NLM_p last">The growth inhibitory activity of compounds in Rec-1 and OCI-LY10 cells was determined using CellTiter-Glo luminescent cell viability assay (Promega). Cells were treated with increasing concentrations of compounds. Following a 6-day exposure to the compounds, a volume of Cell Titer-Glo reagent equal to the volume of cell culture medium present in each well was added. Mixture was mixed on an orbital shaker for 2 min to allow cell lysis, followed by 10 min incubation to allow development and stabilization of luminescent signal, which corresponded to quantity of ATP and thus the quantity of metabolically active cells. Luminescent signal was measured using PHERAstar FS reader (BMG Labtech). IC<sub>50</sub> values for cell viability were determined with GraphPad Prism software.</div></div><div id="sec6_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> EGFR pY1068 Cellular Assay</h5><div class="NLM_p last">A HTRF-based assay (64EG1PEH, Cisbio) was used to detect activation of EGFR when phosphorylated on Tyr1068 in A431 cells. Briefly, cells were treated with indicated concentrations of compounds for 1 h. After that, the cells were stimulated with 100 ng/mL of recombined human EGF for 10 min. Cells were then lysed and mixed with 4 μL of detection solution (anti-EGFR-D2 and anti-EGFRpY1068-Eu3+crypate). The fluorescence emission was measured at two different wavelengths (665 and 620 nm) on a compatible HTRF reader (PHERAstar FS, BMG). The potency of compounds was calculated basing on the inhibition of ratio between signal intensities at 665 and 620 nm. IC<sub>50</sub> values were calculated with GraphPad Prism software using the sigmoidal dose–response function and were the means of two independent experiments.</div></div><div id="sec6_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> ITK pPLCγ<sub>1</sub> Assay</h5><div class="NLM_p last">Jurkat cells were treated with increasing amounts of compounds for 2 h. After the treatment, cells were exposed to 10 mM of hydrogen peroxide for 10 min. The cells were then lysed for Western blot with antibodies detecting total PLCγ<sub>1</sub> and <i>p</i>-PLCγ<sub>1</sub> (Y783), respectively. Inhibition of PLCγ<sub>1</sub> phosphorylation by compounds was calculated basing on band intensity and were the means of two independent experiments.</div></div><div id="sec6_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> TEC <i>p</i>-TEC Assay</h5><div class="NLM_p last">TEC overexpressing HEK293 cells were starved in the serum free medium for overnight before the compound treatment. The cells were then treated with increasing amounts of compounds in 80 μL of medium for 3 h then stimulated with 1 mM pervanadate for 20 min. 40 μL of the cell lysates were loaded on the MULTI-ARRAY 96-well plate (Meso Scale Discovery (MSD), catalogue no. L15XA-3/L11XA-3) coated with anti-TEC antibody (Abcam, catalogue no. ab211748). After binding and washing, the phosphorylated TEC was detected with detection antibody (Sulf-tag anti-PY20 antibody, MSD; catalogue no. R32AP-5). The data were collected on MESO Sector S 600. The IC<sub>50</sub> values were calculated with GraphPad Prism software. The averages were further calculated based on five independent experiments.</div></div><div id="sec6_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Cocrystallization, Data Collection, and Structural Determination of BTK with <b>31a</b></h5><div class="NLM_p last">BTK was incubated with <b>31a</b> for 1 h on ice, and the mixture was carried out for initial crystal screening experiments at 293 K by sitting-drop vapor diffusion. The crystals were obtained in the condition consisting of 0.1 M MIB buffer pH 7, 25% (w/v) PEG 1500. Crystals were soaked in a cryoprotectant solution consisting of reservoir solution supplemented with 20% (v/v) glycerol for several seconds. Diffraction data were collected at beamline BL19U1 at Shanghai Synchrotron Radiation Facility and processed using the XDS program.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Molecular replacement was carried out with Phaser<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> using the BTK crystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>) as search model. Phenix.refine<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> was used to perform rigid body, TLS, restrained refinement against X-ray data. Manually adjustment was performed in COOT program<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and further refinement in the Phenix.refine program.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec6_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Pharmacokinetics and Pharmacodynamics Study</h5><div class="NLM_p last">Female ICR mice with 4–5 weeks of age were purchased from Beijing HFK Bioscience Co., Ltd. Mice were randomly assigned with four mice per group. Treatments were administered by oral gavage (po) in a volume of 10 mL/kg body weight. For pharmacodynamics study, mouse whole blood and spleen were collected at 4 h post drug treatment. The 96-well plate was coated with neutravidin (5 μg/mL, 100 μL per well, Invitrogen, catalogue no. A-2666) and incubated with a biotinylated probe <b>P</b>-<b>1</b> (for <b>31a</b>, preparation see <a class="ref internalNav" href="#notes-1" aria-label="p S44 in Supporting Information">p S44 in Supporting Information</a>) or <b>P</b>-<b>2</b> (for other compounds, preparation see <a class="ref internalNav" href="#notes-1" aria-label="p S48 in Supporting Information">p S48 in Supporting Information</a>) (10 μM, 100 μL per well). Cell lysates of PBMC and splenocytes or recombinant human BTK protein samples were added, and the plates were incubated at 4 °C overnight. Primary anti-BTK rabbit polyclonal antibody (Novus, no. 26560002, diluted 1:1,000 in blocking buffer) was added and incubated for 3 h, and secondary antirabbit-HRP antibody (Cell signaling, no. 7074, diluted 1:5,000 in blocking buffer) was added and incubated for 1.5 h. Following standard ELISA protocols using TMB as substrate, OD450 nm was read using microplate reader (BMGlabtech, PHERAstar FS). For pharmacokinetics study, blood samples were collected from the retro-orbital sinus under isoflurane/oxygen anesthesia at the indicated time points. Plasma was collected by centrifugation at 3000<i>g</i> for 10 min. Bioanalysis was conducted at 3D BioOptima Co., Ltd. (Suzhou, China). After protein precipitation with methanol:acetonitrile (1:1, v/v) containing an internal standard and centrifugation at 14000 rpm for 8 min, compound levels in plasma were determined by LC-MS/MS (Applied Biosystems, API 4000-Qtrap).</div></div><div id="sec6_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Tumor Xenografts</h5><div class="NLM_p last">NCG mice were from GemPharmatech Co., Ltd. Animals were inoculated with tumor cells in the right flank. When the tumors were palpable, animals were randomly assigned into each group. Treatments were administered by oral gavage (po) in a volume of 10 mL/kg body weight. Tumor volume was measured twice weekly in two dimensions using a caliper. One individual was responsible for tumor measurement for the entire duration of the study. Body weights were recorded twice weekly. Mice were also being monitored daily for clinical signs of toxicity for the duration of the study. All experiments were conducted based on the protocols approved by the Animal Care and Use Committee of BeiGene according to the guidelines of the Chinese Association for Laboratory Animal Sciences.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00687" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00687" class="ext-link">10.1021/acs.jmedchem.9b00687</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Biochemical and cellular assay data for <b>I</b>-<b>2</b> and <b>I</b>-<b>3</b>; evaluation of the BTK occupancy capability of studied compounds in mouse; fast dilution and protein precipitation experiment for <b>13</b>/<b>16</b>/<b>31a</b>; serine mutant assay for <b>13</b> and <b>16</b>; biochemical data for <b>20</b>-<b>int</b> and <b>21</b>-<b>int</b>; In vitro data of <b>20a</b>, <b>23a</b>, <b>25a</b>, and <b>29a</b>; second-order rate constants (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) for <b>31a</b>, <b>31b</b>, and ibrutinib; cellular toxicity evaluation of <b>31a</b>; cocrystal of <b>31a</b> with BTK; single crystal structure determination; kinase panel screen; experimental data for two probes (<b>P</b>-<b>1</b> and <b>P</b>-<b>2</b>) and intermediates (<b>37a</b>, <b>37c</b>, <b>38a</b>, <b>39a</b>, <b>39c</b>, <b>41</b>, <b>42</b>, <b>44a</b>, <b>45a</b>, <b>48b</b>, <b>49a</b>, <b>49b</b>, <b>57</b>, <b>68</b>, <b>71</b>, <b>73</b>, <b>76</b>, <b>78</b>, <b>81</b>, <b>82</b>, <b>87</b>, <b>89</b>, <b>90</b>, <b>91b</b>, <b>92a</b>–<b>c</b>); PK conditions (PK study in rats, plasma protein binding, microsome intrinsic clearance, and cytochrome P450 inhibition) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings list (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Crystallographic information file for <b>BGB-3111</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_003.cif" class="ext-link">CIF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_001.pdf">jm9b00687_si_001.pdf (2.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_002.csv">jm9b00687_si_002.csv (9.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_003.cif">jm9b00687_si_003.cif (423.29 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The crystallographic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a> for BTK-BGB-3111)</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00687" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53036" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53036" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiwei Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8792-9573" title="Orcid link">http://orcid.org/0000-0001-8792-9573</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84feecedf3e1edaaf3e5eae3c4e6e1ede3e1eae1aae7ebe9"><span class="__cf_email__" data-cfemail="fc8694958b9995d28b9d929bbc9e99959b999299d29f9391">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunhang Guo</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3980-0673" title="Orcid link">http://orcid.org/0000-0003-3980-0673</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ye Liu</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nan Hu</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Desheng Yu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changyou Zhou</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gongyin Shi</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Zhang</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Wei</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junhua Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lusong Luo</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyu Tang</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huipeng Song</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yin Guo</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuesong Liu</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Su</span> - <span class="hlFld-Affiliation affiliation">Department of DMPK, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuo Zhang</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaomin Song</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xing Zhou</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Hong</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuaishuai Chen</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenzhen Cheng</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steve Young</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiang Wei</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haisheng Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuwen Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Lv</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fan Wang</span> - <span class="hlFld-Affiliation affiliation">Department of DMPK, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haipeng Xu</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanzi Sun</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haimei Xing</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Na Li</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhongbo Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guodong Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhijian Sun</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongping Zhou</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Biology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Libin Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lai Wang</span> - <span class="hlFld-Affiliation affiliation">Department of In
Vivo Pharmacology, , , , , BeiGene (Beijing) Co.,
Ltd, No. 30 Science Park Road, Zhong-Guan-Cun Life Sciences Park, Changping
District, Beijing 102206, P.R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6702-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the contribution to this work of all past and present members of the BTK team. We also thank all supporting functions including the compound management team, Yanli Wang, Hongxia Liu, and their team (analytical group), Xiaofeng Luo (NMR), and Han Dai (cellular data analysis). This work was supported by grant from the National Science and Technology Major Project for Drug Innovation (no. SQ2017ZX090306004).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">XLA</td><td class="NLM_def"><p class="first last">X-linked agammaglobulinemia</p></td></tr><tr><td class="NLM_term">XID</td><td class="NLM_def"><p class="first last">X-linked immunodeficiency</p></td></tr><tr><td class="NLM_term">FcR</td><td class="NLM_def"><p class="first last">Fc receptors</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">WM</td><td class="NLM_def"><p class="first last">Waldenström’s macroglobulinemia</p></td></tr><tr><td class="NLM_term">cGVHD</td><td class="NLM_def"><p class="first last">chronic graft versus host disease</p></td></tr><tr><td class="NLM_term">wt</td><td class="NLM_def"><p class="first last">wild type</p></td></tr><tr><td class="NLM_term">GPVI</td><td class="NLM_def"><p class="first last">glycoprotein VI</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">brine</td><td class="NLM_def"><p class="first last">saturated aqueous sodium chloride solution</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>O<sub>2</sub></td><td class="NLM_def"><p class="first last">hydrogen peroxide solution 30% (w/w) in H<sub>2</sub>O</p></td></tr><tr><td class="NLM_term">Pd/C</td><td class="NLM_def"><p class="first last">palladium on carbon powder</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">Pre-TLC</td><td class="NLM_def"><p class="first last">prepared thin-layer chromatography</p></td></tr><tr><td class="NLM_term">sat.</td><td class="NLM_def"><p class="first last">saturated</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vořechovský, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarström, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. R.</span></span> <span> </span><span class="NLM_article-title">The Gene Involved in X-linked Agammaglobulinaemia is a Member of the Src Family of Protein-tyrosine Kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/361226a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2F361226a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=8380905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=226-233&author=D.+Vetrieauthor=I.+Vo%C5%99echovsk%C3%BDauthor=P.+Siderasauthor=J.+Hollandauthor=A.+Daviesauthor=F.+Flinterauthor=L.+Hammarstr%C3%B6mauthor=C.+Kinnonauthor=R.+Levinskyauthor=M.+Bobrowauthor=C.+I.+E.+Smithauthor=D.+R.+Bentley&title=The+Gene+Involved+in+X-linked+Agammaglobulinaemia+is+a+Member+of+the+Src+Family+of+Protein-tyrosine+Kinases&doi=10.1038%2F361226a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases</span></div><div class="casAuthors">Vetrie, David; Vorechovsky, Igor; Sideras, Paschalis; Holland, Jill; Davies, Angela; Flinter, Frances; Hammarstroem, Lennart; Kinnon, Christine; Levinsky, Roland; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6409</span>),
    <span class="NLM_cas:pages">226-33</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by failure of pre-B cells in the bone marrow to develop into circulating mature B cells.  A novel gene (atk) has been isolated which maps to the XLA locus, is expressed in B cells, and shows mutations in families with the disorder.  The gene is a member of the src family of protooncogenes which encode protein-tyrosine kinases.  This is, to the authors knowledge, the first evidence that mutations in a src-related gene are involved in human genetic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGa0C4aUVMrVg90H21EOLACvtfcHk0ljDZhZ1g8OdDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D&md5=de1b23e0c0328d916633d0f92ddc1d68</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2F361226a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F361226a0%26sid%3Dliteratum%253Aachs%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DVo%25C5%2599echovsk%25C3%25BD%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DFlinter%26aufirst%3DF.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLevinsky%26aufirst%3DR.%26aulast%3DBobrow%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DBentley%26aufirst%3DD.%2BR.%26atitle%3DThe%2520Gene%2520Involved%2520in%2520X-linked%2520Agammaglobulinaemia%2520is%2520a%2520Member%2520of%2520the%2520Src%2520Family%2520of%2520Protein-tyrosine%2520Kinases%26jtitle%3DNature%26date%3D1993%26volume%3D361%26spage%3D226%26epage%3D233%26doi%3D10.1038%2F361226a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Src, Syk, and Tec Family Kinases: Distinct Types of Molecular Switches</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2010.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.cellsig.2010.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20206686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=1175-1184&author=J.+M.+Bradshaw&title=The+Src%2C+Syk%2C+and+Tec+Family+Kinases%3A+Distinct+Types+of+Molecular+Switches&doi=10.1016%2Fj.cellsig.2010.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The Src, Syk, and Tec family kinases: Distinct types of molecular switches</span></div><div class="casAuthors">Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The Src, Syk, and Tec family kinases are three of the most well characterized tyrosine kinase families found in the human genome.  Members of these kinase families function downstream of antigen and Fc receptors in hematopoietic cells and transduce signals leading to calcium mobilization, altered gene expression, cytokine prodn., and cell proliferation.  Over the last several years, structural and biochem. studies have begun to uncover the mol. mechanisms regulating activation of these kinases.  It appears that each kinase family functions as a distinct type of mol. switch.  This review discusses the activation of the Src, Syk, and Tec kinases from the perspective of structure, phosphorylation, allosteric regulation, and kinetics.  The multiple factors that regulate the Src, Syk, and Tec families illustrate the important role played by each of these kinases in immune cell signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PA9QDCCGPLVg90H21EOLACvtfcHk0lhr_RFC-1cNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D&md5=7f562f792a04682d05aa32dc09a7cb6e</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Src%252C%2520Syk%252C%2520and%2520Tec%2520Family%2520Kinases%253A%2520Distinct%2520Types%2520of%2520Molecular%2520Switches%26jtitle%3DCell.%2520Signalling%26date%3D2010%26volume%3D22%26spage%3D1175%26epage%3D1184%26doi%3D10.1016%2Fj.cellsig.2010.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humire-Greiff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniar, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjellén, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarström, L.</span></span> <span> </span><span class="NLM_article-title">Expression of Bruton’s Agammaglobulinemia Tyrosine Kinase Gene, Btk, is Selectively Down-regulated in T Lymphocytes and Plasma Cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=8283037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=557-565&author=C.+I.+Smithauthor=B.+Baskinauthor=B.+Humire-Greiffauthor=J.+N.+Zhouauthor=P.+G.+Olssonauthor=H.+S.+Maniarauthor=P.+Kjell%C3%A9nauthor=J.+D.+Lambrisauthor=B.+Christenssonauthor=L.+Hammarstr%C3%B6m&title=Expression+of+Bruton%E2%80%99s+Agammaglobulinemia+Tyrosine+Kinase+Gene%2C+Btk%2C+is+Selectively+Down-regulated+in+T+Lymphocytes+and+Plasma+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span></div><div class="casAuthors">Smith, C. I. Edvard; Baskin, Berivan; Humire-Greiff, Patricia; Zhou, Jian Nian; Olsson, Per G.; Maniar, Hina S.; Kjellen, Peter; Lambris, John D.; Christensson, Birger; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">557-65</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">The gene mutated in the human disease, X-linked agammaglobulinemia (XLA), is related to the Src gene family of cytoplasmic protein-tyrosine kinases and is designated Btk (Bruton's agammaglobulinemia tyrosine kinase; formerly Atk/Bpk; the human gene is denoted BTK, using capital letters according to the kinase nomenclature).  The authors have recently reported that this gene is expressed in B lymphocytes and that the specific mRNA was undetectable in T cells using Northern blotting.  Further analyses of different sources of B and T lymphocytes confirmed this pattern.  However, BTK transcripts were undetectable in four plasmacytoma lines.  Moreover, as virtually normal amts. of BTK transcripts were found in PBMC from two patients carrying a point mutation in BTK, despite low B cell nos., the authors anticipated that the gene would also be expressed in cells of other lineages.  The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.  BTK mRNA was also detected in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1.  A similar expression pattern was obtained when BTK protein was analyzed by immunopptn. and Western blotting.  Using a polymerase chain reaction-based anal., a small amt. (less than 1% of the level in B cells) of BTK mRNA was identified in T lymphocytes.  The authors' findings are compatible with a general expression of the BTK gene in hematopoietic cells, except in T lymphocytes and plasma cells, in which the transcript level is selectively down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKw_P8osJHjLVg90H21EOLACvtfcHk0lhr_RFC-1cNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D&md5=c18d78dc39ed08bd0c1fb784cbf549a1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHumire-Greiff%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DJ.%2BN.%26aulast%3DOlsson%26aufirst%3DP.%2BG.%26aulast%3DManiar%26aufirst%3DH.%2BS.%26aulast%3DKjell%25C3%25A9n%26aufirst%3DP.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520Agammaglobulinemia%2520Tyrosine%2520Kinase%2520Gene%252C%2520Btk%252C%2520is%2520Selectively%2520Down-regulated%2520in%2520T%2520Lymphocytes%2520and%2520Plasma%2520Cells%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbs, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustan-Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span> <span> </span><span class="NLM_article-title">Primary B Cell Immunodeficiencies: Comparisons and Contrasts</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1146%2Fannurev.immunol.021908.132649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=19302039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=199-227&author=M.+E.+Conleyauthor=A.+K.+Dobbsauthor=D.+M.+Farmerauthor=S.+Kilicauthor=K.+Parisauthor=S.+Grigoriadouauthor=E.+Coustan-Smithauthor=V.+Howardauthor=D.+Campana&title=Primary+B+Cell+Immunodeficiencies%3A+Comparisons+and+Contrasts&doi=10.1146%2Fannurev.immunol.021908.132649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Primary B cell immunodeficiencies: comparisons and contrasts</span></div><div class="casAuthors">Conley, Mary Ellen; Dobbs, A. Kerry; Farmer, Dana M.; Kilic, Sebnem; Paris, Kenneth; Grigoriadou, Sofia; Coustan-Smith, Elaine; Howard, Vanessa; Campana, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199-227</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Sophisticated genetic tools have made possible the identification of the genes responsible for most well-described immunodeficiencies in the past 15 years.  Mutations in Btk, components of the pre-B cell and B cell receptor (λ5, Igα, Igβ), or the scaffold protein BLNK account for approx. 90% of patients with defects in early B cell development.  Hyper-IgM syndromes result from mutations in CD40 ligand, CD40, AID, or UNG in 70-80% of affected patients.  Rare defects in ICOS or CD19 can result in a clin. picture that is consistent with common variable immunodeficiency, and as many as 10% of patients with this disorder have heterozygous amino acid substitutions in TACI.  For all these disorders, there is considerable clin. heterogeneity in patients with the same mutation.  Identifying the genetic and environmental factors that influence the clin. phenotype may enhance patient care and the understanding of normal B cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hgfd2bSrJ7Vg90H21EOLACvtfcHk0lhr_RFC-1cNcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D&md5=83216a7a297af38c2efdf9d3e79a1213</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132649%26sid%3Dliteratum%253Aachs%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DDobbs%26aufirst%3DA.%2BK.%26aulast%3DFarmer%26aufirst%3DD.%2BM.%26aulast%3DKilic%26aufirst%3DS.%26aulast%3DParis%26aufirst%3DK.%26aulast%3DGrigoriadou%26aufirst%3DS.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DCampana%26aufirst%3DD.%26atitle%3DPrimary%2520B%2520Cell%2520Immunodeficiencies%253A%2520Comparisons%2520and%2520Contrasts%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D199%26epage%3D227%26doi%3D10.1146%2Fannurev.immunol.021908.132649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kersseboom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flierman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Zee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middendorp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Bruton’s Tyrosine Kinase Induces the Formation of Autoreactive Igm Plasma Cells</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2643</span>– <span class="NLM_lpage">2654</span>, <span class="refDoi"> DOI: 10.1002/eji.201040521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1002%2Feji.201040521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20623551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2gurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=2643-2654&author=R.+Kersseboomauthor=L.+Kilauthor=R.+Fliermanauthor=M.+van+der+Zeeauthor=G.+M.+Dingjanauthor=S.+Middendorpauthor=A.+Maasauthor=R.+W.+Hendriks&title=Constitutive+Activation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Induces+the+Formation+of+Autoreactive+Igm+Plasma+Cells&doi=10.1002%2Feji.201040521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells</span></div><div class="casAuthors">Kersseboom, Rogier; Kil, Laurens; Flierman, Roelof; van der Zee, Marten; Dingjan, Gemma M.; Middendorp, Sabine; Maas, Alex; Hendriks, Rudi W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2643-2654</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">B-cell receptor (BCR)-mediated signals provide the basis for B-cell differentiation in the BM and subsequently into follicular, marginal zone, or B-1 B-cell subsets.  We have previously shown that B-cell-specific expression of the constitutive active E41K mutant of the BCR-assocd. mol. Bruton's tyrosine kinase (Btk) leads to an almost complete deletion of immature B cells in the BM.  Here, we report that low-level expression of the E41K or E41K-Y223F Btk mutants was assocd. with reduced follicular B-cell nos. and significantly increased proportions of B-1 cells in the spleen.  Crosses with 3-83μδ and VH81X BCR Tg mice showed that constitutive active Btk expression did not change follicular, marginal zone, or B-1 B-cell fate choice, but resulted in selective expansion or survival of B-1 cells.  Residual B cells were hyperresponsive and manifested sustained Ca2+ mobilization.  They were spontaneously driven into germinal center-independent plasma cell differentiation, as evidenced by increased nos. of IgM+ plasma cells in spleen and BM and significantly elevated serum IgM.  Because anti-nucleosome autoantibodies and glomerular IgM deposition were present, we conclude that constitutive Btk activation causes defective B-cell tolerance, emphasizing that Btk signals are essential for appropriate regulation of B-cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqun8TbtbvbDLVg90H21EOLACvtfcHk0ljFj7wLAhcaEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2gurfN&md5=ee792705b0aab409a52c5a5e5874c1d2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Feji.201040521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201040521%26sid%3Dliteratum%253Aachs%26aulast%3DKersseboom%26aufirst%3DR.%26aulast%3DKil%26aufirst%3DL.%26aulast%3DFlierman%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BZee%26aufirst%3DM.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DMiddendorp%26aufirst%3DS.%26aulast%3DMaas%26aufirst%3DA.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DConstitutive%2520Activation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Induces%2520the%2520Formation%2520of%2520Autoreactive%2520Igm%2520Plasma%2520Cells%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2010%26volume%3D40%26spage%3D2643%26epage%3D2654%26doi%3D10.1002%2Feji.201040521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangelmaier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span> <span> </span><span class="NLM_article-title">Tec Kinases Mediate Sustained Calcium Influx via Site-specific Tyrosine Phosphorylation of the Phospholipase C Gamma Src Homology 2-Src Homology 3 Linker</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">37651</span>– <span class="NLM_lpage">37661</span>, <span class="refDoi"> DOI: 10.1074/jbc.M311985200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1074%2Fjbc.M311985200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=15184383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=37651-37661&author=L.+A.+Humphriesauthor=C.+Dangelmaierauthor=K.+Sommerauthor=K.+Kippauthor=R.+M.+Katoauthor=N.+Griffithauthor=I.+Bakmanauthor=C.+W.+Turkauthor=J.+L.+Danielauthor=D.+J.+Rawlings&title=Tec+Kinases+Mediate+Sustained+Calcium+Influx+via+Site-specific+Tyrosine+Phosphorylation+of+the+Phospholipase+C+Gamma+Src+Homology+2-Src+Homology+3+Linker&doi=10.1074%2Fjbc.M311985200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tec Kinases Mediate Sustained Calcium Influx via Site-specific Tyrosine Phosphorylation of the Phospholipase Cγ Src Homology 2-Src Homology 3 Linker</span></div><div class="casAuthors">Humphries, Lisa A.; Dangelmaier, Carol; Sommer, Karen; Kipp, Kevin; Kato, Roberta M.; Griffith, Natasha; Bakman, Irene; Turk, Christoph W.; Daniel, James L.; Rawlings, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">37651-37661</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation of phospholipase Cγ2 (PLCγ2) is a crucial activation switch that initiates and maintains intracellular calcium mobilization in response to B cell antigen receptor (BCR) engagement.  Although members from three distinct families of non-receptor tyrosine kinases can phosphorylate PLCγ in vitro, the specific kinase(s) controlling BCR-dependent PLCγ activation in vivo remains unknown.  Bruton's tyrosine kinase (Btk)-deficient human B cells exhibit diminished inositol 1,4,5-trisphosphate prodn. and calcium signaling despite a normal inducible level of total PLCγ2 tyrosine phosphorylation.  This suggested that Btk might modify a crit. subset of residues essential for PLCγ2 activity.  To evaluate this hypothesis, we generated site-specific phosphotyrosine antibodies recognizing four putative regulatory residues within PLCγ2.  Whereas all four sites were rapidly modified in response to BCR engagement in normal B cells, Btk-deficient B cells exhibited a marked redn. in phosphorylation of the Src homol. 2 (SH2)-SH3 linker region sites, Tyr753 and Tyr759.  Phosphorylation of both sites was restored by expression of Tec, but not Syk, family kinases.  In contrast, phosphorylation of the PLCγ2 carboxyl-terminal sites, Tyr1197 and Tyr1217, was unaffected by the absence of functional Btk.  Together, these data support a model whereby Btk/Tec kinases control sustained calcium signaling via site-specific phosphorylation of key residues within the PLCγ2 SH2-SH3 linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoszBe2J6G6ybVg90H21EOLACvtfcHk0ljFj7wLAhcaEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSns7s%253D&md5=a87ce3b74c0ad325eba8d566f004d18c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311985200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311985200%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DL.%2BA.%26aulast%3DDangelmaier%26aufirst%3DC.%26aulast%3DSommer%26aufirst%3DK.%26aulast%3DKipp%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DGriffith%26aufirst%3DN.%26aulast%3DBakman%26aufirst%3DI.%26aulast%3DTurk%26aufirst%3DC.%2BW.%26aulast%3DDaniel%26aufirst%3DJ.%2BL.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DTec%2520Kinases%2520Mediate%2520Sustained%2520Calcium%2520Influx%2520via%2520Site-specific%2520Tyrosine%2520Phosphorylation%2520of%2520the%2520Phospholipase%2520C%2520Gamma%2520Src%2520Homology%25202-Src%2520Homology%25203%2520Linker%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D37651%26epage%3D37661%26doi%3D10.1074%2Fjbc.M311985200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific BTK Inhibition Suppresses B Cell- and Myeloid Cell-mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+BTK+Inhibition+Suppresses+B+Cell-+and+Myeloid+Cell-mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgGB9Oei1bf0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520BTK%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520and%2520Myeloid%2520Cell-mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romesser, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhammer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Chronic Active B-cell-receptor Signaling in Diffuse Large B-cell Lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1038/nature08638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2Fnature08638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20054396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+Active+B-cell-receptor+Signaling+in+Diffuse+Large+B-cell+Lymphoma&doi=10.1038%2Fnature08638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span></div><div class="casAuthors">Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Tolar, Pavel; Young, Ryan M.; Romesser, Paul B.; Kohlhammer, Holger; Lamy, Laurence; Zhao, Hong; Yang, Yandan; Xu, Weihong; Shaffer, Arthur L.; Wright, George; Xiao, Wenming; Powell, John; Jiang, Jian-kang; Thomas, Craig J.; Rosenwald, Andreas; Ott, German; Muller-Hermelink, Hans Konrad; Gascoyne, Randy D.; Connors, Joseph M.; Johnson, Nathalie A.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Wilson, Wyndham H.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Pierce, Susan K.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7277</span>),
    <span class="NLM_cas:pages">88-92</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A role for B-cell-receptor (BCR) signaling in lymphomagenesis has been inferred by studying Ig genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed.  Here the authors describe a form of chronic active' BCR signaling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).  The signaling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL.  Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown.  An RNA interference genetic screen revealed that a BCR signaling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11.  In addn., knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.  The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells.  Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signaling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-assocd. lymphoid tissue lymphoma.  In 18% of ABC DLBCLs, one functionally crit. residue of CD79B, the first ITAM tyrosine, was mutated.  These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signaling.  These findings establish chronic active BCR signaling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlT4q2Ie4lrVg90H21EOLACvtfcHk0lgGB9Oei1bf0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D&md5=86d4bdf7f9af3fbe120d5b9175389e5a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520Active%2520B-cell-receptor%2520Signaling%2520in%2520Diffuse%2520Large%2520B-cell%2520Lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92%26doi%3D10.1038%2Fnature08638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Y.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0ljel5uvukEswg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+H.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+S.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+L.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0ljel5uvukEswg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%2BS.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A Phase I Clinical Trial of the Selective BTK Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-cell Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+S.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+Phase+I+Clinical+Trial+of+the+Selective+BTK+Inhibitor+ONO%2FGS-4059+in+Relapsed+and+Refractory+Mature+B-cell+Malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0liIlIC-E3RVcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%2520Clinical%2520Trial%2520of%2520the%2520Selective%2520BTK%2520Inhibitor%2520ONO%252FGS-4059%2520in%2520Relapsed%2520and%2520Refractory%2520Mature%2520B-cell%2520Malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BTKk with CC-292 provides Early Pharmacodynamic Assessment of Activity in Mice and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+C.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+D.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+BTKk+with+CC-292+provides+Early+Pharmacodynamic+Assessment+of+Activity+in+Mice+and+Humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0liIlIC-E3RVcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BC.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%2BD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520BTKk%2520with%2520CC-292%2520provides%2520Early%2520Pharmacodynamic%2520Assessment%2520of%2520Activity%2520in%2520Mice%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Branebrutinib (BMS-986195): a Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&author=S.+H.+Wattersonauthor=Q.+J.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+H.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+F.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Y.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Q.+Liauthor=R.+L.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+M.+Burkeauthor=J.+A.+Tino&title=Discovery+of+Branebrutinib+%28BMS-986195%29%3A+a+Strategy+for+Identifying+a+Highly+Potent+and+Selective+Covalent+Inhibitor+Providing+Rapid+in+vivo+Inactivation+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0lgAUIbRgIbHew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%2BJ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%2BF.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%2BY.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26aulast%3DZhao%26aufirst%3DR.%2BL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BM.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520Branebrutinib%2520%2528BMS-986195%2529%253A%2520a%2520Strategy%2520for%2520Identifying%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Covalent%2520Inhibitor%2520Providing%2520Rapid%2520in%2520vivo%2520Inactivation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swami, A.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in CLL: a Focus on Adverse Events, Resistance, and Novel Approaches Beyond Ibrutinib</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-2973-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1007%2Fs00277-017-2973-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=28342031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1175-1184&author=V.+Kaurauthor=A.+Swami&title=Ibrutinib+in+CLL%3A+a+Focus+on+Adverse+Events%2C+Resistance%2C+and+Novel+Approaches+Beyond+Ibrutinib&doi=10.1007%2Fs00277-017-2973-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</span></div><div class="casAuthors">Kaur, Varinder; Swami, Arjun</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).  Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naive, heavily pre-treated, and high-risk CLL/SLL.  With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase.  As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged.  New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets.  Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL.  We provide a comprehensive anal. of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRsUgeFPl8N7Vg90H21EOLACvtfcHk0lgAUIbRgIbHew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D&md5=833537673bfe80fd7931dcc132c9b5aa</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-2973-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-2973-2%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DV.%26aulast%3DSwami%26aufirst%3DA.%26atitle%3DIbrutinib%2520in%2520CLL%253A%2520a%2520Focus%2520on%2520Adverse%2520Events%252C%2520Resistance%252C%2520and%2520Novel%2520Approaches%2520Beyond%2520Ibrutinib%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26spage%3D1175%26epage%3D1184%26doi%3D10.1007%2Fs00277-017-2973-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Q.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lgtxdtOBRabsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%2BQ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Three-year Follow-up of Treatment-naïve and Previously Treated Patients with CLLl and SLL Receiving Single-agent Ibrutinib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-606038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2014-10-606038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=25700432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2497-2506&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=Y.+Shawauthor=E.+Bilottiauthor=C.+Zhouauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Three-year+Follow-up+of+Treatment-na%C3%AFve+and+Previously+Treated+Patients+with+CLLl+and+SLL+Receiving+Single-agent+Ibrutinib&doi=10.1182%2Fblood-2014-10-606038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Burger, Jan A.; Blum, Kristie A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Shaw, Yun; Bilotti, Elizabeth; Zhou, Cathy; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling.  In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).  The durable responses obsd. with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period.  We report on median 3-yr follow-up of 132 patients with symptomatic treatment- naive and relapsed/refractory CLL or small lymphocytic lymphoma.  Longer treatment with ibrutinib was assocd. with improvement in response quality over time and durable remissions.  Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections.  Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease.  Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 yr and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better.  Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbUSbfHjGYebVg90H21EOLACvtfcHk0lgtxdtOBRabsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D&md5=1bedfb4e6798a3f51320d8b8054c13aa</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-606038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-606038%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DY.%26aulast%3DBilotti%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThree-year%2520Follow-up%2520of%2520Treatment-na%25C3%25AFve%2520and%2520Previously%2520Treated%2520Patients%2520with%2520CLLl%2520and%2520SLL%2520Receiving%2520Single-agent%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2497%26epage%3D2506%26doi%3D10.1182%2Fblood-2014-10-606038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-cell Lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+S.+Ouauthor=N.+Chengauthor=B.+L.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0lijd_-JZLZAGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%2BS.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%2BL.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Raedler, L. A.</span></span> <span> </span><span class="NLM_article-title">Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia</span>. <i>Am. Health Drug Benefits</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=27668052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A280%3ADC%252BC2svjvFWrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=89-92&author=L.+A.+Raedler&title=Imbruvica+%28Ibrutinib%29%3A+First+Drug+Approved+for+the+Treatment+of+Patients+with+Waldenstr%C3%B6m%E2%80%99s+Macroglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13eR"><div class="casContent"><span class="casTitleNuber">13e</span><div class="casTitle"><span class="NLM_cas:atitle">Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenstrom's Macroglobulinemia</span></div><div class="casAuthors">Raedler Lisa A</div><div class="citationInfo"><span class="NLM_cas:title">American health & drug benefits</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Spec Feature</span>),
    <span class="NLM_cas:pages">89-92</span>
        ISSN:<span class="NLM_cas:issn">1942-2962</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAmJOZnkDiwUH3Rlp_k91zfW6udTcc2ebEIrcll2qmrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svjvFWrtA%253D%253D&md5=90c7ae5feac36bdea254d779c7715789</span></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaedler%26aufirst%3DL.%2BA.%26atitle%3DImbruvica%2520%2528Ibrutinib%2529%253A%2520First%2520Drug%2520Approved%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Waldenstr%25C3%25B6m%25E2%2580%2599s%2520Macroglobulinemia%26jtitle%3DAm.%2520Health%2520Drug%2520Benefits%26date%3D2016%26volume%3D9%26spage%3D89%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Soler, R.</span></span> <span> </span><span class="NLM_article-title">Skin Toxicities Associated with Epidermal Growth Factor Rreceptor Inhibitors</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1007/s11523-009-0114-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1007%2Fs11523-009-0114-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=19452131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzos1KhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=107-119&author=T.+Liauthor=R.+Perez-Soler&title=Skin+Toxicities+Associated+with+Epidermal+Growth+Factor+Rreceptor+Inhibitors&doi=10.1007%2Fs11523-009-0114-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Skin toxicities associated with epidermal growth factor receptor inhibitors</span></div><div class="casAuthors">Li Tianhong; Perez-Soler Roman</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors has increased considerably in recent years.  Currently, they are approved in non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer and head and neck cancer.  Skin toxicity is a class-specific side effect that is typically manifested as a papulopustular rash in the majority (45-100%) of patients receiving EGFR inhibitors.  The skin toxicity is related to the inhibition of EGFR in the skin, which is crucial for the normal development and physiology of the epidermis.  Although rarely life-threatening, skin toxicity may cause significant physical and psycho-social discomfort.  Nevertheless, the presence and severity of skin rash is associated with improved clinical efficacy in patients receiving EGFR inhibitors.  The goal of managing EGFR inhibitor-associated skin toxicity is to minimize the detrimental effects of the rash on patients' quality of life and treatment course without antagonizing the clinical efficacy of EGFR inhibitors.  There is currently no evidence-based treatment guideline to prevent or treat the EGFR inhibitor-associated skin toxicities.  Expert panels recommend a proactive, multidisciplinary approach that includes patient education and the use of a grade-based treatment algorithm.  Elucidation of the mechanisms of EGFR inhibitor-associated skin toxicity and development of mechanism-based novel therapies are urgently needed.  Preclinical data suggest topical application of a potent phosphatase inhibitor menadione (Vitamin K3) can rescue the inhibition of EGFR and downstream signaling molecules in the skin of mice receiving systemic EGFR inhibitor erlotinib or cetuximab.  A randomized, double-blinded, placebo-controlled study has been initiated to evaluate the clinical efficacy of menadione topical cream, in the treatment or prevention of EGFR inhibitor-induced skin toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBjiE5iFNI-Nts4TFFB11gfW6udTcc2ebEIrcll2qmrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzos1KhtA%253D%253D&md5=bd52132174e886f4a5d63368881e1bdb</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1007%2Fs11523-009-0114-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-009-0114-0%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DPerez-Soler%26aufirst%3DR.%26atitle%3DSkin%2520Toxicities%2520Associated%2520with%2520Epidermal%2520Growth%2520Factor%2520Rreceptor%2520Inhibitors%26jtitle%3DTarget%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D107%26epage%3D119%26doi%3D10.1007%2Fs11523-009-0114-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Melosky, B.</span></span> <span> </span><span class="NLM_article-title">Supportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents</span>. <i>Curr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">S59</span>– <span class="NLM_lpage">S63</span>, <span class="refDoi"> DOI: 10.3747/co.19.1054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.3747%2Fco.19.1054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=22787412" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=S59-S63&author=B.+Melosky&title=Supportive+Care+Treatments+for+Toxicities+of+Anti-EGFR+and+Other+Targeted+Agents&doi=10.3747%2Fco.19.1054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.3747%2Fco.19.1054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.19.1054%26sid%3Dliteratum%253Aachs%26aulast%3DMelosky%26aufirst%3DB.%26atitle%3DSupportive%2520Care%2520Treatments%2520for%2520Toxicities%2520of%2520Anti-EGFR%2520and%2520Other%2520Targeted%2520Agents%26jtitle%3DCurr.%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3DS59%26epage%3DS63%26doi%3D10.3747%2Fco.19.1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S. P.</span></span> <span> </span><span class="NLM_article-title">Tec Regulates Platelet Activation by GPVI in the Absence of BTK</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">3592</span>– <span class="NLM_lpage">3599</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-04-1142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2003-04-1142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=12842985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVymt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=3592-3599&author=B.+T.+Atkinsonauthor=W.+Ellmeierauthor=S.+P.+Watson&title=Tec+Regulates+Platelet+Activation+by+GPVI+in+the+Absence+of+BTK&doi=10.1182%2Fblood-2003-04-1142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tec regulates platelet activation by GPVI in the absence of Btk</span></div><div class="casAuthors">Atkinson, Ben T.; Ellmeier, Wilfried; Watson, Steve P.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3592-3599</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Tec family kinase Btk plays an important role in the regulation of phospholipase Cγ2 (PLCγ2) downstream of the collagen receptor glycoprotein VI (GPVI) in human platelets.  Platelets also express a second member of this family, Tec; however, its function has not been analyzed.  To address the role of Tec, we analyzed Btk-/-, Tec-/-, and Btk/Tec double-deficient (Btk-/-/Tec-/-) platelets.  Tec-/- platelets exhibit a minor redn. in aggregation to threshold concns. of collagen or the GPVI-specific agonist collagen-related peptide (CRP), whereas responses to higher concns. are normal.  Tyrosine phosphorylation of PLCγ2 by collagen and CRP is not altered in Tec-/- platelets.  However, Btk-/-/Tec-/- platelets exhibit a greater redn. in PLCγ2 phosphorylation than is seen in the absence of Btk, thus revealing an important role for Tec in this situation.  Furthermore, Btk-/-/Tec-/- platelets fail to undergo an increase in Ca2+, aggregation, secretion, and spreading in response to collagen or CRP, whereas they aggregate normally to ADP and spread on fibrinogen.  A residual GPVI signal exists in the Btk-/-/Tec-/- platelets as CRP synergizes with ADP to mediate aggregation.  These results demonstrate an essential requirement for Tec and Btk in platelet activation by GPVI and reveal a functional role for Tec in the regulation of PLCγ2 in the absence of Btk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEprLq7CTaCLVg90H21EOLACvtfcHk0lgXRX557yE82g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVymt74%253D&md5=159f65f62c88a803d820e16adc8e109c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-04-1142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-04-1142%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DB.%2BT.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26atitle%3DTec%2520Regulates%2520Platelet%2520Activation%2520by%2520GPVI%2520in%2520the%2520Absence%2520of%2520BTK%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D3592%26epage%3D3599%26doi%3D10.1182%2Fblood-2003-04-1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gururaja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span> <span> </span><span class="NLM_article-title">The Effect of Bruton’s Tyrosine Kinase (BTK) Inhibitors on Collagen-induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hhepatocellular Carcinoma (Tec)</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1111/ejh.13148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1111%2Fejh.13148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2018&pages=604-612&author=J.+Chenauthor=T.+Kinoshitaauthor=T.+Gururajaauthor=J.+Sukbuntherngauthor=D.+Jamesauthor=D.+Luauthor=J.+Whangauthor=M.+Verseleauthor=B.+Y.+Chang&title=The+Effect+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+on+Collagen-induced+Platelet+Aggregation%2C+BTK%2C+and+Tyrosine+Kinase+Expressed+in+Hhepatocellular+Carcinoma+%28Tec%29&doi=10.1111%2Fejh.13148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)</span></div><div class="casAuthors">Chen, Jun; Kinoshita, Taisei; Gururaja, Tarikere; Sukbuntherng, Juthamas; James, Danelle; Lu, Daniel; Whang, Jennifer; Versele, Matthias; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">604-612</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Bruton's tyrosine kinase (BTK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) are expressed by human platelets.  These kinases participate in platelet activation through the collagen receptor glycoprotein VI and may perform overlapping functions.  In clin. studies, BTK inhibitors (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib) have been assocd. with increased bleeding risk, which may result from inhibition of BTK alone or of both BTK and TEC, although the role of TEC in bleeding risk remains unclear.  Methods : Here, in vitro catalytic and binding activities of ibrutinib and acalabrutinib were detd. with four assay systems.  Platelet aggregation assays detd. inhibitor potency and its relationship to selectivity between BTK and TEC.  Results : Neither inhibitor was substantially more selective for BTK over TEC.  The potencies at which BTK inhibitors suppressed platelet aggregation correlated with the potencies in on-target BTK assays, including those in cells.  At clin. relevant plasma concn., ibrutinib, acalabrutinib, and tirabrutinib inhibited collagen-induced platelet aggregation to a similar extent, despite differing in vitro IC50s.  Conclusions : Our results suggest BTK inhibition is the primary driver for inhibition of platelet aggregation.  The subtle differences between these inhibitors suggest only randomized, double-blind, placebo-controlled clin. studies can fully address the bleeding risks of different BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-4t9KmFTj5LVg90H21EOLACvtfcHk0lgXRX557yE82g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J&md5=ef4558e97d19f22350689e75088f1b34</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fejh.13148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.13148%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DGururaja%26aufirst%3DT.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DWhang%26aufirst%3DJ.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DThe%2520Effect%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520on%2520Collagen-induced%2520Platelet%2520Aggregation%252C%2520BTK%252C%2520and%2520Tyrosine%2520Kinase%2520Expressed%2520in%2520Hhepatocellular%2520Carcinoma%2520%2528Tec%2529%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2018%26volume%3D101%26spage%3D604%26epage%3D612%26doi%3D10.1111%2Fejh.13148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senis, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazharian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, J.</span></span> <span> </span><span class="NLM_article-title">Src Family Kinases: at the Forefront of Platelet Activation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-01-453134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2014-01-453134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=25115887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslaiu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2013-2024&author=Y.+A.+Senisauthor=A.+Mazharianauthor=J.+Mori&title=Src+Family+Kinases%3A+at+the+Forefront+of+Platelet+Activation&doi=10.1182%2Fblood-2014-01-453134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases: at the forefront of platelet activation</span></div><div class="casAuthors">Senis, Yotis A.; Mazharian, Alexandra; Mori, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2013-2024</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Src family kinases (SFKs) play a central role in mediating the rapid response of platelets to vascular injury.  They transmit activation signals from a diverse repertoire of platelet surface receptors, including the integrin αIIbβ3, the immunoreceptor tyrosine-based activation motif-contg. collagen receptor complex GPVI-FcR γ-chain, and the von Willebrand factor receptor complex GPIb-IX-V, which are essential for thrombus growth and stability.  Ligand-mediated clustering of these receptors triggers an increase in SFK activity and downstream tyrosine phosphorylation of enzymes, adaptors, and cytoskeletal proteins that collectively propagate the signal and coordinate platelet activation.  A growing body of evidence has established that SFKs also contribute to Gq- and Gi-coupled receptor signaling that synergizes with primary activation signals to maximally activate platelets and render them prothrombotic.  Interestingly, SFKs concomitantly activate inhibitory pathways that limit platelet activation and thrombus size.  In this review, we discuss past discoveries that laid the foundation for this fundamental area of platelet signal transduction, recent progress in our understanding of the distinct and overlapping functions of SFKs in platelets, and new avenues of research into mechanisms of SFK regulation.  We also highlight the thrombotic and hemostatic consequences of targeting platelet SFKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlUuKGcvADrVg90H21EOLACvtfcHk0lgXRX557yE82g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslaiu7jM&md5=462486e3a954db0c557c2d0dcf8d843d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-01-453134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-01-453134%26sid%3Dliteratum%253Aachs%26aulast%3DSenis%26aufirst%3DY.%2BA.%26aulast%3DMazharian%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DJ.%26atitle%3DSrc%2520Family%2520Kinases%253A%2520at%2520the%2520Forefront%2520of%2520Platelet%2520Activation%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2013%26epage%3D2024%26doi%3D10.1182%2Fblood-2014-01-453134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bye, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unsworth, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desborough, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildyard, C. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriek, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbins, J. M.</span></span> <span> </span><span class="NLM_article-title">Severe Platelet Dysfunction in NHL Patients Receiving Ibrutinib is Absent in Patients Receiving Acalabrutinib</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2610</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2017011999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fbloodadvances.2017011999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=29296914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1egsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=2610-2623&author=A.+P.+Byeauthor=A.+J.+Unsworthauthor=M.+J.+Desboroughauthor=C.+A.+T.+Hildyardauthor=N.+Applebyauthor=D.+Bruceauthor=N.+Kriekauthor=S.+H.+Nockauthor=T.+Sageauthor=C.+E.+Hughesauthor=J.+M.+Gibbins&title=Severe+Platelet+Dysfunction+in+NHL+Patients+Receiving+Ibrutinib+is+Absent+in+Patients+Receiving+Acalabrutinib&doi=10.1182%2Fbloodadvances.2017011999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib</span></div><div class="casAuthors">Bye, Alexander P.; Unsworth, Amanda J.; Desborough, Michael J.; Hildyard, Catherine A. T.; Appleby, Niamh; Bruce, David; Kriek, Neline; Nock, Sophie H.; Sage, Tanya; Hughes, Craig E.; Gibbins, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2610</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding.  Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib.  The second-generation Btk inhibitor acalabrutinib was developed with improved specificity for Btk over Tec.  We investigated platelet function in patients with non-Hodgkin lymphoma (NHL) receiving ibrutinib or acalabrutinib by aggregometry and by measuring thrombus formation on collagen under arterial shear.  Both patient groups had similarly dysfunctional aggregation responses to collagen and collagen-related peptide, and comparison with mechanistic expts. in which platelets from healthy donors were treated with the Btk inhibitors suggested that both drugs inhibit platelet Btk and Tec at physiol. concns.  Only ibrutinib caused dysfunctional thrombus formation, whereas size and morphol. of thrombi following acalabrutinib treatment were of normal size and morphol.  We found that ibrutinib but not acalabrutinib inhibited Src family kinases, which have a crit. role in platelet adhesion to collagen that is likely to underpin unstable thrombus formation obsd. in ibrutinib patients.  We found that platelet function was enhanced by increasing levels of von Willebrand factor (VWF) and factor VIII (FVIII) ex vivo by addn. of intermediate purity FVIII (Haemate P) to blood from patients, resulting in consistently larger thrombi.  We conclude that acalabrutinib avoids major platelet dysfunction assocd. with ibrutinib therapy, and platelet function may be enhanced in patients with B-cell NHL by increasing plasma VWF and FVIII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI3BCm7LTLELVg90H21EOLACvtfcHk0lis7MC_Rh_2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1egsrk%253D&md5=4519ab76d09fa0f825e744d8a67fb130</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2017011999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2017011999%26sid%3Dliteratum%253Aachs%26aulast%3DBye%26aufirst%3DA.%2BP.%26aulast%3DUnsworth%26aufirst%3DA.%2BJ.%26aulast%3DDesborough%26aufirst%3DM.%2BJ.%26aulast%3DHildyard%26aufirst%3DC.%2BA.%2BT.%26aulast%3DAppleby%26aufirst%3DN.%26aulast%3DBruce%26aufirst%3DD.%26aulast%3DKriek%26aufirst%3DN.%26aulast%3DNock%26aufirst%3DS.%2BH.%26aulast%3DSage%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DC.%2BE.%26aulast%3DGibbins%26aufirst%3DJ.%2BM.%26atitle%3DSevere%2520Platelet%2520Dysfunction%2520in%2520NHL%2520Patients%2520Receiving%2520Ibrutinib%2520is%2520Absent%2520in%2520Patients%2520Receiving%2520Acalabrutinib%26jtitle%3DBlood%2520Adv.%26date%3D2017%26volume%3D1%26spage%3D2610%26epage%3D2623%26doi%3D10.1182%2Fbloodadvances.2017011999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The Resurgence of Covalent Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+Resurgence+of+Covalent+Drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lis7MC_Rh_2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520Resurgence%2520of%2520Covalent%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R. A.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibitors in Drug Discovery: From Accidental Discoveries to Avoided Liabilities and Designed Therapies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.drudis.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26002380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1061-1073&author=R.+A.+Bauer&title=Covalent+Inhibitors+in+Drug+Discovery%3A+From+Accidental+Discoveries+to+Avoided+Liabilities+and+Designed+Therapies&doi=10.1016%2Fj.drudis.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span></div><div class="casAuthors">Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drugs that covalently bond to their biol. targets have a long history in drug discovery.  A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come.  Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients.  Covalent inhibition can also dissoc. drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure.  Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncol. and infectious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkBDsUEu4arVg90H21EOLACvtfcHk0lis7MC_Rh_2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D&md5=6ba5b016d2804c7d56838a2724b9a0b9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DCovalent%2520Inhibitors%2520in%2520Drug%2520Discovery%253A%2520From%2520Accidental%2520Discoveries%2520to%2520Avoided%2520Liabilities%2520and%2520Designed%2520Therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1061%26epage%3D1073%26doi%3D10.1016%2Fj.drudis.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Cesco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittermaier, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitessier, N.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibitors Design and Discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.ejmech.2017.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=28651155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=96-114&author=S.+De%0ACescoauthor=J.+Kurianauthor=C.+Dufresneauthor=A.+K.+Mittermaierauthor=N.+Moitessier&title=Covalent+Inhibitors+Design+and+Discovery&doi=10.1016%2Fj.ejmech.2017.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors design and discovery</span></div><div class="casAuthors">De Cesco, Stephane; Kurian, Jerry; Dufresne, Caroline; Mittermaier, Anthony K.; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-114</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the history of therapeutics, covalent drugs occupy a very distinct category.  While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biol. target.  In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.  All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods.  The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLNDmLtBdB7Vg90H21EOLACvtfcHk0lis7MC_Rh_2Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI&md5=551c9a9c4bd69d4ad4d9156c315d5a94</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DJ.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DMittermaier%26aufirst%3DA.%2BK.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DCovalent%2520Inhibitors%2520Design%2520and%2520Discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114%26doi%3D10.1016%2Fj.ejmech.2017.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vliegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, J.</span></span> <span> </span><span class="NLM_article-title">Stable Isotope-labelled Intravenous Microdose for Absolute Bioavailability and Effect of Grapefruit Juice on Ibrutinib in Healthy Adults</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1111/bcp.12787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1111%2Fbcp.12787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26382728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFKqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=235-245&author=R.+de+Vriesauthor=J.+W.+Smitauthor=P.+Hellemansauthor=J.+Jiaoauthor=J.+Murphyauthor=D.+Skeeauthor=J.+Snoeysauthor=J.+Sukbuntherngauthor=M.+Vliegenauthor=L.+de+Zwartauthor=E.+Mannaertauthor=J.+de+Jong&title=Stable+Isotope-labelled+Intravenous+Microdose+for+Absolute+Bioavailability+and+Effect+of+Grapefruit+Juice+on+Ibrutinib+in+Healthy+Adults&doi=10.1111%2Fbcp.12787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults</span></div><div class="casAuthors">de Vries, Ronald; Smit, Johan W.; Hellemans, Peter; Jiao, James; Murphy, Joseph; Skee, Donna; Snoeys, Jan; Sukbuntherng, Juthamas; Vliegen, Maarten; de Zwart, Loeckie; Mannaert, Erik; de Jong, Jan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-245</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.  Ibrutinib undergoes extensive rapid oxidative metab. mediated by cytochrome P 450 3A both at the level of first pass and clearance, which might result in low oral bioavailability.  The present study was designed to investigate the abs. bioavailability (F) of ibrutinib in the fasting and fed state and assess the effect of grapefruit juice (GFJ) on the systemic exposure of ibrutinib in order to det. the fraction escaping the gut (Fg) and the fraction escaping hepatic extn. (Fh) in the fed state.  Methods : All participants received treatment A [560 mg oral ibrutinib, under fasting conditions], B (560 mg PO ibrutinib, fed, administered after drinking glucose drink) and C (140 mg oral ibrutinib, fed, with intake of GFJ before dosing).  A single i.v. (i.v.) dose of 100 μg 13C6-ibrutinib was administered 2 h after each oral dose.  Results : The estd. 'F' for treatments A, B and C was 3.9%, 8.4% and 15.9%, resp.  Fg and Fh in the fed state were 47.0% and 15.9%, resp.  Adverse events were mild to moderate in severity (Grade 1-2) and resolved without sequelae by the end of the study.  Conclusion : The abs. oral bioavailability of ibrutinib was low, ranging from 3.9% in the fasting state to 8.4% when administered 30 min before a std. breakfast without GFJ and 15.9% with GFJ.  Ibrutinib was well tolerated following a single oral and i.v. dose, under both fasted and fed conditions and regardless of GFJ intake status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAj7TEGNR7gLVg90H21EOLACvtfcHk0lgrHyCFiG2RiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFKqu7o%253D&md5=0b04c96322b03fbad3d52b79fbc20551</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12787%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVries%26aufirst%3DR.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DJiao%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DSkee%26aufirst%3DD.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DVliegen%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DL.%26aulast%3DMannaert%26aufirst%3DE.%26aulast%3Dde%2BJong%26aufirst%3DJ.%26atitle%3DStable%2520Isotope-labelled%2520Intravenous%2520Microdose%2520for%2520Absolute%2520Bioavailability%2520and%2520Effect%2520of%2520Grapefruit%2520Juice%2520on%2520Ibrutinib%2520in%2520Healthy%2520Adults%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D81%26spage%3D235%26epage%3D245%26doi%3D10.1111%2Fbcp.12787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scheers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laenen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyckens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannens, G.</span></span> <span> </span><span class="NLM_article-title">Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An open-label, Phase 1, Single-dose Study in Healthy Men</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.060061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1124%2Fdmd.114.060061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=25488930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpt1ansg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=289-297&author=E.+Scheersauthor=L.+Leclercqauthor=J.+de+Jongauthor=N.+Bodeauthor=M.+Bockxauthor=A.+Laenenauthor=F.+Cuyckensauthor=D.+Skeeauthor=J.+Murphyauthor=J.+Sukbuntherngauthor=G.+Mannens&title=Absorption%2C+Metabolism%2C+and+Excretion+of+Oral+14C+Radiolabeled+Ibrutinib%3A+An+open-label%2C+Phase+1%2C+Single-dose+Study+in+Healthy+Men&doi=10.1124%2Fdmd.114.060061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, metabolism, and excretion of pral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men</span></div><div class="casAuthors">Scheers, Ellen; Leclercq, Laurent; de Jong, Jan; Bode, Nini; Bockx, Marc; Laenen, Aline; Cuyckens, Filip; Skee, Donna; Murphy, Joe; Sukbuntherng, Juthamas; Mannens, Geert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">289-297, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The absorption, metab., and excretion of ibrutinib were investigated in healthy men after administration of a single oral dose of 140 mg of 14C-labeled ibrutinib.  The mean S.D. cumulative excretion of radioactivity of the dose was 7.8% 1.4% in urine and 80.6% 3.1% in feces with <1% excreted as parent ibrutinib.  Only oxidative metabolites and very limited parent compd. were detected in feces, and this indicated that ibrutinib was completely absorbed from the gastrointestinal tract.  Metab. occurred via three major pathways hydroxylation of the Ph M35, opening of the piperidine M25 and M34, and epoxidn. of the ethylene on the acryloyl moiety with further hydrolysis to dihydrodiol PCI-45227, and M37.  Addnl. metabolites were formed by combinations of the primary metabolic pathways or by further metab.  In blood and plasma, a rapid initial decline in radioactivity was obsd. along with long terminal elimination half-life for total radioactivity.  The max. concn. Cmax and area under the concn.-time curve AUC for total radioactivity were higher in plasma compared with blood.  The main circulating entities in blood and plasma were M21 sulfate conjugate of a monooxidized metabolite on phenoxyphenyl, M25, M34, M37 PCI-45227, and ibrutinib.  At Cmax of radioactivity, 12% of total radioactivity was accounted for by covalent binding in human plasma.  More than 50% of total plasma radioactivity was attributed to covalently bound material from 8 h onward; as a result, covalent binding accounted for 38% and 51% of total radioactivity AUC0-24 h and AUC0-72 h, resp.  No effect of CYP2D6 genotype was obsd. on ibrutinib metab.  Ibrutinib was well-tolerated by healthy participants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHfk3z0sBmMLVg90H21EOLACvtfcHk0lgrHyCFiG2RiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpt1ansg%253D%253D&md5=1f1e728078220c9d7cd973d4992c7308</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.060061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.060061%26sid%3Dliteratum%253Aachs%26aulast%3DScheers%26aufirst%3DE.%26aulast%3DLeclercq%26aufirst%3DL.%26aulast%3Dde%2BJong%26aufirst%3DJ.%26aulast%3DBode%26aufirst%3DN.%26aulast%3DBockx%26aufirst%3DM.%26aulast%3DLaenen%26aufirst%3DA.%26aulast%3DCuyckens%26aufirst%3DF.%26aulast%3DSkee%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DMannens%26aufirst%3DG.%26atitle%3DAbsorption%252C%2520Metabolism%252C%2520and%2520Excretion%2520of%2520Oral%252014C%2520Radiolabeled%2520Ibrutinib%253A%2520An%2520open-label%252C%2520Phase%25201%252C%2520Single-dose%2520Study%2520in%2520Healthy%2520Men%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D289%26epage%3D297%26doi%3D10.1124%2Fdmd.114.060061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parolini, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitch-Hilgenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span> <span> </span><span class="NLM_article-title">A Point Mutation in the SH2 Domain of Bruton’s Tyrosine Kinase in Atypical X-Linked Agammaglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.1056/NEJM199405263302104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJM199405263302104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=8164701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADyaK2MXis12itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1994&pages=1488-1491&author=D.+C.+Saffranauthor=O.+Paroliniauthor=M.+E.+Fitch-Hilgenbergauthor=D.+J.+Rawlingsauthor=D.+Afarauthor=O.+N.+Witteauthor=M.+E.+Conley&title=A+Point+Mutation+in+the+SH2+Domain+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+Atypical+X-Linked+Agammaglobulinemia&doi=10.1056%2FNEJM199405263302104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">A point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia</span></div><div class="casAuthors">Saffran, Douglas C.; Parolini, Ornella; Fitch-Hilgenberg, Marjorie E.; Rawlings, David J.; Afar, Daniel E.H.; Witte, Owen N.; Conley, Mary Ellen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1488-91</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">A novel mutation was described in the gene encoding Btk (Bruton's tyrosine kinase) in atypical X-linked agammaglobulinemia.  This mutation in the SH2 domain allowed the expression of normal levels of Btk transcript but encoded a protein with decreased stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppsSq_90aaNbVg90H21EOLACvtfcHk0lg59ZIeeu5gbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXis12itA%253D%253D&md5=926fe55d343510e2f616deed99cbe4ab</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1056%2FNEJM199405263302104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199405263302104%26sid%3Dliteratum%253Aachs%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DParolini%26aufirst%3DO.%26aulast%3DFitch-Hilgenberg%26aufirst%3DM.%2BE.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DAfar%26aufirst%3DD.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DConley%26aufirst%3DM.%2BE.%26atitle%3DA%2520Point%2520Mutation%2520in%2520the%2520SH2%2520Domain%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Atypical%2520X-Linked%2520Agammaglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1994%26volume%3D330%26spage%3D1488%26epage%3D1491%26doi%3D10.1056%2FNEJM199405263302104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitenlechner, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kairies, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koll, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of Active Src Kinase Domain Complexes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2005.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.jmb.2005.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=16168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=222-231&author=C.+B.+Breitenlechnerauthor=N.+A.+Kairiesauthor=K.+Honoldauthor=S.+Scheiblichauthor=H.+Kollauthor=E.+Greiterauthor=S.+Kochauthor=W.+Sch%C3%A4ferauthor=R.+Huberauthor=R.+A.+Engh&title=Crystal+Structures+of+Active+Src+Kinase+Domain+Complexes&doi=10.1016%2Fj.jmb.2005.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Active Src Kinase Domain Complexes</span></div><div class="casAuthors">Breitenlechner, Christine B.; Kairies, Norman A.; Honold, Konrad; Scheiblich, Stefan; Koll, Hans; Greiter, Eva; Koch, Stefan; Schaefer, Wolfgang; Huber, Robert; Engh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">C-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs.  Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form.  Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms.  Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolns. ranging from 2.9 Å to 1.95 Å.  The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation.  The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340.  In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3P258chhrbVg90H21EOLACvtfcHk0lg59ZIeeu5gbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF&md5=9bc8e1670457d34ac88e6b5b20efea21</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenlechner%26aufirst%3DC.%2BB.%26aulast%3DKairies%26aufirst%3DN.%2BA.%26aulast%3DHonold%26aufirst%3DK.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKoll%26aufirst%3DH.%26aulast%3DGreiter%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Active%2520Src%2520Kinase%2520Domain%2520Complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D222%26epage%3D231%26doi%3D10.1016%2Fj.jmb.2005.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span>; <span class="NLM_string-name">Calderwood, D.</span>; <span class="NLM_string-name">Wishart, N.</span>; <span class="NLM_string-name">Rafferty, P.</span>; <span class="NLM_string-name">Ritter, K.</span>; <span class="NLM_string-name">Arnold, L. D.</span>; <span class="NLM_string-name">Friedman, M. M.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyrimidines as Therapeutic Agents</span>. World Patent <span class="NLM_patent">WO0119829</span>, Mar 22, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=G.+C.+Hirst&author=D.+Calderwood&author=N.+Wishart&author=P.+Rafferty&author=K.+Ritter&author=L.+D.+Arnold&author=M.+M.+Friedman&title=Pyrazolopyrimidines+as+Therapeutic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHirst%26aufirst%3DG.%2BC.%26atitle%3DPyrazolopyrimidines%2520as%2520Therapeutic%2520Agents%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamens, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munschauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafferty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnofsky, S. E.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Lck I</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2167</span>– <span class="NLM_lpage">2170</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00441-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2FS0960-894X%2800%2900441-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=11012021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFKksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2167-2170&author=L.+D.+Arnoldauthor=D.+J.+Calderwoodauthor=R.+W.+Dixonauthor=D.+N.+Johnstonauthor=J.+S.+Kamensauthor=R.+Munschauerauthor=P.+Raffertyauthor=S.+E.+Ratnofsky&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+Containing+an+Extended+5-Substituent+as+Potent+and+Selective+Inhibitors+of+Lck+I&doi=10.1016%2FS0960-894X%2800%2900441-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I</span></div><div class="casAuthors">Arnold, L. D.; Calderwood, D. J.; Dixon, R. W.; Johnston, D. N.; Kamens, J. S.; Munschauer, R.; Rafferty, P.; Ratnofsky, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2167-2170</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Pyrrolo[2,3-d]pyrimidines contg. a 5-(4-phenoxyphenyl) substituent are potent and selective inhibitors of lck in vitro; some compds. are selective for lck over src.  Data are shown for two compds. demonstrating that they are potent and selective inhibitors of IL2 prodn. in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUbxHkjKto7Vg90H21EOLACvtfcHk0lg59ZIeeu5gbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFKksbg%253D&md5=74f53acc0bcae20393a59e1113156d67</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900441-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900441-8%26sid%3Dliteratum%253Aachs%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DCalderwood%26aufirst%3DD.%2BJ.%26aulast%3DDixon%26aufirst%3DR.%2BW.%26aulast%3DJohnston%26aufirst%3DD.%2BN.%26aulast%3DKamens%26aufirst%3DJ.%2BS.%26aulast%3DMunschauer%26aufirst%3DR.%26aulast%3DRafferty%26aufirst%3DP.%26aulast%3DRatnofsky%26aufirst%3DS.%2BE.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520Containing%2520an%2520Extended%25205-Substituent%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Lck%2520I%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2167%26epage%3D2170%26doi%3D10.1016%2FS0960-894X%2800%2900441-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geierstanger, B. H.</span></span> <span> </span><span class="NLM_article-title">Verification of a Designed Intramolecular Hydrogen Bond in a Drug Scaffold by Nuclear Magnetic Resonance Spectroscopy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5875</span>– <span class="NLM_lpage">5877</span>, <span class="refDoi"> DOI: 10.1021/jm700983a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700983a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5875-5877&author=A.+Jansmaauthor=Q.+Zhangauthor=B.+Liauthor=Q.+Dingauthor=T.+Unoauthor=B.+Bursulayaauthor=Y.+Liuauthor=P.+Furetauthor=N.+S.+Grayauthor=B.+H.+Geierstanger&title=Verification+of+a+Designed+Intramolecular+Hydrogen+Bond+in+a+Drug+Scaffold+by+Nuclear+Magnetic+Resonance+Spectroscopy&doi=10.1021%2Fjm700983a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Verification of a Designed Intramolecular Hydrogen Bond in a Drug Scaffold by Nuclear Magnetic Resonance Spectroscopy</span></div><div class="casAuthors">Jansma, Ariane; Zhang, Qiong; Li, Bing; Ding, Qiang; Uno, Tetsuo; Bursulaya, Badry; Liu, Yi; Furet, Pascal; Gray, Nathanael S.; Geierstanger, Bernhard H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5875-5877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2D 1H-15N HMBC NMR acquired at natural abundance and DMSO titrn. monitored by 1D 1H NMR verified the existence of an intramol. hydrogen bond that was designed to mimic the pyrimidinone ring of a class of kinase inhibitors.  A scalar coupling across the hydrogen bond was detected in org. and aq. solvent, suggesting a simple and general approach for testing the propensity of intramol. hydrogen bonds to stabilize pseudo-rings in drug scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzLJyCMZPJ17Vg90H21EOLACvtfcHk0lhu8gj08p749w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitrjM&md5=3b5662c258471320fc367eb9bc4f1c10</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm700983a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700983a%26sid%3Dliteratum%253Aachs%26aulast%3DJansma%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGeierstanger%26aufirst%3DB.%2BH.%26atitle%3DVerification%2520of%2520a%2520Designed%2520Intramolecular%2520Hydrogen%2520Bond%2520in%2520a%2520Drug%2520Scaffold%2520by%2520Nuclear%2520Magnetic%2520Resonance%2520Spectroscopy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5875%26epage%3D5877%26doi%3D10.1021%2Fjm700983a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. W.</span>; <span class="NLM_string-name">Guo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase Inhibitors and Uses thereof</span>. US Patent <span class="NLM_patent">US2015005277</span>, Jan 1, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+W.+Wang&author=Y.+H.+Guo&title=Protein+Kinase+Inhibitors+and+Uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BW.%26atitle%3DProtein%2520Kinase%2520Inhibitors%2520and%2520Uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of Human Bruton’s Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for Tec Family Kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+Human+Bruton%E2%80%99s+Tyrosine+Kinase+in+Active+and+Inactive+Conformations+Suggest+a+Mechanism+of+Activation+for+Tec+Family+Kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0lhu8gj08p749w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520Human%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Active%2520and%2520Inactive%2520Conformations%2520Suggest%2520a%2520Mechanism%2520of%2520Activation%2520for%2520Tec%2520Family%2520Kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, V.
H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchingham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocharski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surendran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span> <span> </span><span class="NLM_article-title">The Road Map to Oral Bioavailability: an Industrial Perspective</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1517/17425255.2.4.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1517%2F17425255.2.4.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=16859407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=591-608&author=V.%0AH.+Thomasauthor=S.+Bhattacharauthor=L.+Hitchinghamauthor=P.+Zocharskiauthor=M.+Naathauthor=N.+Surendranauthor=C.+L.+Stonerauthor=A.+El-Kattan&title=The+Road+Map+to+Oral+Bioavailability%3A+an+Industrial+Perspective&doi=10.1517%2F17425255.2.4.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The road map to oral bioavailability: an industrial perspective</span></div><div class="casAuthors">Thomas, V. Hayden; Bhattachar, Shobha; Hitchingham, Linda; Zocharski, Philip; Naath, Maryanne; Surendran, Narayanan; Stoner, Chad L.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-608</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Optimization of oral bioavailability is a continuing challenge for the pharmaceutical and biotechnol. industries.  The no. of potential drug candidates requiring in vivo evaluation has significantly increased with the advent of combinatorial chem.  In addn., drug discovery programs are increasingly forced into more lipophilic and lower soly. chem. space.  To aid in the use of in vitro and in silico tools as well as reduce the no. of in vivo studies required, a team-based discussion tool is proposed that provides a road map' to guide the selection of profiling assays that should be considered when optimizing oral bioavailability.  This road map divides the factors that contribute to poor oral bioavailability into two interrelated categories: absorption and metab.  This road map provides an interface for cross discipline discussions and a systematic approach to the experimentation that drives the drug discovery process towards a common goal - acceptable oral bioavailability using minimal resources in an acceptable time frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7_zZKacXE7Vg90H21EOLACvtfcHk0lhu8gj08p749w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D&md5=79cf4cea1b89914bd3a8826b5d7360f9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.4.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.4.591%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DBhattachar%26aufirst%3DS.%26aulast%3DHitchingham%26aufirst%3DL.%26aulast%3DZocharski%26aufirst%3DP.%26aulast%3DNaath%26aufirst%3DM.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DEl-Kattan%26aufirst%3DA.%26atitle%3DThe%2520Road%2520Map%2520to%2520Oral%2520Bioavailability%253A%2520an%2520Industrial%2520Perspective%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26spage%3D591%26epage%3D608%26doi%3D10.1517%2F17425255.2.4.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cull, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnasingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span> <span> </span><span class="NLM_article-title">Twice Daily Dosing with the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=642&author=C.+S.+Tamauthor=S.+Opatauthor=G.+Cullauthor=J.+Trotmanauthor=D.+Gottliebauthor=D.+Simpsonauthor=P.+Marltonauthor=M.+A.+Andersonauthor=M.+Kuauthor=D.+Ritchieauthor=S.+Ratnasingamauthor=B.+Augustsonauthor=M.+Kirschbaumauthor=L.+Wangauthor=L.+Xueauthor=J.+X.+Yangauthor=E.+Hedrickauthor=J.+F.+Seymourauthor=A.+W.+Roberts&title=Twice+Daily+Dosing+with+the+Highly+Specific+BTK+Inhibitor%2C+BGB-3111%2C+Achieves+Complete+and+Continuous+BTK+Occupancy+in+Lymph+Nodes%2C+and+is+Associated+with+Durable+Responses+in+Patients+%28pts%29+with+Chronic+Lymphocytic+Leukemia+%28CLL%29%2FSmall+Lymphocytic+Lymphoma+%28SLL%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DOpat%26aufirst%3DS.%26aulast%3DCull%26aufirst%3DG.%26aulast%3DTrotman%26aufirst%3DJ.%26aulast%3DGottlieb%26aufirst%3DD.%26aulast%3DSimpson%26aufirst%3DD.%26aulast%3DMarlton%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DKu%26aufirst%3DM.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DRatnasingam%26aufirst%3DS.%26aulast%3DAugustson%26aufirst%3DB.%26aulast%3DKirschbaum%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%2BX.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26atitle%3DTwice%2520Daily%2520Dosing%2520with%2520the%2520Highly%2520Specific%2520BTK%2520Inhibitor%252C%2520BGB-3111%252C%2520Achieves%2520Complete%2520and%2520Continuous%2520BTK%2520Occupancy%2520in%2520Lymph%2520Nodes%252C%2520and%2520is%2520Associated%2520with%2520Durable%2520Responses%2520in%2520Patients%2520%2528pts%2529%2520with%2520Chronic%2520Lymphocytic%2520Leukemia%2520%2528CLL%2529%252FSmall%2520Lymphocytic%2520Lymphoma%2520%2528SLL%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-cell Activation and is Efficacious in Models of Autoimmune Disease and B-cell Malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+Tyrosine+Kinase+Inhibitor+PCI-32765+Blocks+B-cell+Activation+and+is+Efficacious+in+Models+of+Autoimmune+Disease+and+B-cell+Malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0linUSM5uzdneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520PCI-32765%2520Blocks%2520B-cell%2520Activation%2520and%2520is%2520Efficacious%2520in%2520Models%2520of%2520Autoimmune%2520Disease%2520and%2520B-cell%2520Malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">Xds</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Xds&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0linUSM5uzdneA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXds%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser Crystallographic Software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+Crystallographic+Software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0ljwOEwvdJiTtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520Crystallographic%2520Software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustyakimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span> <span> </span><span class="NLM_article-title">Towards Automated Crystallographic Structure Refinement with Phenix. Refine</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1107/S0907444912001308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0907444912001308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=22505256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=352-367&author=P.+V.+Afonineauthor=R.+W.+Grosse-Kunstleveauthor=N.+Echolsauthor=J.+J.+Headdauthor=N.+W.+Moriartyauthor=M.+Mustyakimovauthor=T.+C.+Terwilligerauthor=A.+Urzhumtsevauthor=P.+H.+Zwartauthor=P.+D.+Adams&title=Towards+Automated+Crystallographic+Structure+Refinement+with+Phenix.+Refine&doi=10.1107%2FS0907444912001308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Towards automated crystallographic structure refinement with phenix.refine</span></div><div class="casAuthors">Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Echols, Nathaniel; Headd, Jeffrey J.; Moriarty, Nigel W.; Mustyakimov, Marat; Terwilliger, Thomas C.; Urzhumtsev, Alexandre; Zwart, Peter H.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">352-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phenix.refine is a program within the PHENIX package that supports crystallog. structure refinement against exptl. data with a wide range of upper resoln. limits using a large repertoire of model parameterizations.  It has several automation features and is also highly flexible.  Several hundred parameters enable extensive customizations for complex use cases.  Multiple user-defined refinement strategies can be applied to specific parts of the model in a single refinement run.  An intuitive graphical user interface is available to guide novice users and to assist advanced users in managing refinement projects.  X-ray or neutron diffraction data can be used sep. or jointly in refinement. phenix.refine is tightly integrated into the PHENIX suite, where it serves as a crit. component in automated model building, final structure refinement, structure validation and deposition to the wwPDB.  This paper presents an overview of the major phenix.refine features, with extensive literature refs. for readers interested in more detailed discussions of the methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhn9QwIEkTbVg90H21EOLACvtfcHk0ljwOEwvdJiTtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D&md5=1cc7da2cea396f1a75646ea709140cf1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444912001308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444912001308%26sid%3Dliteratum%253Aachs%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DMustyakimov%26aufirst%3DM.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DTowards%2520Automated%2520Crystallographic%2520Structure%2520Refinement%2520with%2520Phenix.%2520Refine%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D68%26spage%3D352%26epage%3D367%26doi%3D10.1107%2FS0907444912001308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: Model-Building Tools for Molecular Graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-Building+Tools+for+Molecular+Graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljwOEwvdJiTtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-Building%2520Tools%2520for%2520Molecular%2520Graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b','cit22c'],'ref23':['cit23'],'ref24':['cit24a','cit24b'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 61 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable, <span class="NLM_string-name hlFld-ContribAuthor">James P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 782-790. <a href="https://doi.org/10.1021/acsmedchemlett.1c00044" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BOral%252BAnti-Inflammatory%252BActivity%26aulast%3DTichenor%26aufirst%3DMark%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D28032021%26date%3D05042021%26volume%3D12%26issue%3D5%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Chen, Hao Xiong, Jing-Fang Yang, Xiao-Lei Zhu, Ren-Yu Qu, <span class="NLM_string-name hlFld-ContribAuthor">Guang-Fu Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2020,</strong> <em>68 </em>
                                    (37)
                                     , 9839-9877. <a href="https://doi.org/10.1021/acs.jafc.0c03369" title="DOI URL">https://doi.org/10.1021/acs.jafc.0c03369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.0c03369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.0c03369%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DDiaryl%252BEther%25253A%252BA%252BPrivileged%252BScaffold%252Bfor%252BDrug%252Band%252BAgrochemical%252BDiscovery%26aulast%3DChen%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27052020%26date%3D11082020%26date%3D11082020%26date%3D29082020%26date%3D11082020%26volume%3D68%26issue%3D37%26spage%3D9839%26epage%3D9877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James J. Crawford, Wendy Lee, Adam R. Johnson, Kelly J. Delatorre, Jacob Chen, Charles Eigenbrot, Julia Heidmann, Satoko Kakiuchi-Kiyota, Arna Katewa, James R. Kiefer, Lichuan Liu, Joseph W. Lubach, Dinah Misner, Hans Purkey, Karin Reif, Jennifer Vogt, Harvey Wong, Christine Yu, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     , 1588-1597. <a href="https://doi.org/10.1021/acsmedchemlett.0c00249" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00249%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStereochemical%252BDifferences%252Bin%252BFluorocyclopropyl%252BAmides%252BEnable%252BTuning%252Bof%252BBtk%252BInhibition%252Band%252BOff-Target%252BActivity%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D13072020%26date%3D20072020%26date%3D13072020%26volume%3D11%26issue%3D8%26spage%3D1588%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Bin    Ma    </span><span class="hlFld-ContribAuthor "> Chaomin    Li </span><span class="hlFld-ContribAuthor "> Brian T.    Hopkins </span><span class="hlFld-ContribAuthor "> Lloyd    Franklin </span><span class="hlFld-ContribAuthor "> Robbie    Chen    </span><span class="hlFld-ContribAuthor "> Tamera    Mack </span><span class="hlFld-ContribAuthor "> Daniel    Patience </span><span class="hlFld-ContribAuthor "> William F.    Kiesman </span><span class="hlFld-ContribAuthor "> Erin M.    O’Brien    </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 313-337. <a href="https://doi.org/10.1021/bk-2020-1369.ch010" title="DOI URL">https://doi.org/10.1021/bk-2020-1369.ch010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2020-1369.ch010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2020-1369.ch010%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BProcess%252BDevelopment%252Bof%252BBIIB068%25253A%252BA%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26spage%3D313%26epage%3D337%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B3%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2020%26date%3D2020%26volume%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor T.  Sabe</span>, <span class="hlFld-ContribAuthor ">Thandokuhle  Ntombela</span>, <span class="hlFld-ContribAuthor ">Lindiwe A.  Jhamba</span>, <span class="hlFld-ContribAuthor ">Glenn E.M.  Maguire</span>, <span class="hlFld-ContribAuthor ">Thavendran  Govender</span>, <span class="hlFld-ContribAuthor ">Tricia  Naicker</span>, <span class="hlFld-ContribAuthor ">Hendrik G.  Kruger</span>. </span><span class="cited-content_cbyCitation_article-title">Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113705. <a href="https://doi.org/10.1016/j.ejmech.2021.113705" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113705%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Btrends%252Bin%252Bcomputer%252Baided%252Bdrug%252Bdesign%252Band%252Ba%252Bhighlight%252Bof%252Bdrugs%252Bdiscovered%252Bvia%252Bcomputational%252Btechniques%25253A%252BA%252Breview%26aulast%3DSabe%26aufirst%3DVictor%2BT.%26date%3D2021%26volume%3D224%26spage%3D113705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katharine L  Lewis</span>, <span class="hlFld-ContribAuthor ">Chan Y  Cheah</span>. </span><span class="cited-content_cbyCitation_article-title">Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Personalized Medicine</span><span> <strong>2021,</strong> <em>11 </em>
                                    (8)
                                     , 764. <a href="https://doi.org/10.3390/jpm11080764" title="DOI URL">https://doi.org/10.3390/jpm11080764</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jpm11080764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjpm11080764%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Personalized%2520Medicine%26atitle%3DNon-Covalent%252BBTK%252BInhibitors%2525E2%252580%252594The%252BNew%252BBTKids%252Bon%252Bthe%252BBlock%252Bfor%252BB-Cell%252BMalignancies%26aulast%3DLewis%26aufirst%3DKatharine%2BL%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D8%26spage%3D764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">Mauno  Vihinen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fimmu.2021.694853" title="DOI URL">https://doi.org/10.3389/fimmu.2021.694853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2021.694853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2021.694853%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DStructure-Function%252BRelationships%252Bof%252BCovalent%252Band%252BNon-Covalent%252BBTK%252BInhibitors%26aulast%3DZain%26aufirst%3DRula%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ilias  Pessach</span>, <span class="hlFld-ContribAuthor ">Meletios A.  Dimopoulos</span>, <span class="hlFld-ContribAuthor ">Efstathios  Kastritis</span>. </span><span class="cited-content_cbyCitation_article-title">Managing complications secondary to Waldenström’s macroglobulinemia. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2021,</strong> <em>98 </em>, 1-12. <a href="https://doi.org/10.1080/17474086.2021.1947236" title="DOI URL">https://doi.org/10.1080/17474086.2021.1947236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474086.2021.1947236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474086.2021.1947236%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DManaging%252Bcomplications%252Bsecondary%252Bto%252BWaldenstr%2525C3%2525B6m%2525E2%252580%252599s%252Bmacroglobulinemia%26aulast%3DPessach%26aufirst%3DIlias%26date%3D2021%26date%3D2021%26volume%3D98%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fansheng  Ran</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Huijun  Zhuo</span>, <span class="hlFld-ContribAuthor ">Changqing  Xu</span>, <span class="hlFld-ContribAuthor ">Yuxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Duan</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104968. <a href="https://doi.org/10.1016/j.bioorg.2021.104968" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104968%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bsubstituted%252Bbenzyl%252Bpyrrolopyrimidine%252Bderivatives%252Bas%252Bselective%252BBTK%252Binhibitors%252Bfor%252Btreating%252Bmantle%252Bcell%252Blymphoma%26aulast%3DRan%26aufirst%3DFansheng%26date%3D2021%26volume%3D112%26spage%3D104968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Carla  Villa</span>, <span class="hlFld-ContribAuthor ">Bruno  Tasso</span>, <span class="hlFld-ContribAuthor ">Eleonora  Russo</span>, <span class="hlFld-ContribAuthor ">Andrea  Spallarossa</span>. </span><span class="cited-content_cbyCitation_article-title">Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (14)
                                     , 7641. <a href="https://doi.org/10.3390/ijms22147641" title="DOI URL">https://doi.org/10.3390/ijms22147641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22147641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22147641%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DBtk%252BInhibitors%25253A%252BA%252BMedicinal%252BChemistry%252Band%252BDrug%252BDelivery%252BPerspective%26aulast%3DBrullo%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D14%26spage%3D7641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Zhang</span>, <span class="hlFld-ContribAuthor ">Guiqing  Xu</span>, <span class="hlFld-ContribAuthor ">Jie  Zhao</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Wu</span>, <span class="hlFld-ContribAuthor ">Xing  He</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Shuting  Zhang</span>, <span class="hlFld-ContribAuthor ">Shouning  Yang</span>, <span class="hlFld-ContribAuthor ">Chunhua  Ma</span>, <span class="hlFld-ContribAuthor ">Yuqin  Jiang</span>, <span class="hlFld-ContribAuthor ">Qingjie  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>4 </em>, 113724. <a href="https://doi.org/10.1016/j.ejmech.2021.113724" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113724%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Binvestigation%252Bfor%252Bimidazopyrazole-3-carboxamide%252Bderivatives%252Bas%252Bnovel%252Bselective%252Binhibitors%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%26aulast%3DZhang%26aufirst%3DDandan%26date%3D2021%26volume%3D4%26spage%3D113724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Ming  Cai</span>, <span class="hlFld-ContribAuthor ">Liang  Shao</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein Kinases Degradation by PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fchem.2021.679120" title="DOI URL">https://doi.org/10.3389/fchem.2021.679120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2021.679120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2021.679120%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DTargeting%252BProtein%252BKinases%252BDegradation%252Bby%252BPROTACs%26aulast%3DYu%26aufirst%3DFei%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauren E.  Kueffer</span>, <span class="hlFld-ContribAuthor ">Raji E.  Joseph</span>, <span class="hlFld-ContribAuthor ">Amy H.  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.655489" title="DOI URL">https://doi.org/10.3389/fcell.2021.655489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.655489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.655489%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DReining%252Bin%252BBTK%25253A%252BInterdomain%252BInteractions%252Band%252BTheir%252BImportance%252Bin%252Bthe%252BRegulatory%252BControl%252Bof%252BBTK%26aulast%3DKueffer%26aufirst%3DLauren%2BE.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying C.  Ou</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Tang</span>, <span class="hlFld-ContribAuthor ">William  Novotny</span>, <span class="hlFld-ContribAuthor ">Aileen  Cohen</span>, <span class="hlFld-ContribAuthor ">Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Lucy  Liu</span>, <span class="hlFld-ContribAuthor ">Yuying  Gao</span>, <span class="hlFld-ContribAuthor ">Srikumar  Sahasranaman</span>. </span><span class="cited-content_cbyCitation_article-title">Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Leukemia & Lymphoma</span><span> <strong>2021,</strong> <em>26 </em>, 1-13. <a href="https://doi.org/10.1080/10428194.2021.1929961" title="DOI URL">https://doi.org/10.1080/10428194.2021.1929961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10428194.2021.1929961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10428194.2021.1929961%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%2520%2526%2520Lymphoma%26atitle%3DRationale%252Bfor%252Bonce-daily%252Bor%252Btwice-daily%252Bdosing%252Bof%252Bzanubrutinib%252Bin%252Bpatients%252Bwith%252Bmantle%252Bcell%252Blymphoma%26aulast%3DOu%26aufirst%3DYing%2BC.%26date%3D2021%26date%3D2021%26volume%3D26%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Gerard C. P.  Schaafsma</span>, <span class="hlFld-ContribAuthor ">Yuye  Shi</span>, <span class="hlFld-ContribAuthor ">Litao  Zhou</span>, <span class="hlFld-ContribAuthor ">Dara K.  Mohammad</span>, <span class="hlFld-ContribAuthor ">Liang  Yu</span>, <span class="hlFld-ContribAuthor ">Mauno  Vihinen</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2021,</strong> <em>35 </em>
                                    (5)
                                     , 1317-1329. <a href="https://doi.org/10.1038/s41375-021-01123-6" title="DOI URL">https://doi.org/10.1038/s41375-021-01123-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41375-021-01123-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41375-021-01123-6%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DBTK%252Bgatekeeper%252Bresidue%252Bvariation%252Bcombined%252Bwith%252Bcysteine%252B481%252Bsubstitution%252Bcauses%252Bsuper-resistance%252Bto%252Birreversible%252Binhibitors%252Bacalabrutinib%25252C%252Bibrutinib%252Band%252Bzanubrutinib%26aulast%3DEstupin%25CC%2583%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D5%26spage%3D1317%26epage%3D1329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andres  Arias-Gómez</span>, <span class="hlFld-ContribAuthor ">Andrés  Godoy</span>, <span class="hlFld-ContribAuthor ">Jaime  Portilla</span>. </span><span class="cited-content_cbyCitation_article-title">Functional Pyrazolo[1,5-a]pyrimidines: Current Approaches in Synthetic Transformations and Uses as an Antitumor Scaffold. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2708. <a href="https://doi.org/10.3390/molecules26092708" title="DOI URL">https://doi.org/10.3390/molecules26092708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092708%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DFunctional%252BPyrazolo%25255B1%25252C5-a%25255Dpyrimidines%25253A%252BCurrent%252BApproaches%252Bin%252BSynthetic%252BTransformations%252Band%252BUses%252Bas%252Ban%252BAntitumor%252BScaffold%26aulast%3DArias-G%25C3%25B3mez%26aufirst%3DAndres%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Xueting  Yao</span>, <span class="hlFld-ContribAuthor ">Miao  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongyang  Liu</span>, <span class="hlFld-ContribAuthor ">Yuying  Gao</span>, <span class="hlFld-ContribAuthor ">Srikumar  Sahasranaman</span>, <span class="hlFld-ContribAuthor ">Ying C.  Ou</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator. </span><span class="cited-content_cbyCitation_journal-name">CPT: Pharmacometrics & Systems Pharmacology</span><span> <strong>2021,</strong> <em>10 </em>
                                    (5)
                                     , 441-454. <a href="https://doi.org/10.1002/psp4.12605" title="DOI URL">https://doi.org/10.1002/psp4.12605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/psp4.12605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpsp4.12605%26sid%3Dliteratum%253Aachs%26jtitle%3DCPT%253A%2520Pharmacometrics%2520%2526%2520Systems%2520Pharmacology%26atitle%3DComprehensive%252BPBPK%252Bmodel%252Bto%252Bpredict%252Bdrug%252Binteraction%252Bpotential%252Bof%252BZanubrutinib%252Bas%252Ba%252Bvictim%252Bor%252Bperpetrator%26aulast%3DWang%26aufirst%3DKun%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D5%26spage%3D441%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moritz  Bewarder</span>, <span class="hlFld-ContribAuthor ">Stephan  Stilgenbauer</span>, <span class="hlFld-ContribAuthor ">Lorenz  Thurner</span>, <span class="hlFld-ContribAuthor ">Dominic  Kaddu-Mulindwa</span>. </span><span class="cited-content_cbyCitation_article-title">Current Treatment Options in CLL. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (10)
                                     , 2468. <a href="https://doi.org/10.3390/cancers13102468" title="DOI URL">https://doi.org/10.3390/cancers13102468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13102468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13102468%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCurrent%252BTreatment%252BOptions%252Bin%252BCLL%26aulast%3DBewarder%26aufirst%3DMoritz%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D10%26spage%3D2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting-Ting  Yang</span>, <span class="hlFld-ContribAuthor ">Wei-Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Yan-Min  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua-Rui  Fu</span>, <span class="hlFld-ContribAuthor ">He  Huang</span>, <span class="hlFld-ContribAuthor ">Ji-Min  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.672052" title="DOI URL">https://doi.org/10.3389/fonc.2021.672052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.672052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.672052%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DZanubrutinib%252BTreatment%252Bof%252BCentral%252BNervous%252BSystem%252BPosttransplant%252BLymphoproliferative%252BDisorder%252BAfter%252BAllogeneic%252BHematopoietic%252BStem%252BCell%252BTransplantation%25253A%252BA%252BCase%252BReport%26aulast%3DYang%26aufirst%3DTing-Ting%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tobias  Litzenburger</span>, <span class="hlFld-ContribAuthor ">Jürgen  Steffgen</span>, <span class="hlFld-ContribAuthor ">Ewald  Benediktus</span>, <span class="hlFld-ContribAuthor ">Fabian  Müller</span>, <span class="hlFld-ContribAuthor ">Armin  Schultz</span>, <span class="hlFld-ContribAuthor ">Elliott  Klein</span>, <span class="hlFld-ContribAuthor ">Meera  Ramanujam</span>, <span class="hlFld-ContribAuthor ">Christian  Harcken</span>, <span class="hlFld-ContribAuthor ">Alpana  Gupta</span>, <span class="hlFld-ContribAuthor ">Jing  Wu</span>, <span class="hlFld-ContribAuthor ">Sabrina  Wiebe</span>, <span class="hlFld-ContribAuthor ">Xiujiang  Li</span>, <span class="hlFld-ContribAuthor ">Mary  Flack</span>, <span class="hlFld-ContribAuthor ">Steven J.  Padula</span>, <span class="hlFld-ContribAuthor ">Sudha  Visvanathan</span>, <span class="hlFld-ContribAuthor ">Andreas  Hünnemeyer</span>, <span class="hlFld-ContribAuthor ">Jianan  Hui</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2021,</strong> <em>87 </em>
                                    (4)
                                     , 1824-1838. <a href="https://doi.org/10.1111/bcp.14571" title="DOI URL">https://doi.org/10.1111/bcp.14571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14571%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DSafety%25252C%252Bpharmacokinetics%252Band%252Bpharmacodynamics%252Bof%252BBI%252B705564%25252C%252Ba%252Bhighly%252Bselective%25252C%252Bcovalent%252Binhibitor%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%25252C%252Bin%252BPhase%252BI%252Bclinical%252Btrials%252Bin%252Bhealthy%252Bvolunteers%26aulast%3DLitzenburger%26aufirst%3DTobias%26date%3D2021%26date%3D2020%26volume%3D87%26issue%3D4%26spage%3D1824%26epage%3D1838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.630942" title="DOI URL">https://doi.org/10.3389/fcell.2021.630942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.630942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.630942%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DComparative%252BAnalysis%252Bof%252BBTK%252BInhibitors%252Band%252BMechanisms%252BUnderlying%252BAdverse%252BEffects%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>165 </em>, 105463. <a href="https://doi.org/10.1016/j.phrs.2021.105463" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105463%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bprotein%252Bkinase%252Binhibitors%25253A%252BA%252B2021%252Bupdate%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2021%26volume%3D165%26spage%3D105463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying C.  Ou</span>, <span class="hlFld-ContribAuthor ">Lucy  Liu</span>, <span class="hlFld-ContribAuthor ">Bilal  Tariq</span>, <span class="hlFld-ContribAuthor ">Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Ashutosh  Jindal</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Tang</span>, <span class="hlFld-ContribAuthor ">Yuying  Gao</span>, <span class="hlFld-ContribAuthor ">Srikumar  Sahasranaman</span>. </span><span class="cited-content_cbyCitation_article-title">Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Science</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     , 764-772. <a href="https://doi.org/10.1111/cts.12948" title="DOI URL">https://doi.org/10.1111/cts.12948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cts.12948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcts.12948%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Science%26atitle%3DPopulation%252BPharmacokinetic%252BAnalysis%252Bof%252Bthe%252BBTK%252BInhibitor%252BZanubrutinib%252Bin%252BHealthy%252BVolunteers%252Band%252BPatients%252BWith%252BB%2525E2%252580%252590Cell%252BMalignancies%26aulast%3DOu%26aufirst%3DYing%2BC.%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D2%26spage%3D764%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1103. <a href="https://doi.org/10.3390/cancers13051103" title="DOI URL">https://doi.org/10.3390/cancers13051103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051103%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBleeding%252Bby%252BBruton%252BTyrosine%252BKinase-Inhibitors%25253A%252BDependency%252Bon%252BDrug%252BType%252Band%252BDisease%26aulast%3Dvon%2BHundelshausen%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A  Bond</span>, <span class="hlFld-ContribAuthor ">Peter  Martin</span>, <span class="hlFld-ContribAuthor ">Kami J  Maddocks</span>. </span><span class="cited-content_cbyCitation_article-title">Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1207. <a href="https://doi.org/10.3390/jcm10061207" title="DOI URL">https://doi.org/10.3390/jcm10061207</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm10061207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm10061207%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DRelapsed%252BMantle%252BCell%252BLymphoma%25253A%252BCurrent%252BManagement%25252C%252BRecent%252BProgress%25252C%252Band%252BFuture%252BDirections%26aulast%3DBond%26aufirst%3DDavid%2BA%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harsh  Shah</span>, <span class="hlFld-ContribAuthor ">Deborah  Stephens</span>, <span class="hlFld-ContribAuthor ">John  Seymour</span>, <span class="hlFld-ContribAuthor ">Kami  Maddocks</span>. </span><span class="cited-content_cbyCitation_article-title">Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas. </span><span class="cited-content_cbyCitation_journal-name">American Society of Clinical Oncology Educational Book</span><span> <strong>2021,</strong> <em>136 </em>
                                    (41)
                                     , 310-327. <a href="https://doi.org/10.1200/EDBK_320117" title="DOI URL">https://doi.org/10.1200/EDBK_320117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/EDBK_320117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FEDBK_320117%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%2520Educational%2520Book%26atitle%3DIncorporating%252BNovel%252BTargeted%252Band%252BImmunotherapeutic%252BAgents%252Bin%252Bthe%252BTreatment%252Bof%252BB-Cell%252BLymphomas%26aulast%3DShah%26aufirst%3DHarsh%26date%3D2021%26volume%3D136%26issue%3D41%26spage%3D310%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett  Cosgrove</span>, <span class="hlFld-ContribAuthor ">Kenneth  Down</span>, <span class="hlFld-ContribAuthor ">Sophie  Bertrand</span>, <span class="hlFld-ContribAuthor ">Nicholas C.O.  Tomkinson</span>, <span class="hlFld-ContribAuthor ">Michael D.  Barker</span>. </span><span class="cited-content_cbyCitation_article-title">Investigating the effects of the core nitrogen atom configuration on the thermodynamic solubility of 6,5-bicyclic heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>33 </em>, 127752. <a href="https://doi.org/10.1016/j.bmcl.2020.127752" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127752</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127752%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInvestigating%252Bthe%252Beffects%252Bof%252Bthe%252Bcore%252Bnitrogen%252Batom%252Bconfiguration%252Bon%252Bthe%252Bthermodynamic%252Bsolubility%252Bof%252B6%25252C5-bicyclic%252Bheterocycles%26aulast%3DCosgrove%26aufirst%3DBrett%26date%3D2021%26volume%3D33%26spage%3D127752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingyu  Wen</span>, <span class="hlFld-ContribAuthor ">Jinsong  Wang</span>, <span class="hlFld-ContribAuthor ">Yuankai  Shi</span>, <span class="hlFld-ContribAuthor ">Haili  Qian</span>, <span class="hlFld-ContribAuthor ">Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2021,</strong> <em>35 </em>
                                    (2)
                                     , 312-332. <a href="https://doi.org/10.1038/s41375-020-01072-6" title="DOI URL">https://doi.org/10.1038/s41375-020-01072-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41375-020-01072-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41375-020-01072-6%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DInhibitors%252Btargeting%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Bin%252Bcancers%25253A%252Bdrug%252Bdevelopment%252Badvances%26aulast%3DWen%26aufirst%3DTingyu%26date%3D2021%26date%3D2020%26volume%3D35%26issue%3D2%26spage%3D312%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fandi  Sutanto</span>, <span class="hlFld-ContribAuthor ">Shabnam  Shaabani</span>, <span class="hlFld-ContribAuthor ">Constantinos G.  Neochoritis</span>, <span class="hlFld-ContribAuthor ">Tryfon  Zarganes-Tzitzikas</span>, <span class="hlFld-ContribAuthor ">Pravin  Patil</span>, <span class="hlFld-ContribAuthor ">Ehsan  Ghonchepour</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent reaction–derived covalent inhibitor space. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , eabd9307. <a href="https://doi.org/10.1126/sciadv.abd9307" title="DOI URL">https://doi.org/10.1126/sciadv.abd9307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.abd9307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.abd9307%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DMulticomponent%252Breaction%2525E2%252580%252593derived%252Bcovalent%252Binhibitor%252Bspace%26aulast%3DSutanto%26aufirst%3DFandi%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D6%26spage%3Deabd9307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">David  Vanda</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113094. <a href="https://doi.org/10.1016/j.ejmech.2020.113094" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113094%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C4%25252C6-Trisubstituted%252Bimidazo%25255B4%25252C5-c%25255Dpyridines%252Bas%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DKraj%25C4%258Dovi%25C4%258Dov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2021%26volume%3D211%26spage%3D113094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuping  Zhao</span>, <span class="hlFld-ContribAuthor ">Muhammad  Bilal</span>, <span class="hlFld-ContribAuthor ">Ali  Raza</span>, <span class="hlFld-ContribAuthor ">Muhammad Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Shahid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Uzma  Hayat</span>, <span class="hlFld-ContribAuthor ">Sherif T.S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hafiz M.N.  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>168 </em>, 22-37. <a href="https://doi.org/10.1016/j.ijbiomac.2020.12.009" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTyrosine%252Bkinase%252Binhibitors%252Band%252Btheir%252Bunique%252Btherapeutic%252Bpotentialities%252Bto%252Bcombat%252Bcancer%26aulast%3DZhao%26aufirst%3DYuping%26date%3D2021%26volume%3D168%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joanna M  Rhodes</span>, <span class="hlFld-ContribAuthor ">Anthony R  Mato</span>. </span><span class="cited-content_cbyCitation_article-title">Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Drug Design, Development and Therapy</span><span> <strong>2021,</strong> <em>Volume 15 </em>, 919-926. <a href="https://doi.org/10.2147/DDDT.S250823" title="DOI URL">https://doi.org/10.2147/DDDT.S250823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/DDDT.S250823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FDDDT.S250823%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Design%252C%2520Development%2520and%2520Therapy%26atitle%3DZanubrutinib%252B%252528BGB-3111%252529%25252C%252Ba%252BSecond-Generation%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Band%252BIts%252BUtility%252Bin%252BTreating%252BChronic%252BLymphocytic%252BLeukemia%26aulast%3DRhodes%26aufirst%3DJoanna%2BM%26date%3D2021%26date%3D2021%26volume%3DVolume%252015%26spage%3D919%26epage%3D926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Dreyling</span>, <span class="hlFld-ContribAuthor ">Constantine S  Tam</span>, <span class="hlFld-ContribAuthor ">Michael  Wang</span>, <span class="hlFld-ContribAuthor ">Stephen D  Smith</span>, <span class="hlFld-ContribAuthor ">Marco  Ladetto</span>, <span class="hlFld-ContribAuthor ">Huiqiang  Huang</span>, <span class="hlFld-ContribAuthor ">William  Novotny</span>, <span class="hlFld-ContribAuthor ">Melannie  Co</span>, <span class="hlFld-ContribAuthor ">Alfredo  Romano</span>, <span class="hlFld-ContribAuthor ">Eric  Holmgren</span>, <span class="hlFld-ContribAuthor ">Jane  Huang</span>, <span class="hlFld-ContribAuthor ">Steven Le  Gouill</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (3)
                                     , 255-262. <a href="https://doi.org/10.2217/fon-2020-0794" title="DOI URL">https://doi.org/10.2217/fon-2020-0794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2020-0794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2020-0794%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DA%252BPhase%252BIII%252Bstudy%252Bof%252Bzanubrutinib%252Bplus%252Brituximab%252Bversus%252Bbendamustine%252Bplus%252Brituximab%252Bin%252Btransplant-ineligible%25252C%252Buntreated%252Bmantle%252Bcell%252Blymphoma%26aulast%3DDreyling%26aufirst%3DMartin%26date%3D2021%26volume%3D17%26issue%3D3%26spage%3D255%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiansong  Cheng</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Chenglan  Lv</span>, <span class="hlFld-ContribAuthor ">Jingyan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib. </span><span class="cited-content_cbyCitation_journal-name">OncoTargets and Therapy</span><span> <strong>2021,</strong> <em>Volume 14 </em>, 3367-3372. <a href="https://doi.org/10.2147/OTT.S309408" title="DOI URL">https://doi.org/10.2147/OTT.S309408</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/OTT.S309408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FOTT.S309408%26sid%3Dliteratum%253Aachs%26jtitle%3DOncoTargets%2520and%2520Therapy%26atitle%3DSuccessful%252BManagement%252Bof%252Ba%252BPatient%252Bwith%252BRefractory%252BPrimary%252BCentral%252BNervous%252BSystem%252BLymphoma%252Bby%252BZanubrutinib%26aulast%3DCheng%26aufirst%3DQiansong%26date%3D2021%26date%3D2021%26volume%3DVolume%252014%26spage%3D3367%26epage%3D3372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meletios  Dimopoulos</span>, <span class="hlFld-ContribAuthor ">Ramon Garcia  Sanz</span>, <span class="hlFld-ContribAuthor ">Hui-Peng  Lee</span>, <span class="hlFld-ContribAuthor ">Marek  Trneny</span>, <span class="hlFld-ContribAuthor ">Marzia  Varettoni</span>, <span class="hlFld-ContribAuthor ">Stephen  Opat</span>, <span class="hlFld-ContribAuthor ">Shirley  D'Sa</span>, <span class="hlFld-ContribAuthor ">Roger G.  Owen</span>, <span class="hlFld-ContribAuthor ">Gavin  Cull</span>, <span class="hlFld-ContribAuthor ">Stephen  Mulligan</span>, <span class="hlFld-ContribAuthor ">Jaroslaw  Czyz</span>, <span class="hlFld-ContribAuthor ">Jorge J.  Castillo</span>, <span class="hlFld-ContribAuthor ">Marina  Motta</span>, <span class="hlFld-ContribAuthor ">Tanya  Siddiqi</span>, <span class="hlFld-ContribAuthor ">Mercedes  Gironella Mesa</span>, <span class="hlFld-ContribAuthor ">Miquel  Granell Gorrochategui</span>, <span class="hlFld-ContribAuthor ">Dipti  Talaulikar</span>, <span class="hlFld-ContribAuthor ">Pier Luigi  Zinzani</span>, <span class="hlFld-ContribAuthor ">Elham  Askari</span>, <span class="hlFld-ContribAuthor ">Sebastian  Grosicki</span>, <span class="hlFld-ContribAuthor ">Albert  Oriol</span>, <span class="hlFld-ContribAuthor ">Simon  Rule</span>, <span class="hlFld-ContribAuthor ">Janusz  Kloczko</span>, <span class="hlFld-ContribAuthor ">Alessandra  Tedeschi</span>, <span class="hlFld-ContribAuthor ">Christian  Buske</span>, <span class="hlFld-ContribAuthor ">Veronique  Leblond</span>, <span class="hlFld-ContribAuthor ">Judith  Trotman</span>, <span class="hlFld-ContribAuthor ">Wai Y.  Chan</span>, <span class="hlFld-ContribAuthor ">Jan  Michel</span>, <span class="hlFld-ContribAuthor ">Jingjing  Schneider</span>, <span class="hlFld-ContribAuthor ">Ziwen  Tan</span>, <span class="hlFld-ContribAuthor ">Aileen  Cohen</span>, <span class="hlFld-ContribAuthor ">Jane  Huang</span>, <span class="hlFld-ContribAuthor ">Constantine S.  Tam</span>. </span><span class="cited-content_cbyCitation_article-title">Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. </span><span class="cited-content_cbyCitation_journal-name">Blood Advances</span><span> <strong>2020,</strong> <em>4 </em>
                                    (23)
                                     , 6009-6018. <a href="https://doi.org/10.1182/bloodadvances.2020003010" title="DOI URL">https://doi.org/10.1182/bloodadvances.2020003010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/bloodadvances.2020003010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fbloodadvances.2020003010%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Advances%26atitle%3DZanubrutinib%252Bfor%252Bthe%252Btreatment%252Bof%252BMYD88%252Bwild-type%252BWaldenstr%2525C3%2525B6m%252Bmacroglobulinemia%25253A%252Ba%252Bsubstudy%252Bof%252Bthe%252Bphase%252B3%252BASPEN%252Btrial%26aulast%3DDimopoulos%26aufirst%3DMeletios%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D23%26spage%3D6009%26epage%3D6018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khalid  El Bairi</span>, <span class="hlFld-ContribAuthor ">Dario  Trapani</span>, <span class="hlFld-ContribAuthor ">Angelica  Petrillo</span>, <span class="hlFld-ContribAuthor ">Cécile  Le Page</span>, <span class="hlFld-ContribAuthor ">Hanaa  Zbakh</span>, <span class="hlFld-ContribAuthor ">Bruno  Daniele</span>, <span class="hlFld-ContribAuthor ">Rhizlane  Belbaraka</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Curigliano</span>, <span class="hlFld-ContribAuthor ">Said  Afqir</span>. </span><span class="cited-content_cbyCitation_article-title">Repurposing anticancer drugs for the management of COVID-19. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Cancer</span><span> <strong>2020,</strong> <em>141 </em>, 40-61. <a href="https://doi.org/10.1016/j.ejca.2020.09.014" title="DOI URL">https://doi.org/10.1016/j.ejca.2020.09.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejca.2020.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejca.2020.09.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Cancer%26atitle%3DRepurposing%252Banticancer%252Bdrugs%252Bfor%252Bthe%252Bmanagement%252Bof%252BCOVID-19%26aulast%3DEl%2BBairi%26aufirst%3DKhalid%26date%3D2020%26volume%3D141%26spage%3D40%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Qianmao  Liang</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2020,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-020-00309-1" title="DOI URL">https://doi.org/10.1038/s41392-020-00309-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-020-00309-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-020-00309-1%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bpotent%252Band%252Bselective%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitor%252Bavoiding%252Bimpairment%252Bof%252BADCC%252Beffects%252Bfor%252BB-cell%252Bnon-Hodgkin%252Blymphoma%26aulast%3DLiu%26aufirst%3DJuan%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Xiaojun Julia  Liang</span>, <span class="hlFld-ContribAuthor ">Martin  Schröder</span>, <span class="hlFld-ContribAuthor ">Stefan  Gerstenecker</span>, <span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 9269. <a href="https://doi.org/10.3390/ijms21239269" title="DOI URL">https://doi.org/10.3390/ijms21239269</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21239269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21239269%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BClass%252Bof%252BCovalent%252BDual%252BInhibitors%252BTargeting%252Bthe%252BProtein%252BKinases%252BBMX%252Band%252BBTK%26aulast%3DForster%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D9269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel P.  Duarte</span>, <span class="hlFld-ContribAuthor ">Allan J.  Lamontanara</span>, <span class="hlFld-ContribAuthor ">Giuseppina  La Sala</span>, <span class="hlFld-ContribAuthor ">Sukyo  Jeong</span>, <span class="hlFld-ContribAuthor ">Yoo-Kyoung  Sohn</span>, <span class="hlFld-ContribAuthor ">Alejandro  Panjkovich</span>, <span class="hlFld-ContribAuthor ">Sandrine  Georgeon</span>, <span class="hlFld-ContribAuthor ">Tim  Kükenshöner</span>, <span class="hlFld-ContribAuthor ">Maria J.  Marcaida</span>, <span class="hlFld-ContribAuthor ">Florence  Pojer</span>, <span class="hlFld-ContribAuthor ">Marco  De Vivo</span>, <span class="hlFld-ContribAuthor ">Dmitri  Svergun</span>, <span class="hlFld-ContribAuthor ">Hak-Sung  Kim</span>, <span class="hlFld-ContribAuthor ">Matteo  Dal Peraro</span>, <span class="hlFld-ContribAuthor ">Oliver  Hantschel</span>. </span><span class="cited-content_cbyCitation_article-title">Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-020-16128-5" title="DOI URL">https://doi.org/10.1038/s41467-020-16128-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-020-16128-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-020-16128-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DBtk%252BSH2-kinase%252Binterface%252Bis%252Bcritical%252Bfor%252Ballosteric%252Bkinase%252Bactivation%252Band%252Bits%252Btargeting%252Binhibits%252BB-cell%252Bneoplasms%26aulast%3DDuarte%26aufirst%3DDaniel%2BP.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Walter  Hanel</span>, <span class="hlFld-ContribAuthor ">Narendranath  Epperla</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging therapies in mantle cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-020-00914-1" title="DOI URL">https://doi.org/10.1186/s13045-020-00914-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-020-00914-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-020-00914-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DEmerging%252Btherapies%252Bin%252Bmantle%252Bcell%252Blymphoma%26aulast%3DHanel%26aufirst%3DWalter%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raji E  Joseph</span>, <span class="hlFld-ContribAuthor ">Neha  Amatya</span>, <span class="hlFld-ContribAuthor ">D Bruce  Fulton</span>, <span class="hlFld-ContribAuthor ">John R  Engen</span>, <span class="hlFld-ContribAuthor ">Thomas E  Wales</span>, <span class="hlFld-ContribAuthor ">Amy  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2020,</strong> <em>9 </em><a href="https://doi.org/10.7554/eLife.60470" title="DOI URL">https://doi.org/10.7554/eLife.60470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.60470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.60470%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DDifferential%252Bimpact%252Bof%252BBTK%252Bactive%252Bsite%252Binhibitors%252Bon%252Bthe%252Bconformational%252Bstate%252Bof%252Bfull-length%252BBTK%26aulast%3DJoseph%26aufirst%3DRaji%2BE%26date%3D2020%26date%3D2020%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin F.  Creeden</span>, <span class="hlFld-ContribAuthor ">Khaled  Alganem</span>, <span class="hlFld-ContribAuthor ">Ali S.  Imami</span>, <span class="hlFld-ContribAuthor ">Nicholas D.  Henkel</span>, <span class="hlFld-ContribAuthor ">F. Charles  Brunicardi</span>, <span class="hlFld-ContribAuthor ">Shi-He  Liu</span>, <span class="hlFld-ContribAuthor ">Rammohan  Shukla</span>, <span class="hlFld-ContribAuthor ">Tushar  Tomar</span>, <span class="hlFld-ContribAuthor ">Faris  Naji</span>, <span class="hlFld-ContribAuthor ">Robert E.  McCullumsmith</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (22)
                                     , 8823. <a href="https://doi.org/10.3390/ijms21228823" title="DOI URL">https://doi.org/10.3390/ijms21228823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21228823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21228823%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DEmerging%252BKinase%252BTherapeutic%252BTargets%252Bin%252BPancreatic%252BDuctal%252BAdenocarcinoma%252Band%252BPancreatic%252BCancer%252BDesmoplasia%26aulast%3DCreeden%26aufirst%3DJustin%2BF.%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D22%26spage%3D8823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Constantine S.  Tam</span>, <span class="hlFld-ContribAuthor ">Hang  Quach</span>, <span class="hlFld-ContribAuthor ">Andrew  Nicol</span>, <span class="hlFld-ContribAuthor ">Xavier  Badoux</span>, <span class="hlFld-ContribAuthor ">Hannah  Rose</span>, <span class="hlFld-ContribAuthor ">H. Miles  Prince</span>, <span class="hlFld-ContribAuthor ">Michael F.  Leahy</span>, <span class="hlFld-ContribAuthor ">Richard  Eek</span>, <span class="hlFld-ContribAuthor ">Nicholas  Wickham</span>, <span class="hlFld-ContribAuthor ">Sushrut S.  Patil</span>, <span class="hlFld-ContribAuthor ">Jane  Huang</span>, <span class="hlFld-ContribAuthor ">Radha  Prathikanti</span>, <span class="hlFld-ContribAuthor ">Aileen  Cohen</span>, <span class="hlFld-ContribAuthor ">Rebecca  Elstrom</span>, <span class="hlFld-ContribAuthor ">William  Reed</span>, <span class="hlFld-ContribAuthor ">Jingjing  Schneider</span>, <span class="hlFld-ContribAuthor ">Ian W.  Flinn</span>. </span><span class="cited-content_cbyCitation_article-title">Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Blood Advances</span><span> <strong>2020,</strong> <em>4 </em>
                                    (19)
                                     , 4802-4811. <a href="https://doi.org/10.1182/bloodadvances.2020002183" title="DOI URL">https://doi.org/10.1182/bloodadvances.2020002183</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/bloodadvances.2020002183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fbloodadvances.2020002183%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Advances%26atitle%3DZanubrutinib%252B%252528BGB-3111%252529%252Bplus%252Bobinutuzumab%252Bin%252Bpatients%252Bwith%252Bchronic%252Blymphocytic%252Bleukemia%252Band%252Bfollicular%252Blymphoma%26aulast%3DTam%26aufirst%3DConstantine%2BS.%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D19%26spage%3D4802%26epage%3D4811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Praveen Ramakrishnan  Geethakumari</span>, <span class="hlFld-ContribAuthor ">Farrukh  Awan</span>. </span><span class="cited-content_cbyCitation_article-title">An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (10)
                                     , 1039-1046. <a href="https://doi.org/10.1080/17474086.2020.1817735" title="DOI URL">https://doi.org/10.1080/17474086.2020.1817735</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474086.2020.1817735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474086.2020.1817735%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DAn%252Bevaluation%252Bof%252Bzanubrutinib%25252C%252Ba%252BBTK%252Binhibitor%25252C%252Bfor%252Bthe%252Btreatment%252Bof%252Bchronic%252Blymphocytic%252Bleukemia%26aulast%3DGeethakumari%26aufirst%3DPraveen%2BRamakrishnan%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D10%26spage%3D1039%26epage%3D1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A.  Bond</span>, <span class="hlFld-ContribAuthor ">Kami J.  Maddocks</span>. </span><span class="cited-content_cbyCitation_article-title">Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Hematology/Oncology Clinics of North America</span><span> <strong>2020,</strong> <em>34 </em>
                                    (5)
                                     , 903-921. <a href="https://doi.org/10.1016/j.hoc.2020.06.007" title="DOI URL">https://doi.org/10.1016/j.hoc.2020.06.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.hoc.2020.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.hoc.2020.06.007%26sid%3Dliteratum%253Aachs%26jtitle%3DHematology%252FOncology%2520Clinics%2520of%2520North%2520America%26atitle%3DCurrent%252BRole%252Band%252BEmerging%252BEvidence%252Bfor%252BBruton%252BTyrosine%252BKinase%252BInhibitors%252Bin%252Bthe%252BTreatment%252Bof%252BMantle%252BCell%252BLymphoma%26aulast%3DBond%26aufirst%3DDavid%2BA.%26date%3D2020%26volume%3D34%26issue%3D5%26spage%3D903%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zizhen  Yin</span>, <span class="hlFld-ContribAuthor ">Wenfei  Hu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Konno</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2020,</strong> <em>52 </em>
                                    (9)
                                     , 1227-1261. <a href="https://doi.org/10.1007/s00726-020-02887-4" title="DOI URL">https://doi.org/10.1007/s00726-020-02887-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-020-02887-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-020-02887-4%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DTailor-made%252Bamino%252Bacid-derived%252Bpharmaceuticals%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DYin%26aufirst%3DZizhen%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D9%26spage%3D1227%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhenbang  Li</span>, <span class="hlFld-ContribAuthor ">Yumei  Zou</span>, <span class="hlFld-ContribAuthor ">Shengnan  Ren</span>, <span class="hlFld-ContribAuthor ">Yu  Cheng</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and highly selective covalent inhibitors of Bruton’s tyrosine kinase bearing triazine scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112339. <a href="https://doi.org/10.1016/j.ejmech.2020.112339" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112339%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bhighly%252Bselective%252Bcovalent%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Bbearing%252Btriazine%252Bscaffold%26aulast%3DTeng%26aufirst%3DYu%26date%3D2020%26volume%3D199%26spage%3D112339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elżbieta  Iskierka-Jażdżewska</span>, <span class="hlFld-ContribAuthor ">Tadeusz  Robak</span>. </span><span class="cited-content_cbyCitation_article-title">Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (7)
                                     , 709-722. <a href="https://doi.org/10.1080/13543784.2020.1770225" title="DOI URL">https://doi.org/10.1080/13543784.2020.1770225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1770225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1770225%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInvestigational%252Btreatments%252Bfor%252Bchronic%252Blymphocytic%252Bleukemia%25253A%252Ba%252Bfocus%252Bon%252Bphase%252B1%252Band%252B2%252Bclinical%252Btrials%26aulast%3DIskierka-Ja%25C5%25BCd%25C5%25BCewska%26aufirst%3DEl%25C5%25BCbieta%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D7%26spage%3D709%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Zanubrutinib Shows Clinical Benefits in Waldenström Macroglobulinemia. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1634/theoncologist.2020-0557" title="DOI URL">https://doi.org/10.1634/theoncologist.2020-0557</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2020-0557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2020-0557%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DZanubrutinib%252BShows%252BClinical%252BBenefits%252Bin%252BWaldenstr%2525C3%2525B6m%252BMacroglobulinemia%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3DS1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kuanglei  Wang</span>, <span class="hlFld-ContribAuthor ">Hongxi  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongqian  Zhao</span>, <span class="hlFld-ContribAuthor ">Kun  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongshou  Tian</span>. </span><span class="cited-content_cbyCitation_article-title">Application of carbamyl in structural optimization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103757. <a href="https://doi.org/10.1016/j.bioorg.2020.103757" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103757</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103757%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DApplication%252Bof%252Bcarbamyl%252Bin%252Bstructural%252Boptimization%26aulast%3DWang%26aufirst%3DKuanglei%26date%3D2020%26volume%3D98%26spage%3D103757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Rogers</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Woyach</span>. </span><span class="cited-content_cbyCitation_article-title">BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Hematology</span><span> <strong>2020,</strong> <em>11 </em>, 204062072091299. <a href="https://doi.org/10.1177/2040620720912990" title="DOI URL">https://doi.org/10.1177/2040620720912990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2040620720912990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2040620720912990%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Hematology%26atitle%3DBTK%252Binhibitors%252Band%252Banti-CD20%252Bmonoclonal%252Bantibodies%252Bfor%252Btreatment-na%2525C3%2525AFve%252Belderly%252Bpatients%252Bwith%252BCLL%26aulast%3DRogers%26aufirst%3DAndrew%26date%3D2020%26date%3D2020%26volume%3D11%26spage%3D204062072091299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lori A.  Leslie</span>, <span class="hlFld-ContribAuthor ">Tatyana A.  Feldman</span>, <span class="hlFld-ContribAuthor ">Ann  McNeill</span>, <span class="hlFld-ContribAuthor ">Mary  Timberg</span>, <span class="hlFld-ContribAuthor ">Hoshiyuki  Iida</span>, <span class="hlFld-ContribAuthor ">Andre H.  Goy</span>. </span><span class="cited-content_cbyCitation_article-title">Contemporary management of nodal and primary splenic marginal zone lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (12)
                                     , 1011-1022. <a href="https://doi.org/10.1080/17474086.2020.1681962" title="DOI URL">https://doi.org/10.1080/17474086.2020.1681962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474086.2020.1681962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474086.2020.1681962%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DContemporary%252Bmanagement%252Bof%252Bnodal%252Band%252Bprimary%252Bsplenic%252Bmarginal%252Bzone%252Blymphoma%26aulast%3DLeslie%26aufirst%3DLori%2BA.%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D12%26spage%3D1011%26epage%3D1022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jorge J.  Castillo</span>, <span class="hlFld-ContribAuthor ">Steven P.  Treon</span>. </span><span class="cited-content_cbyCitation_article-title">What is new in the treatment of Waldenstrom macroglobulinemia?. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2019,</strong> <em>33 </em>
                                    (11)
                                     , 2555-2562. <a href="https://doi.org/10.1038/s41375-019-0592-8" title="DOI URL">https://doi.org/10.1038/s41375-019-0592-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41375-019-0592-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41375-019-0592-8%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DWhat%252Bis%252Bnew%252Bin%252Bthe%252Btreatment%252Bof%252BWaldenstrom%252Bmacroglobulinemia%25253F%26aulast%3DCastillo%26aufirst%3DJorge%2BJ.%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D11%26spage%3D2555%26epage%3D2562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan A.  Burger</span>. </span><span class="cited-content_cbyCitation_article-title">Bruton Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Cancer Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (6)
                                     , 386-393. <a href="https://doi.org/10.1097/PPO.0000000000000412" title="DOI URL">https://doi.org/10.1097/PPO.0000000000000412</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/PPO.0000000000000412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FPPO.0000000000000412%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Cancer%2520Journal%26atitle%3DBruton%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DBurger%26aufirst%3DJan%2BA.%26date%3D2019%26volume%3D25%26issue%3D6%26spage%3D386%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Yao</span>, <span class="hlFld-ContribAuthor ">Nan  Du</span>, <span class="hlFld-ContribAuthor ">Shasha  Hu</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid advances in research on and development of anticancer drugs in China. </span><span class="cited-content_cbyCitation_journal-name">BioScience Trends</span><span> <strong>2019,</strong> <em>13 </em>
                                    (5)
                                     , 461-463. <a href="https://doi.org/10.5582/bst.2019.01243" title="DOI URL">https://doi.org/10.5582/bst.2019.01243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5582/bst.2019.01243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5582%2Fbst.2019.01243%26sid%3Dliteratum%253Aachs%26jtitle%3DBioScience%2520Trends%26atitle%3DRapid%252Badvances%252Bin%252Bresearch%252Bon%252Band%252Bdevelopment%252Bof%252Banticancer%252Bdrugs%252Bin%252BChina%26aulast%3DYao%26aufirst%3DXu%26date%3D2019%26volume%3D13%26issue%3D5%26spage%3D461%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known irreversible BTK inhibitors in the clinic.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of new series of compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Electron density map corresponding to <b>31a</b> and Cys481 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a>). <b>31a</b> is shown as sticks and colored in magenta. The key residues of human BTK around the compound are shown as sticks and colored in green. Water molecules are shown as spheres. The density map of <b>31a</b> and Cys481 is shown as mesh in gray. The <i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> electron-density map for <b>31a</b> was contoured at 3.0σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode comparison between <b>31a</b> and Ibrutinib. (a) Binding mode of Ibrutinib and BTK from cocrystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J">5P9J</a>). (b) Binding mode of <b>31a</b> and BTK from cocrystal structure (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a>). (c) Alignment between Ibrutinib and <b>31a</b>. BTK is shown as ribbon and colored in orange. Ibrutinib, <b>31a</b>, and the amino acid residues of BTK interacting with compound are shown as stick and are colored in green, magenta, and gray, respectively. Water molecules are shown as spheres. The figure is generated using Schrödinger software (Maestro 11.2 in Schrödinger Suite 2017-2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) ICR mice were treated with 14.5 mg/kg of <b>31a</b> and euthanized at different time points after dosing as indicated. PBMC and spleens were collected for BTK occupancy assay. Plasma drug concentration of <b>31a</b> was also determined at different time points. (B) ICR mice were treated with different dose levels of <b>31a</b> or Ibrutinib and euthanized 4 h after dosing. PBMC and spleens were collected from euthanized mice, and protein lysates were prepared for BTK occupancy assay. (C) Plasma drug concentration of <b>31a</b> or Ibrutinib was measured at 0.5 h after dosing. Data are presented as mean ± SEM of four animals in each group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) OCI-LY10 tumor cells (5 × 10<sup>6</sup>) were implanted subcutaneously in female NCG mice. When the tumors were palpable, mice were randomly divided into five groups and treated for 28 days as indicated. Data are presented as mean tumor volume ± SEM of 12 animals in each group. (B) Plasma drug concentration of <b>31a</b> and Ibrutinib was measured at the indicated time points after dosing. Data are presented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of <b>5</b>, <b>6</b>, <b>7</b>, and <b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EtOH, 2-(methoxy(4-phenoxyphenyl)methylene)malononitrile, 70 °C; (ii) phosphorous acid (85% in H<sub>2</sub>O), 100 °C; (iii) DMF, CuI, <i>N</i><sub>1</sub>,<i>N</i><sub>2</sub>-dimethylethane-1,2-diamine, K<sub>3</sub>PO<sub>4</sub>, 60 °C; (iv) HOAc, Zn, rt; (v) DCM, acryloyl chloride, TEA, 0 °C to rt; (vi) THF, benzyl bromide, 65 °C, then MeOH, NaBH<sub>4</sub>, rt; (vii) MeOH, Pd/C (10%), H<sub>2</sub> (1 atm), rt.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of <b>8</b>, <b>9</b>, <b>11</b>, and <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 5-amino-3-(4-phenoxyphenyl)-1<i>H</i>-pyrazole-4-carbonitrile, DMF, K<sub>2</sub>CO<sub>3</sub>, 80 °C; (ii) H<sub>3</sub>PO<sub>4</sub> (85% in H<sub>2</sub>O), 100 °C; (iii) DCM, acryloyl chloride, TEA, 0 °C to rt or 4-(dimethylamino)but-2-enoic acid hydrochloride, HATU, TEA, DCM, rt.</p></p></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Synthesis of <b>13</b>–<b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) H<sub>3</sub>PO<sub>4</sub> (85% in water), 120 °C; (ii) EtOH, haloketone, 80 °C; (iii) MeOH/DCM, Pd/C (10%), H<sub>2</sub> (balloon), rt; (iv) HCl, MeOH, rt; (v) DCM, TEA, acryloyl chloride, rt.</p></p></figure><figure data-id="sch4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. General Synthesis of <b>18</b>–<b>20</b> and <b>25</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) 3-dimethylamino-1-(aryl, heteroaryl, or alkyl)-2-propen-1-one; acetic acid, reflux; (ii) EtOH or MeOH, HCl (conc), 75 or 60 °C, or hydrazine hydrate, MeOH/dioxane, 60 °C, or Pd/C (10%), MeOH/DCM, rt, H<sub>2</sub>; (iii) EtOH, NaBH<sub>4</sub>, 60 °C; (iv) DMSO/EtOH (v:v = 1:1), 5 N NaOH, H<sub>2</sub>O<sub>2</sub> (30%), 60 °C; (v) chiral separation; (vi) DCM, pyridine or Et<sub>3</sub>N, acryloyl chloride, rt.</p></p></figure><figure data-id="sch5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/medium/jm9b00687_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. General Synthesis of <b>22</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-17/acs.jmedchem.9b00687/20190905/images/large/jm9b00687_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00687&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) MeOH/DCM, Pd/C (10%), H<sub>2</sub> (3 atm), rt; (ii) acetone, R<sub>1</sub>Br, K<sub>2</sub>CO<sub>3</sub>, rt or reflux; (iii) DMSO/EtOH (v:v = 1:1), NaOH (1N), H<sub>2</sub>O<sub>2</sub> (30%), 60 °C; (iv) DCM, Et<sub>3</sub>N, acryloyl chloride, rt; (v) chiral separation.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10066" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10066" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vořechovský, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarström, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. R.</span></span> <span> </span><span class="NLM_article-title">The Gene Involved in X-linked Agammaglobulinaemia is a Member of the Src Family of Protein-tyrosine Kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/361226a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2F361226a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=8380905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=226-233&author=D.+Vetrieauthor=I.+Vo%C5%99echovsk%C3%BDauthor=P.+Siderasauthor=J.+Hollandauthor=A.+Daviesauthor=F.+Flinterauthor=L.+Hammarstr%C3%B6mauthor=C.+Kinnonauthor=R.+Levinskyauthor=M.+Bobrowauthor=C.+I.+E.+Smithauthor=D.+R.+Bentley&title=The+Gene+Involved+in+X-linked+Agammaglobulinaemia+is+a+Member+of+the+Src+Family+of+Protein-tyrosine+Kinases&doi=10.1038%2F361226a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases</span></div><div class="casAuthors">Vetrie, David; Vorechovsky, Igor; Sideras, Paschalis; Holland, Jill; Davies, Angela; Flinter, Frances; Hammarstroem, Lennart; Kinnon, Christine; Levinsky, Roland; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6409</span>),
    <span class="NLM_cas:pages">226-33</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by failure of pre-B cells in the bone marrow to develop into circulating mature B cells.  A novel gene (atk) has been isolated which maps to the XLA locus, is expressed in B cells, and shows mutations in families with the disorder.  The gene is a member of the src family of protooncogenes which encode protein-tyrosine kinases.  This is, to the authors knowledge, the first evidence that mutations in a src-related gene are involved in human genetic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGa0C4aUVMrVg90H21EOLACvtfcHk0ljmjPsXDUgV7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D&md5=de1b23e0c0328d916633d0f92ddc1d68</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2F361226a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F361226a0%26sid%3Dliteratum%253Aachs%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DVo%25C5%2599echovsk%25C3%25BD%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DFlinter%26aufirst%3DF.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLevinsky%26aufirst%3DR.%26aulast%3DBobrow%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DBentley%26aufirst%3DD.%2BR.%26atitle%3DThe%2520Gene%2520Involved%2520in%2520X-linked%2520Agammaglobulinaemia%2520is%2520a%2520Member%2520of%2520the%2520Src%2520Family%2520of%2520Protein-tyrosine%2520Kinases%26jtitle%3DNature%26date%3D1993%26volume%3D361%26spage%3D226%26epage%3D233%26doi%3D10.1038%2F361226a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, J. M.</span></span> <span> </span><span class="NLM_article-title">The Src, Syk, and Tec Family Kinases: Distinct Types of Molecular Switches</span>. <i>Cell. Signalling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1016/j.cellsig.2010.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.cellsig.2010.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20206686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=1175-1184&author=J.+M.+Bradshaw&title=The+Src%2C+Syk%2C+and+Tec+Family+Kinases%3A+Distinct+Types+of+Molecular+Switches&doi=10.1016%2Fj.cellsig.2010.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The Src, Syk, and Tec family kinases: Distinct types of molecular switches</span></div><div class="casAuthors">Bradshaw, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The Src, Syk, and Tec family kinases are three of the most well characterized tyrosine kinase families found in the human genome.  Members of these kinase families function downstream of antigen and Fc receptors in hematopoietic cells and transduce signals leading to calcium mobilization, altered gene expression, cytokine prodn., and cell proliferation.  Over the last several years, structural and biochem. studies have begun to uncover the mol. mechanisms regulating activation of these kinases.  It appears that each kinase family functions as a distinct type of mol. switch.  This review discusses the activation of the Src, Syk, and Tec kinases from the perspective of structure, phosphorylation, allosteric regulation, and kinetics.  The multiple factors that regulate the Src, Syk, and Tec families illustrate the important role played by each of these kinases in immune cell signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PA9QDCCGPLVg90H21EOLACvtfcHk0lg2ZpB3zneRxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtlyntbw%253D&md5=7f562f792a04682d05aa32dc09a7cb6e</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2010.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2010.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520Src%252C%2520Syk%252C%2520and%2520Tec%2520Family%2520Kinases%253A%2520Distinct%2520Types%2520of%2520Molecular%2520Switches%26jtitle%3DCell.%2520Signalling%26date%3D2010%26volume%3D22%26spage%3D1175%26epage%3D1184%26doi%3D10.1016%2Fj.cellsig.2010.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humire-Greiff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniar, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjellén, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarström, L.</span></span> <span> </span><span class="NLM_article-title">Expression of Bruton’s Agammaglobulinemia Tyrosine Kinase Gene, Btk, is Selectively Down-regulated in T Lymphocytes and Plasma Cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">557</span>– <span class="NLM_lpage">565</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=8283037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1994&pages=557-565&author=C.+I.+Smithauthor=B.+Baskinauthor=B.+Humire-Greiffauthor=J.+N.+Zhouauthor=P.+G.+Olssonauthor=H.+S.+Maniarauthor=P.+Kjell%C3%A9nauthor=J.+D.+Lambrisauthor=B.+Christenssonauthor=L.+Hammarstr%C3%B6m&title=Expression+of+Bruton%E2%80%99s+Agammaglobulinemia+Tyrosine+Kinase+Gene%2C+Btk%2C+is+Selectively+Down-regulated+in+T+Lymphocytes+and+Plasma+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells</span></div><div class="casAuthors">Smith, C. I. Edvard; Baskin, Berivan; Humire-Greiff, Patricia; Zhou, Jian Nian; Olsson, Per G.; Maniar, Hina S.; Kjellen, Peter; Lambris, John D.; Christensson, Birger; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">557-65</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">The gene mutated in the human disease, X-linked agammaglobulinemia (XLA), is related to the Src gene family of cytoplasmic protein-tyrosine kinases and is designated Btk (Bruton's agammaglobulinemia tyrosine kinase; formerly Atk/Bpk; the human gene is denoted BTK, using capital letters according to the kinase nomenclature).  The authors have recently reported that this gene is expressed in B lymphocytes and that the specific mRNA was undetectable in T cells using Northern blotting.  Further analyses of different sources of B and T lymphocytes confirmed this pattern.  However, BTK transcripts were undetectable in four plasmacytoma lines.  Moreover, as virtually normal amts. of BTK transcripts were found in PBMC from two patients carrying a point mutation in BTK, despite low B cell nos., the authors anticipated that the gene would also be expressed in cells of other lineages.  The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.  BTK mRNA was also detected in monocytes from healthy donors as well as in the human immature basophilic cell line KU812, in the human mast cell leukemia cell line HMC-1 and in the CD34 expressing myeloblast KG-1.  A similar expression pattern was obtained when BTK protein was analyzed by immunopptn. and Western blotting.  Using a polymerase chain reaction-based anal., a small amt. (less than 1% of the level in B cells) of BTK mRNA was identified in T lymphocytes.  The authors' findings are compatible with a general expression of the BTK gene in hematopoietic cells, except in T lymphocytes and plasma cells, in which the transcript level is selectively down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKw_P8osJHjLVg90H21EOLACvtfcHk0lg2ZpB3zneRxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCrsb0%253D&md5=c18d78dc39ed08bd0c1fb784cbf549a1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHumire-Greiff%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DJ.%2BN.%26aulast%3DOlsson%26aufirst%3DP.%2BG.%26aulast%3DManiar%26aufirst%3DH.%2BS.%26aulast%3DKjell%25C3%25A9n%26aufirst%3DP.%26aulast%3DLambris%26aufirst%3DJ.%2BD.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520Agammaglobulinemia%2520Tyrosine%2520Kinase%2520Gene%252C%2520Btk%252C%2520is%2520Selectively%2520Down-regulated%2520in%2520T%2520Lymphocytes%2520and%2520Plasma%2520Cells%26jtitle%3DJ.%2520Immunol.%26date%3D1994%26volume%3D152%26spage%3D557%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbs, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coustan-Smith, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campana, D.</span></span> <span> </span><span class="NLM_article-title">Primary B Cell Immunodeficiencies: Comparisons and Contrasts</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.021908.132649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1146%2Fannurev.immunol.021908.132649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=19302039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=199-227&author=M.+E.+Conleyauthor=A.+K.+Dobbsauthor=D.+M.+Farmerauthor=S.+Kilicauthor=K.+Parisauthor=S.+Grigoriadouauthor=E.+Coustan-Smithauthor=V.+Howardauthor=D.+Campana&title=Primary+B+Cell+Immunodeficiencies%3A+Comparisons+and+Contrasts&doi=10.1146%2Fannurev.immunol.021908.132649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Primary B cell immunodeficiencies: comparisons and contrasts</span></div><div class="casAuthors">Conley, Mary Ellen; Dobbs, A. Kerry; Farmer, Dana M.; Kilic, Sebnem; Paris, Kenneth; Grigoriadou, Sofia; Coustan-Smith, Elaine; Howard, Vanessa; Campana, Dario</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">199-227</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Sophisticated genetic tools have made possible the identification of the genes responsible for most well-described immunodeficiencies in the past 15 years.  Mutations in Btk, components of the pre-B cell and B cell receptor (λ5, Igα, Igβ), or the scaffold protein BLNK account for approx. 90% of patients with defects in early B cell development.  Hyper-IgM syndromes result from mutations in CD40 ligand, CD40, AID, or UNG in 70-80% of affected patients.  Rare defects in ICOS or CD19 can result in a clin. picture that is consistent with common variable immunodeficiency, and as many as 10% of patients with this disorder have heterozygous amino acid substitutions in TACI.  For all these disorders, there is considerable clin. heterogeneity in patients with the same mutation.  Identifying the genetic and environmental factors that influence the clin. phenotype may enhance patient care and the understanding of normal B cell development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_hgfd2bSrJ7Vg90H21EOLACvtfcHk0lg2ZpB3zneRxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFSlsbY%253D&md5=83216a7a297af38c2efdf9d3e79a1213</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.021908.132649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.021908.132649%26sid%3Dliteratum%253Aachs%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DDobbs%26aufirst%3DA.%2BK.%26aulast%3DFarmer%26aufirst%3DD.%2BM.%26aulast%3DKilic%26aufirst%3DS.%26aulast%3DParis%26aufirst%3DK.%26aulast%3DGrigoriadou%26aufirst%3DS.%26aulast%3DCoustan-Smith%26aufirst%3DE.%26aulast%3DHoward%26aufirst%3DV.%26aulast%3DCampana%26aufirst%3DD.%26atitle%3DPrimary%2520B%2520Cell%2520Immunodeficiencies%253A%2520Comparisons%2520and%2520Contrasts%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D27%26spage%3D199%26epage%3D227%26doi%3D10.1146%2Fannurev.immunol.021908.132649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kersseboom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flierman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Zee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middendorp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Constitutive Activation of Bruton’s Tyrosine Kinase Induces the Formation of Autoreactive Igm Plasma Cells</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2643</span>– <span class="NLM_lpage">2654</span>, <span class="refDoi"> DOI: 10.1002/eji.201040521</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1002%2Feji.201040521" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20623551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2gurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=2643-2654&author=R.+Kersseboomauthor=L.+Kilauthor=R.+Fliermanauthor=M.+van+der+Zeeauthor=G.+M.+Dingjanauthor=S.+Middendorpauthor=A.+Maasauthor=R.+W.+Hendriks&title=Constitutive+Activation+of+Bruton%E2%80%99s+Tyrosine+Kinase+Induces+the+Formation+of+Autoreactive+Igm+Plasma+Cells&doi=10.1002%2Feji.201040521"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells</span></div><div class="casAuthors">Kersseboom, Rogier; Kil, Laurens; Flierman, Roelof; van der Zee, Marten; Dingjan, Gemma M.; Middendorp, Sabine; Maas, Alex; Hendriks, Rudi W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2643-2654</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">B-cell receptor (BCR)-mediated signals provide the basis for B-cell differentiation in the BM and subsequently into follicular, marginal zone, or B-1 B-cell subsets.  We have previously shown that B-cell-specific expression of the constitutive active E41K mutant of the BCR-assocd. mol. Bruton's tyrosine kinase (Btk) leads to an almost complete deletion of immature B cells in the BM.  Here, we report that low-level expression of the E41K or E41K-Y223F Btk mutants was assocd. with reduced follicular B-cell nos. and significantly increased proportions of B-1 cells in the spleen.  Crosses with 3-83μδ and VH81X BCR Tg mice showed that constitutive active Btk expression did not change follicular, marginal zone, or B-1 B-cell fate choice, but resulted in selective expansion or survival of B-1 cells.  Residual B cells were hyperresponsive and manifested sustained Ca2+ mobilization.  They were spontaneously driven into germinal center-independent plasma cell differentiation, as evidenced by increased nos. of IgM+ plasma cells in spleen and BM and significantly elevated serum IgM.  Because anti-nucleosome autoantibodies and glomerular IgM deposition were present, we conclude that constitutive Btk activation causes defective B-cell tolerance, emphasizing that Btk signals are essential for appropriate regulation of B-cell activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqun8TbtbvbDLVg90H21EOLACvtfcHk0lildJpwtP0tmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2gurfN&md5=ee792705b0aab409a52c5a5e5874c1d2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Feji.201040521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.201040521%26sid%3Dliteratum%253Aachs%26aulast%3DKersseboom%26aufirst%3DR.%26aulast%3DKil%26aufirst%3DL.%26aulast%3DFlierman%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BZee%26aufirst%3DM.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DMiddendorp%26aufirst%3DS.%26aulast%3DMaas%26aufirst%3DA.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DConstitutive%2520Activation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Induces%2520the%2520Formation%2520of%2520Autoreactive%2520Igm%2520Plasma%2520Cells%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2010%26volume%3D40%26spage%3D2643%26epage%3D2654%26doi%3D10.1002%2Feji.201040521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humphries, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangelmaier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span> <span> </span><span class="NLM_article-title">Tec Kinases Mediate Sustained Calcium Influx via Site-specific Tyrosine Phosphorylation of the Phospholipase C Gamma Src Homology 2-Src Homology 3 Linker</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">37651</span>– <span class="NLM_lpage">37661</span>, <span class="refDoi"> DOI: 10.1074/jbc.M311985200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1074%2Fjbc.M311985200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=15184383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=37651-37661&author=L.+A.+Humphriesauthor=C.+Dangelmaierauthor=K.+Sommerauthor=K.+Kippauthor=R.+M.+Katoauthor=N.+Griffithauthor=I.+Bakmanauthor=C.+W.+Turkauthor=J.+L.+Danielauthor=D.+J.+Rawlings&title=Tec+Kinases+Mediate+Sustained+Calcium+Influx+via+Site-specific+Tyrosine+Phosphorylation+of+the+Phospholipase+C+Gamma+Src+Homology+2-Src+Homology+3+Linker&doi=10.1074%2Fjbc.M311985200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tec Kinases Mediate Sustained Calcium Influx via Site-specific Tyrosine Phosphorylation of the Phospholipase Cγ Src Homology 2-Src Homology 3 Linker</span></div><div class="casAuthors">Humphries, Lisa A.; Dangelmaier, Carol; Sommer, Karen; Kipp, Kevin; Kato, Roberta M.; Griffith, Natasha; Bakman, Irene; Turk, Christoph W.; Daniel, James L.; Rawlings, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">37651-37661</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation of phospholipase Cγ2 (PLCγ2) is a crucial activation switch that initiates and maintains intracellular calcium mobilization in response to B cell antigen receptor (BCR) engagement.  Although members from three distinct families of non-receptor tyrosine kinases can phosphorylate PLCγ in vitro, the specific kinase(s) controlling BCR-dependent PLCγ activation in vivo remains unknown.  Bruton's tyrosine kinase (Btk)-deficient human B cells exhibit diminished inositol 1,4,5-trisphosphate prodn. and calcium signaling despite a normal inducible level of total PLCγ2 tyrosine phosphorylation.  This suggested that Btk might modify a crit. subset of residues essential for PLCγ2 activity.  To evaluate this hypothesis, we generated site-specific phosphotyrosine antibodies recognizing four putative regulatory residues within PLCγ2.  Whereas all four sites were rapidly modified in response to BCR engagement in normal B cells, Btk-deficient B cells exhibited a marked redn. in phosphorylation of the Src homol. 2 (SH2)-SH3 linker region sites, Tyr753 and Tyr759.  Phosphorylation of both sites was restored by expression of Tec, but not Syk, family kinases.  In contrast, phosphorylation of the PLCγ2 carboxyl-terminal sites, Tyr1197 and Tyr1217, was unaffected by the absence of functional Btk.  Together, these data support a model whereby Btk/Tec kinases control sustained calcium signaling via site-specific phosphorylation of key residues within the PLCγ2 SH2-SH3 linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoszBe2J6G6ybVg90H21EOLACvtfcHk0lildJpwtP0tmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSns7s%253D&md5=a87ce3b74c0ad325eba8d566f004d18c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311985200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311985200%26sid%3Dliteratum%253Aachs%26aulast%3DHumphries%26aufirst%3DL.%2BA.%26aulast%3DDangelmaier%26aufirst%3DC.%26aulast%3DSommer%26aufirst%3DK.%26aulast%3DKipp%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DGriffith%26aufirst%3DN.%26aulast%3DBakman%26aufirst%3DI.%26aulast%3DTurk%26aufirst%3DC.%2BW.%26aulast%3DDaniel%26aufirst%3DJ.%2BL.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DTec%2520Kinases%2520Mediate%2520Sustained%2520Calcium%2520Influx%2520via%2520Site-specific%2520Tyrosine%2520Phosphorylation%2520of%2520the%2520Phospholipase%2520C%2520Gamma%2520Src%2520Homology%25202-Src%2520Homology%25203%2520Linker%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D37651%26epage%3D37661%26doi%3D10.1074%2Fjbc.M311985200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific BTK Inhibition Suppresses B Cell- and Myeloid Cell-mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+BTK+Inhibition+Suppresses+B+Cell-+and+Myeloid+Cell-mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lg7Whmn96J60w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520BTK%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520and%2520Myeloid%2520Cell-mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romesser, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhammer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaffer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hermelink, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gascoyne, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connors, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsza, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braziel, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubbs, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenburger, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Chronic Active B-cell-receptor Signaling in Diffuse Large B-cell Lymphoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1038/nature08638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2Fnature08638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20054396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+Active+B-cell-receptor+Signaling+in+Diffuse+Large+B-cell+Lymphoma&doi=10.1038%2Fnature08638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</span></div><div class="casAuthors">Davis, R. Eric; Ngo, Vu N.; Lenz, Georg; Tolar, Pavel; Young, Ryan M.; Romesser, Paul B.; Kohlhammer, Holger; Lamy, Laurence; Zhao, Hong; Yang, Yandan; Xu, Weihong; Shaffer, Arthur L.; Wright, George; Xiao, Wenming; Powell, John; Jiang, Jian-kang; Thomas, Craig J.; Rosenwald, Andreas; Ott, German; Muller-Hermelink, Hans Konrad; Gascoyne, Randy D.; Connors, Joseph M.; Johnson, Nathalie A.; Rimsza, Lisa M.; Campo, Elias; Jaffe, Elaine S.; Wilson, Wyndham H.; Delabie, Jan; Smeland, Erlend B.; Fisher, Richard I.; Braziel, Rita M.; Tubbs, Raymond R.; Cook, J. R.; Weisenburger, Dennis D.; Chan, Wing C.; Pierce, Susan K.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7277</span>),
    <span class="NLM_cas:pages">88-92</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A role for B-cell-receptor (BCR) signaling in lymphomagenesis has been inferred by studying Ig genes in human lymphomas and by engineering mouse models, but genetic and functional evidence for its oncogenic role in human lymphomas is needed.  Here the authors describe a form of chronic active' BCR signaling that is required for cell survival in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).  The signaling adaptor CARD11 is required for constitutive NF-κB pathway activity and survival in ABC DLBCL.  Roughly 10% of ABC DLBCLs have mutant CARD11 isoforms that activate NF-κB, but the mechanism that engages wild-type CARD11 in other ABC DLBCLs was unknown.  An RNA interference genetic screen revealed that a BCR signaling component, Bruton's tyrosine kinase, is essential for the survival of ABC DLBCLs with wild-type CARD11.  In addn., knockdown of proximal BCR subunits (IgM, Ig-κ, CD79A and CD79B) killed ABC DLBCLs with wild-type CARD11 but not other lymphomas.  The BCRs in these ABC DLBCLs formed prominent clusters in the plasma membrane with low diffusion, similarly to BCRs in antigen-stimulated normal B cells.  Somatic mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) signaling modules of CD79B and CD79A were detected frequently in ABC DLBCL biopsy samples but rarely in other DLBCLs and never in Burkitt's lymphoma or mucosa-assocd. lymphoid tissue lymphoma.  In 18% of ABC DLBCLs, one functionally crit. residue of CD79B, the first ITAM tyrosine, was mutated.  These mutations increased surface BCR expression and attenuated Lyn kinase, a feedback inhibitor of BCR signaling.  These findings establish chronic active BCR signaling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzlT4q2Ie4lrVg90H21EOLACvtfcHk0lg7Whmn96J60w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFCitw%253D%253D&md5=86d4bdf7f9af3fbe120d5b9175389e5a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520Active%2520B-cell-receptor%2520Signaling%2520in%2520Diffuse%2520Large%2520B-cell%2520Lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92%26doi%3D10.1038%2Fnature08638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Y.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lidD0VrnBNzKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+H.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+S.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+L.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0lidD0VrnBNzKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%2BH.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%2BS.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%2BL.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A Phase I Clinical Trial of the Selective BTK Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-cell Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+S.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+Phase+I+Clinical+Trial+of+the+Selective+BTK+Inhibitor+ONO%2FGS-4059+in+Relapsed+and+Refractory+Mature+B-cell+Malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0lidD0VrnBNzKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%2520Clinical%2520Trial%2520of%2520the%2520Selective%2520BTK%2520Inhibitor%2520ONO%252FGS-4059%2520in%2520Relapsed%2520and%2520Refractory%2520Mature%2520B-cell%2520Malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BTKk with CC-292 provides Early Pharmacodynamic Assessment of Activity in Mice and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+C.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+D.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+BTKk+with+CC-292+provides+Early+Pharmacodynamic+Assessment+of+Activity+in+Mice+and+Humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0li-UoP3kom40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BC.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%2BD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520BTKk%2520with%2520CC-292%2520provides%2520Early%2520Pharmacodynamic%2520Assessment%2520of%2520Activity%2520in%2520Mice%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Branebrutinib (BMS-986195): a Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&author=S.+H.+Wattersonauthor=Q.+J.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+H.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+F.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Y.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Q.+Liauthor=R.+L.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+M.+Burkeauthor=J.+A.+Tino&title=Discovery+of+Branebrutinib+%28BMS-986195%29%3A+a+Strategy+for+Identifying+a+Highly+Potent+and+Selective+Covalent+Inhibitor+Providing+Rapid+in+vivo+Inactivation+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0li-UoP3kom40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%2BJ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%2BH.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%2BF.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%2BY.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BQ.%26aulast%3DZhao%26aufirst%3DR.%2BL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BM.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520Branebrutinib%2520%2528BMS-986195%2529%253A%2520a%2520Strategy%2520for%2520Identifying%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Covalent%2520Inhibitor%2520Providing%2520Rapid%2520in%2520vivo%2520Inactivation%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swami, A.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in CLL: a Focus on Adverse Events, Resistance, and Novel Approaches Beyond Ibrutinib</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-2973-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1007%2Fs00277-017-2973-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=28342031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1175-1184&author=V.+Kaurauthor=A.+Swami&title=Ibrutinib+in+CLL%3A+a+Focus+on+Adverse+Events%2C+Resistance%2C+and+Novel+Approaches+Beyond+Ibrutinib&doi=10.1007%2Fs00277-017-2973-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</span></div><div class="casAuthors">Kaur, Varinder; Swami, Arjun</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).  Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naive, heavily pre-treated, and high-risk CLL/SLL.  With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase.  As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged.  New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets.  Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL.  We provide a comprehensive anal. of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRsUgeFPl8N7Vg90H21EOLACvtfcHk0lg-HgLaVs5_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D&md5=833537673bfe80fd7931dcc132c9b5aa</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-2973-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-2973-2%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DV.%26aulast%3DSwami%26aufirst%3DA.%26atitle%3DIbrutinib%2520in%2520CLL%253A%2520a%2520Focus%2520on%2520Adverse%2520Events%252C%2520Resistance%252C%2520and%2520Novel%2520Approaches%2520Beyond%2520Ibrutinib%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26spage%3D1175%26epage%3D1184%26doi%3D10.1007%2Fs00277-017-2973-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Q.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lg-HgLaVs5_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%2BQ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Three-year Follow-up of Treatment-naïve and Previously Treated Patients with CLLl and SLL Receiving Single-agent Ibrutinib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-606038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2014-10-606038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=25700432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2497-2506&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=Y.+Shawauthor=E.+Bilottiauthor=C.+Zhouauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Three-year+Follow-up+of+Treatment-na%C3%AFve+and+Previously+Treated+Patients+with+CLLl+and+SLL+Receiving+Single-agent+Ibrutinib&doi=10.1182%2Fblood-2014-10-606038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Burger, Jan A.; Blum, Kristie A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Shaw, Yun; Bilotti, Elizabeth; Zhou, Cathy; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling.  In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).  The durable responses obsd. with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period.  We report on median 3-yr follow-up of 132 patients with symptomatic treatment- naive and relapsed/refractory CLL or small lymphocytic lymphoma.  Longer treatment with ibrutinib was assocd. with improvement in response quality over time and durable remissions.  Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections.  Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease.  Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 yr and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better.  Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbUSbfHjGYebVg90H21EOLACvtfcHk0ljFl1CAO4VlFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D&md5=1bedfb4e6798a3f51320d8b8054c13aa</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-606038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-606038%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DY.%26aulast%3DBilotti%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThree-year%2520Follow-up%2520of%2520Treatment-na%25C3%25AFve%2520and%2520Previously%2520Treated%2520Patients%2520with%2520CLLl%2520and%2520SLL%2520Receiving%2520Single-agent%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2497%26epage%3D2506%26doi%3D10.1182%2Fblood-2014-10-606038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-cell Lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+S.+Ouauthor=N.+Chengauthor=B.+L.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13dR"><div class="casContent"><span class="casTitleNuber">13d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0ljFl1CAO4VlFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%2BS.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%2BL.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Raedler, L. A.</span></span> <span> </span><span class="NLM_article-title">Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia</span>. <i>Am. Health Drug Benefits</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=27668052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A280%3ADC%252BC2svjvFWrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=89-92&author=L.+A.+Raedler&title=Imbruvica+%28Ibrutinib%29%3A+First+Drug+Approved+for+the+Treatment+of+Patients+with+Waldenstr%C3%B6m%E2%80%99s+Macroglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13eR"><div class="casContent"><span class="casTitleNuber">13e</span><div class="casTitle"><span class="NLM_cas:atitle">Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenstrom's Macroglobulinemia</span></div><div class="casAuthors">Raedler Lisa A</div><div class="citationInfo"><span class="NLM_cas:title">American health & drug benefits</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">Spec Feature</span>),
    <span class="NLM_cas:pages">89-92</span>
        ISSN:<span class="NLM_cas:issn">1942-2962</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAmJOZnkDiwUH3Rlp_k91zfW6udTcc2eaj7lSvF-EVQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svjvFWrtA%253D%253D&md5=90c7ae5feac36bdea254d779c7715789</span></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaedler%26aufirst%3DL.%2BA.%26atitle%3DImbruvica%2520%2528Ibrutinib%2529%253A%2520First%2520Drug%2520Approved%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Waldenstr%25C3%25B6m%25E2%2580%2599s%2520Macroglobulinemia%26jtitle%3DAm.%2520Health%2520Drug%2520Benefits%26date%3D2016%26volume%3D9%26spage%3D89%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Soler, R.</span></span> <span> </span><span class="NLM_article-title">Skin Toxicities Associated with Epidermal Growth Factor Rreceptor Inhibitors</span>. <i>Target Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1007/s11523-009-0114-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1007%2Fs11523-009-0114-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=19452131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A280%3ADC%252BD1Mzos1KhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=107-119&author=T.+Liauthor=R.+Perez-Soler&title=Skin+Toxicities+Associated+with+Epidermal+Growth+Factor+Rreceptor+Inhibitors&doi=10.1007%2Fs11523-009-0114-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Skin toxicities associated with epidermal growth factor receptor inhibitors</span></div><div class="casAuthors">Li Tianhong; Perez-Soler Roman</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors has increased considerably in recent years.  Currently, they are approved in non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer and head and neck cancer.  Skin toxicity is a class-specific side effect that is typically manifested as a papulopustular rash in the majority (45-100%) of patients receiving EGFR inhibitors.  The skin toxicity is related to the inhibition of EGFR in the skin, which is crucial for the normal development and physiology of the epidermis.  Although rarely life-threatening, skin toxicity may cause significant physical and psycho-social discomfort.  Nevertheless, the presence and severity of skin rash is associated with improved clinical efficacy in patients receiving EGFR inhibitors.  The goal of managing EGFR inhibitor-associated skin toxicity is to minimize the detrimental effects of the rash on patients' quality of life and treatment course without antagonizing the clinical efficacy of EGFR inhibitors.  There is currently no evidence-based treatment guideline to prevent or treat the EGFR inhibitor-associated skin toxicities.  Expert panels recommend a proactive, multidisciplinary approach that includes patient education and the use of a grade-based treatment algorithm.  Elucidation of the mechanisms of EGFR inhibitor-associated skin toxicity and development of mechanism-based novel therapies are urgently needed.  Preclinical data suggest topical application of a potent phosphatase inhibitor menadione (Vitamin K3) can rescue the inhibition of EGFR and downstream signaling molecules in the skin of mice receiving systemic EGFR inhibitor erlotinib or cetuximab.  A randomized, double-blinded, placebo-controlled study has been initiated to evaluate the clinical efficacy of menadione topical cream, in the treatment or prevention of EGFR inhibitor-induced skin toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBjiE5iFNI-Nts4TFFB11gfW6udTcc2eY5Ze0dGjlqc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mzos1KhtA%253D%253D&md5=bd52132174e886f4a5d63368881e1bdb</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1007%2Fs11523-009-0114-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-009-0114-0%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DPerez-Soler%26aufirst%3DR.%26atitle%3DSkin%2520Toxicities%2520Associated%2520with%2520Epidermal%2520Growth%2520Factor%2520Rreceptor%2520Inhibitors%26jtitle%3DTarget%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D107%26epage%3D119%26doi%3D10.1007%2Fs11523-009-0114-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Melosky, B.</span></span> <span> </span><span class="NLM_article-title">Supportive Care Treatments for Toxicities of Anti-EGFR and Other Targeted Agents</span>. <i>Curr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">S59</span>– <span class="NLM_lpage">S63</span>, <span class="refDoi"> DOI: 10.3747/co.19.1054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.3747%2Fco.19.1054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=22787412" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=S59-S63&author=B.+Melosky&title=Supportive+Care+Treatments+for+Toxicities+of+Anti-EGFR+and+Other+Targeted+Agents&doi=10.3747%2Fco.19.1054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.3747%2Fco.19.1054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.19.1054%26sid%3Dliteratum%253Aachs%26aulast%3DMelosky%26aufirst%3DB.%26atitle%3DSupportive%2520Care%2520Treatments%2520for%2520Toxicities%2520of%2520Anti-EGFR%2520and%2520Other%2520Targeted%2520Agents%26jtitle%3DCurr.%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3DS59%26epage%3DS63%26doi%3D10.3747%2Fco.19.1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S. P.</span></span> <span> </span><span class="NLM_article-title">Tec Regulates Platelet Activation by GPVI in the Absence of BTK</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">3592</span>– <span class="NLM_lpage">3599</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-04-1142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2003-04-1142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=12842985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVymt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=3592-3599&author=B.+T.+Atkinsonauthor=W.+Ellmeierauthor=S.+P.+Watson&title=Tec+Regulates+Platelet+Activation+by+GPVI+in+the+Absence+of+BTK&doi=10.1182%2Fblood-2003-04-1142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tec regulates platelet activation by GPVI in the absence of Btk</span></div><div class="casAuthors">Atkinson, Ben T.; Ellmeier, Wilfried; Watson, Steve P.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3592-3599</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Tec family kinase Btk plays an important role in the regulation of phospholipase Cγ2 (PLCγ2) downstream of the collagen receptor glycoprotein VI (GPVI) in human platelets.  Platelets also express a second member of this family, Tec; however, its function has not been analyzed.  To address the role of Tec, we analyzed Btk-/-, Tec-/-, and Btk/Tec double-deficient (Btk-/-/Tec-/-) platelets.  Tec-/- platelets exhibit a minor redn. in aggregation to threshold concns. of collagen or the GPVI-specific agonist collagen-related peptide (CRP), whereas responses to higher concns. are normal.  Tyrosine phosphorylation of PLCγ2 by collagen and CRP is not altered in Tec-/- platelets.  However, Btk-/-/Tec-/- platelets exhibit a greater redn. in PLCγ2 phosphorylation than is seen in the absence of Btk, thus revealing an important role for Tec in this situation.  Furthermore, Btk-/-/Tec-/- platelets fail to undergo an increase in Ca2+, aggregation, secretion, and spreading in response to collagen or CRP, whereas they aggregate normally to ADP and spread on fibrinogen.  A residual GPVI signal exists in the Btk-/-/Tec-/- platelets as CRP synergizes with ADP to mediate aggregation.  These results demonstrate an essential requirement for Tec and Btk in platelet activation by GPVI and reveal a functional role for Tec in the regulation of PLCγ2 in the absence of Btk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEprLq7CTaCLVg90H21EOLACvtfcHk0ljMJ1TwW1dh6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVymt74%253D&md5=159f65f62c88a803d820e16adc8e109c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-04-1142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-04-1142%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DB.%2BT.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DWatson%26aufirst%3DS.%2BP.%26atitle%3DTec%2520Regulates%2520Platelet%2520Activation%2520by%2520GPVI%2520in%2520the%2520Absence%2520of%2520BTK%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D3592%26epage%3D3599%26doi%3D10.1182%2Fblood-2003-04-1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gururaja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span> <span> </span><span class="NLM_article-title">The Effect of Bruton’s Tyrosine Kinase (BTK) Inhibitors on Collagen-induced Platelet Aggregation, BTK, and Tyrosine Kinase Expressed in Hhepatocellular Carcinoma (Tec)</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1111/ejh.13148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1111%2Fejh.13148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2018&pages=604-612&author=J.+Chenauthor=T.+Kinoshitaauthor=T.+Gururajaauthor=J.+Sukbuntherngauthor=D.+Jamesauthor=D.+Luauthor=J.+Whangauthor=M.+Verseleauthor=B.+Y.+Chang&title=The+Effect+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors+on+Collagen-induced+Platelet+Aggregation%2C+BTK%2C+and+Tyrosine+Kinase+Expressed+in+Hhepatocellular+Carcinoma+%28Tec%29&doi=10.1111%2Fejh.13148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)</span></div><div class="casAuthors">Chen, Jun; Kinoshita, Taisei; Gururaja, Tarikere; Sukbuntherng, Juthamas; James, Danelle; Lu, Daniel; Whang, Jennifer; Versele, Matthias; Chang, Betty Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">604-612</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Objectives : Bruton's tyrosine kinase (BTK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) are expressed by human platelets.  These kinases participate in platelet activation through the collagen receptor glycoprotein VI and may perform overlapping functions.  In clin. studies, BTK inhibitors (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib) have been assocd. with increased bleeding risk, which may result from inhibition of BTK alone or of both BTK and TEC, although the role of TEC in bleeding risk remains unclear.  Methods : Here, in vitro catalytic and binding activities of ibrutinib and acalabrutinib were detd. with four assay systems.  Platelet aggregation assays detd. inhibitor potency and its relationship to selectivity between BTK and TEC.  Results : Neither inhibitor was substantially more selective for BTK over TEC.  The potencies at which BTK inhibitors suppressed platelet aggregation correlated with the potencies in on-target BTK assays, including those in cells.  At clin. relevant plasma concn., ibrutinib, acalabrutinib, and tirabrutinib inhibited collagen-induced platelet aggregation to a similar extent, despite differing in vitro IC50s.  Conclusions : Our results suggest BTK inhibition is the primary driver for inhibition of platelet aggregation.  The subtle differences between these inhibitors suggest only randomized, double-blind, placebo-controlled clin. studies can fully address the bleeding risks of different BTK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-4t9KmFTj5LVg90H21EOLACvtfcHk0ljMJ1TwW1dh6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKgu73J&md5=ef4558e97d19f22350689e75088f1b34</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fejh.13148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejh.13148%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DGururaja%26aufirst%3DT.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DWhang%26aufirst%3DJ.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DB.%2BY.%26atitle%3DThe%2520Effect%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%2520on%2520Collagen-induced%2520Platelet%2520Aggregation%252C%2520BTK%252C%2520and%2520Tyrosine%2520Kinase%2520Expressed%2520in%2520Hhepatocellular%2520Carcinoma%2520%2528Tec%2529%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2018%26volume%3D101%26spage%3D604%26epage%3D612%26doi%3D10.1111%2Fejh.13148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senis, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazharian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, J.</span></span> <span> </span><span class="NLM_article-title">Src Family Kinases: at the Forefront of Platelet Activation</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-01-453134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fblood-2014-01-453134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=25115887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslaiu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=2013-2024&author=Y.+A.+Senisauthor=A.+Mazharianauthor=J.+Mori&title=Src+Family+Kinases%3A+at+the+Forefront+of+Platelet+Activation&doi=10.1182%2Fblood-2014-01-453134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Src family kinases: at the forefront of platelet activation</span></div><div class="casAuthors">Senis, Yotis A.; Mazharian, Alexandra; Mori, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2013-2024</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Src family kinases (SFKs) play a central role in mediating the rapid response of platelets to vascular injury.  They transmit activation signals from a diverse repertoire of platelet surface receptors, including the integrin αIIbβ3, the immunoreceptor tyrosine-based activation motif-contg. collagen receptor complex GPVI-FcR γ-chain, and the von Willebrand factor receptor complex GPIb-IX-V, which are essential for thrombus growth and stability.  Ligand-mediated clustering of these receptors triggers an increase in SFK activity and downstream tyrosine phosphorylation of enzymes, adaptors, and cytoskeletal proteins that collectively propagate the signal and coordinate platelet activation.  A growing body of evidence has established that SFKs also contribute to Gq- and Gi-coupled receptor signaling that synergizes with primary activation signals to maximally activate platelets and render them prothrombotic.  Interestingly, SFKs concomitantly activate inhibitory pathways that limit platelet activation and thrombus size.  In this review, we discuss past discoveries that laid the foundation for this fundamental area of platelet signal transduction, recent progress in our understanding of the distinct and overlapping functions of SFKs in platelets, and new avenues of research into mechanisms of SFK regulation.  We also highlight the thrombotic and hemostatic consequences of targeting platelet SFKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlUuKGcvADrVg90H21EOLACvtfcHk0ljkahvCQjlSrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslaiu7jM&md5=462486e3a954db0c557c2d0dcf8d843d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-01-453134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-01-453134%26sid%3Dliteratum%253Aachs%26aulast%3DSenis%26aufirst%3DY.%2BA.%26aulast%3DMazharian%26aufirst%3DA.%26aulast%3DMori%26aufirst%3DJ.%26atitle%3DSrc%2520Family%2520Kinases%253A%2520at%2520the%2520Forefront%2520of%2520Platelet%2520Activation%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D2013%26epage%3D2024%26doi%3D10.1182%2Fblood-2014-01-453134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bye, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unsworth, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desborough, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildyard, C. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriek, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbins, J. M.</span></span> <span> </span><span class="NLM_article-title">Severe Platelet Dysfunction in NHL Patients Receiving Ibrutinib is Absent in Patients Receiving Acalabrutinib</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2610</span>– <span class="NLM_lpage">2623</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2017011999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1182%2Fbloodadvances.2017011999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=29296914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjs1egsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=2610-2623&author=A.+P.+Byeauthor=A.+J.+Unsworthauthor=M.+J.+Desboroughauthor=C.+A.+T.+Hildyardauthor=N.+Applebyauthor=D.+Bruceauthor=N.+Kriekauthor=S.+H.+Nockauthor=T.+Sageauthor=C.+E.+Hughesauthor=J.+M.+Gibbins&title=Severe+Platelet+Dysfunction+in+NHL+Patients+Receiving+Ibrutinib+is+Absent+in+Patients+Receiving+Acalabrutinib&doi=10.1182%2Fbloodadvances.2017011999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib</span></div><div class="casAuthors">Bye, Alexander P.; Unsworth, Amanda J.; Desborough, Michael J.; Hildyard, Catherine A. T.; Appleby, Niamh; Bruce, David; Kriek, Neline; Nock, Sophie H.; Sage, Tanya; Hughes, Craig E.; Gibbins, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2610</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding.  Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib.  The second-generation Btk inhibitor acalabrutinib was developed with improved specificity for Btk over Tec.  We investigated platelet function in patients with non-Hodgkin lymphoma (NHL) receiving ibrutinib or acalabrutinib by aggregometry and by measuring thrombus formation on collagen under arterial shear.  Both patient groups had similarly dysfunctional aggregation responses to collagen and collagen-related peptide, and comparison with mechanistic expts. in which platelets from healthy donors were treated with the Btk inhibitors suggested that both drugs inhibit platelet Btk and Tec at physiol. concns.  Only ibrutinib caused dysfunctional thrombus formation, whereas size and morphol. of thrombi following acalabrutinib treatment were of normal size and morphol.  We found that ibrutinib but not acalabrutinib inhibited Src family kinases, which have a crit. role in platelet adhesion to collagen that is likely to underpin unstable thrombus formation obsd. in ibrutinib patients.  We found that platelet function was enhanced by increasing levels of von Willebrand factor (VWF) and factor VIII (FVIII) ex vivo by addn. of intermediate purity FVIII (Haemate P) to blood from patients, resulting in consistently larger thrombi.  We conclude that acalabrutinib avoids major platelet dysfunction assocd. with ibrutinib therapy, and platelet function may be enhanced in patients with B-cell NHL by increasing plasma VWF and FVIII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI3BCm7LTLELVg90H21EOLACvtfcHk0ljkahvCQjlSrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjs1egsrk%253D&md5=4519ab76d09fa0f825e744d8a67fb130</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2017011999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2017011999%26sid%3Dliteratum%253Aachs%26aulast%3DBye%26aufirst%3DA.%2BP.%26aulast%3DUnsworth%26aufirst%3DA.%2BJ.%26aulast%3DDesborough%26aufirst%3DM.%2BJ.%26aulast%3DHildyard%26aufirst%3DC.%2BA.%2BT.%26aulast%3DAppleby%26aufirst%3DN.%26aulast%3DBruce%26aufirst%3DD.%26aulast%3DKriek%26aufirst%3DN.%26aulast%3DNock%26aufirst%3DS.%2BH.%26aulast%3DSage%26aufirst%3DT.%26aulast%3DHughes%26aufirst%3DC.%2BE.%26aulast%3DGibbins%26aufirst%3DJ.%2BM.%26atitle%3DSevere%2520Platelet%2520Dysfunction%2520in%2520NHL%2520Patients%2520Receiving%2520Ibrutinib%2520is%2520Absent%2520in%2520Patients%2520Receiving%2520Acalabrutinib%26jtitle%3DBlood%2520Adv.%26date%3D2017%26volume%3D1%26spage%3D2610%26epage%3D2623%26doi%3D10.1182%2Fbloodadvances.2017011999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span> <span> </span><span class="NLM_article-title">The Resurgence of Covalent Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+Resurgence+of+Covalent+Drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljkahvCQjlSrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520Resurgence%2520of%2520Covalent%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, R. A.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibitors in Drug Discovery: From Accidental Discoveries to Avoided Liabilities and Designed Therapies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1061</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.drudis.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26002380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=1061-1073&author=R.+A.+Bauer&title=Covalent+Inhibitors+in+Drug+Discovery%3A+From+Accidental+Discoveries+to+Avoided+Liabilities+and+Designed+Therapies&doi=10.1016%2Fj.drudis.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies</span></div><div class="casAuthors">Bauer, Renato A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1061-1073</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Drugs that covalently bond to their biol. targets have a long history in drug discovery.  A look at drug approvals in recent years suggests that covalent drugs will continue to make impacts on human health for years to come.  Although fraught with concerns about toxicity, the high potencies and prolonged effects achievable with covalent drugs may result in less-frequent drug dosing and in wide therapeutic margins for patients.  Covalent inhibition can also dissoc. drug pharmacodynamics (PD) from pharmacokinetics (PK), which can result in desired drug efficacy for inhibitors that have short systemic exposure.  Evidence suggests that there is a reduced risk for the development of resistance against covalent drugs, which is a major challenge in areas such as oncol. and infectious disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMkBDsUEu4arVg90H21EOLACvtfcHk0ljPhemQzodZ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlOnu7s%253D&md5=6ba5b016d2804c7d56838a2724b9a0b9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DR.%2BA.%26atitle%3DCovalent%2520Inhibitors%2520in%2520Drug%2520Discovery%253A%2520From%2520Accidental%2520Discoveries%2520to%2520Avoided%2520Liabilities%2520and%2520Designed%2520Therapies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2015%26volume%3D20%26spage%3D1061%26epage%3D1073%26doi%3D10.1016%2Fj.drudis.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Cesco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittermaier, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitessier, N.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibitors Design and Discovery</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.ejmech.2017.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=28651155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=96-114&author=S.+De%0ACescoauthor=J.+Kurianauthor=C.+Dufresneauthor=A.+K.+Mittermaierauthor=N.+Moitessier&title=Covalent+Inhibitors+Design+and+Discovery&doi=10.1016%2Fj.ejmech.2017.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibitors design and discovery</span></div><div class="casAuthors">De Cesco, Stephane; Kurian, Jerry; Dufresne, Caroline; Mittermaier, Anthony K.; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">96-114</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In the history of therapeutics, covalent drugs occupy a very distinct category.  While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biol. target.  In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors.  All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods.  The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLNDmLtBdB7Vg90H21EOLACvtfcHk0ljPhemQzodZ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKhsLrI&md5=551c9a9c4bd69d4ad4d9156c315d5a94</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DKurian%26aufirst%3DJ.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DMittermaier%26aufirst%3DA.%2BK.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DCovalent%2520Inhibitors%2520Design%2520and%2520Discovery%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114%26doi%3D10.1016%2Fj.ejmech.2017.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellemans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vliegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, J.</span></span> <span> </span><span class="NLM_article-title">Stable Isotope-labelled Intravenous Microdose for Absolute Bioavailability and Effect of Grapefruit Juice on Ibrutinib in Healthy Adults</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1111/bcp.12787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1111%2Fbcp.12787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=26382728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFKqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=235-245&author=R.+de+Vriesauthor=J.+W.+Smitauthor=P.+Hellemansauthor=J.+Jiaoauthor=J.+Murphyauthor=D.+Skeeauthor=J.+Snoeysauthor=J.+Sukbuntherngauthor=M.+Vliegenauthor=L.+de+Zwartauthor=E.+Mannaertauthor=J.+de+Jong&title=Stable+Isotope-labelled+Intravenous+Microdose+for+Absolute+Bioavailability+and+Effect+of+Grapefruit+Juice+on+Ibrutinib+in+Healthy+Adults&doi=10.1111%2Fbcp.12787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults</span></div><div class="casAuthors">de Vries, Ronald; Smit, Johan W.; Hellemans, Peter; Jiao, James; Murphy, Joseph; Skee, Donna; Snoeys, Jan; Sukbuntherng, Juthamas; Vliegen, Maarten; de Zwart, Loeckie; Mannaert, Erik; de Jong, Jan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-245</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is used in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.  Ibrutinib undergoes extensive rapid oxidative metab. mediated by cytochrome P 450 3A both at the level of first pass and clearance, which might result in low oral bioavailability.  The present study was designed to investigate the abs. bioavailability (F) of ibrutinib in the fasting and fed state and assess the effect of grapefruit juice (GFJ) on the systemic exposure of ibrutinib in order to det. the fraction escaping the gut (Fg) and the fraction escaping hepatic extn. (Fh) in the fed state.  Methods : All participants received treatment A [560 mg oral ibrutinib, under fasting conditions], B (560 mg PO ibrutinib, fed, administered after drinking glucose drink) and C (140 mg oral ibrutinib, fed, with intake of GFJ before dosing).  A single i.v. (i.v.) dose of 100 μg 13C6-ibrutinib was administered 2 h after each oral dose.  Results : The estd. 'F' for treatments A, B and C was 3.9%, 8.4% and 15.9%, resp.  Fg and Fh in the fed state were 47.0% and 15.9%, resp.  Adverse events were mild to moderate in severity (Grade 1-2) and resolved without sequelae by the end of the study.  Conclusion : The abs. oral bioavailability of ibrutinib was low, ranging from 3.9% in the fasting state to 8.4% when administered 30 min before a std. breakfast without GFJ and 15.9% with GFJ.  Ibrutinib was well tolerated following a single oral and i.v. dose, under both fasted and fed conditions and regardless of GFJ intake status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAj7TEGNR7gLVg90H21EOLACvtfcHk0ljPhemQzodZ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFKqu7o%253D&md5=0b04c96322b03fbad3d52b79fbc20551</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12787%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVries%26aufirst%3DR.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DHellemans%26aufirst%3DP.%26aulast%3DJiao%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DSkee%26aufirst%3DD.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DVliegen%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DL.%26aulast%3DMannaert%26aufirst%3DE.%26aulast%3Dde%2BJong%26aufirst%3DJ.%26atitle%3DStable%2520Isotope-labelled%2520Intravenous%2520Microdose%2520for%2520Absolute%2520Bioavailability%2520and%2520Effect%2520of%2520Grapefruit%2520Juice%2520on%2520Ibrutinib%2520in%2520Healthy%2520Adults%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D81%26spage%3D235%26epage%3D245%26doi%3D10.1111%2Fbcp.12787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scheers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laenen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuyckens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannens, G.</span></span> <span> </span><span class="NLM_article-title">Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An open-label, Phase 1, Single-dose Study in Healthy Men</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.060061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1124%2Fdmd.114.060061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=25488930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpt1ansg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=289-297&author=E.+Scheersauthor=L.+Leclercqauthor=J.+de+Jongauthor=N.+Bodeauthor=M.+Bockxauthor=A.+Laenenauthor=F.+Cuyckensauthor=D.+Skeeauthor=J.+Murphyauthor=J.+Sukbuntherngauthor=G.+Mannens&title=Absorption%2C+Metabolism%2C+and+Excretion+of+Oral+14C+Radiolabeled+Ibrutinib%3A+An+open-label%2C+Phase+1%2C+Single-dose+Study+in+Healthy+Men&doi=10.1124%2Fdmd.114.060061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, metabolism, and excretion of pral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men</span></div><div class="casAuthors">Scheers, Ellen; Leclercq, Laurent; de Jong, Jan; Bode, Nini; Bockx, Marc; Laenen, Aline; Cuyckens, Filip; Skee, Donna; Murphy, Joe; Sukbuntherng, Juthamas; Mannens, Geert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">289-297, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The absorption, metab., and excretion of ibrutinib were investigated in healthy men after administration of a single oral dose of 140 mg of 14C-labeled ibrutinib.  The mean S.D. cumulative excretion of radioactivity of the dose was 7.8% 1.4% in urine and 80.6% 3.1% in feces with <1% excreted as parent ibrutinib.  Only oxidative metabolites and very limited parent compd. were detected in feces, and this indicated that ibrutinib was completely absorbed from the gastrointestinal tract.  Metab. occurred via three major pathways hydroxylation of the Ph M35, opening of the piperidine M25 and M34, and epoxidn. of the ethylene on the acryloyl moiety with further hydrolysis to dihydrodiol PCI-45227, and M37.  Addnl. metabolites were formed by combinations of the primary metabolic pathways or by further metab.  In blood and plasma, a rapid initial decline in radioactivity was obsd. along with long terminal elimination half-life for total radioactivity.  The max. concn. Cmax and area under the concn.-time curve AUC for total radioactivity were higher in plasma compared with blood.  The main circulating entities in blood and plasma were M21 sulfate conjugate of a monooxidized metabolite on phenoxyphenyl, M25, M34, M37 PCI-45227, and ibrutinib.  At Cmax of radioactivity, 12% of total radioactivity was accounted for by covalent binding in human plasma.  More than 50% of total plasma radioactivity was attributed to covalently bound material from 8 h onward; as a result, covalent binding accounted for 38% and 51% of total radioactivity AUC0-24 h and AUC0-72 h, resp.  No effect of CYP2D6 genotype was obsd. on ibrutinib metab.  Ibrutinib was well-tolerated by healthy participants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHfk3z0sBmMLVg90H21EOLACvtfcHk0lg1kG9mU-dYUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpt1ansg%253D%253D&md5=1f1e728078220c9d7cd973d4992c7308</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.060061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.060061%26sid%3Dliteratum%253Aachs%26aulast%3DScheers%26aufirst%3DE.%26aulast%3DLeclercq%26aufirst%3DL.%26aulast%3Dde%2BJong%26aufirst%3DJ.%26aulast%3DBode%26aufirst%3DN.%26aulast%3DBockx%26aufirst%3DM.%26aulast%3DLaenen%26aufirst%3DA.%26aulast%3DCuyckens%26aufirst%3DF.%26aulast%3DSkee%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DMannens%26aufirst%3DG.%26atitle%3DAbsorption%252C%2520Metabolism%252C%2520and%2520Excretion%2520of%2520Oral%252014C%2520Radiolabeled%2520Ibrutinib%253A%2520An%2520open-label%252C%2520Phase%25201%252C%2520Single-dose%2520Study%2520in%2520Healthy%2520Men%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D289%26epage%3D297%26doi%3D10.1124%2Fdmd.114.060061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parolini, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitch-Hilgenberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span> <span> </span><span class="NLM_article-title">A Point Mutation in the SH2 Domain of Bruton’s Tyrosine Kinase in Atypical X-Linked Agammaglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1488</span>– <span class="NLM_lpage">1491</span>, <span class="refDoi"> DOI: 10.1056/NEJM199405263302104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1056%2FNEJM199405263302104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=8164701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADyaK2MXis12itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=1994&pages=1488-1491&author=D.+C.+Saffranauthor=O.+Paroliniauthor=M.+E.+Fitch-Hilgenbergauthor=D.+J.+Rawlingsauthor=D.+Afarauthor=O.+N.+Witteauthor=M.+E.+Conley&title=A+Point+Mutation+in+the+SH2+Domain+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+Atypical+X-Linked+Agammaglobulinemia&doi=10.1056%2FNEJM199405263302104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">A point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia</span></div><div class="casAuthors">Saffran, Douglas C.; Parolini, Ornella; Fitch-Hilgenberg, Marjorie E.; Rawlings, David J.; Afar, Daniel E.H.; Witte, Owen N.; Conley, Mary Ellen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1488-91</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">A novel mutation was described in the gene encoding Btk (Bruton's tyrosine kinase) in atypical X-linked agammaglobulinemia.  This mutation in the SH2 domain allowed the expression of normal levels of Btk transcript but encoded a protein with decreased stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppsSq_90aaNbVg90H21EOLACvtfcHk0lg1kG9mU-dYUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXis12itA%253D%253D&md5=926fe55d343510e2f616deed99cbe4ab</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1056%2FNEJM199405263302104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199405263302104%26sid%3Dliteratum%253Aachs%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DParolini%26aufirst%3DO.%26aulast%3DFitch-Hilgenberg%26aufirst%3DM.%2BE.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DAfar%26aufirst%3DD.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DConley%26aufirst%3DM.%2BE.%26atitle%3DA%2520Point%2520Mutation%2520in%2520the%2520SH2%2520Domain%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Atypical%2520X-Linked%2520Agammaglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1994%26volume%3D330%26spage%3D1488%26epage%3D1491%26doi%3D10.1056%2FNEJM199405263302104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breitenlechner, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kairies, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiblich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koll, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engh, R. A.</span></span> <span> </span><span class="NLM_article-title">Crystal Structures of Active Src Kinase Domain Complexes</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2005.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2Fj.jmb.2005.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=16168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=222-231&author=C.+B.+Breitenlechnerauthor=N.+A.+Kairiesauthor=K.+Honoldauthor=S.+Scheiblichauthor=H.+Kollauthor=E.+Greiterauthor=S.+Kochauthor=W.+Sch%C3%A4ferauthor=R.+Huberauthor=R.+A.+Engh&title=Crystal+Structures+of+Active+Src+Kinase+Domain+Complexes&doi=10.1016%2Fj.jmb.2005.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of Active Src Kinase Domain Complexes</span></div><div class="casAuthors">Breitenlechner, Christine B.; Kairies, Norman A.; Honold, Konrad; Scheiblich, Stefan; Koll, Hans; Greiter, Eva; Koch, Stefan; Schaefer, Wolfgang; Huber, Robert; Engh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">C-Src was the first proto-oncoprotein to be identified, and has become the focus of many drug discovery programs.  Src structures of a major inactive form have shown how the protein kinase is rigidified by several interdomain interactions; active configurations of Src are generated by release from this "assembled" or "bundled" form.  Despite the importance of Src as a drug target, there is relatively little structural information available regarding the presumably more flexible active forms.  Here we report three crystal structures of a dimeric active c-Src kinase domain, in an apo and two ligand complexed forms, with resolns. ranging from 2.9 Å to 1.95 Å.  The structures show how the kinase domain, in the absence of the rigidifying interdomain interactions of the inactivation state, adopts a more open and flexible conformation.  The ATP site inhibitor CGP77675 binds to the protein kinase with canonical hinge hydrogen bonds and also to the c-Src specific threonine 340.  In contrast to purvalanol B binding in CDK2, purvalanol A binds in c-Src with a conformational change in a more open ATP pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc3P258chhrbVg90H21EOLACvtfcHk0lg1kG9mU-dYUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGrtrnF&md5=9bc8e1670457d34ac88e6b5b20efea21</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DBreitenlechner%26aufirst%3DC.%2BB.%26aulast%3DKairies%26aufirst%3DN.%2BA.%26aulast%3DHonold%26aufirst%3DK.%26aulast%3DScheiblich%26aufirst%3DS.%26aulast%3DKoll%26aufirst%3DH.%26aulast%3DGreiter%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DS.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DW.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DEngh%26aufirst%3DR.%2BA.%26atitle%3DCrystal%2520Structures%2520of%2520Active%2520Src%2520Kinase%2520Domain%2520Complexes%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D222%26epage%3D231%26doi%3D10.1016%2Fj.jmb.2005.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, G. C.</span>; <span class="NLM_string-name">Calderwood, D.</span>; <span class="NLM_string-name">Wishart, N.</span>; <span class="NLM_string-name">Rafferty, P.</span>; <span class="NLM_string-name">Ritter, K.</span>; <span class="NLM_string-name">Arnold, L. D.</span>; <span class="NLM_string-name">Friedman, M. M.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyrimidines as Therapeutic Agents</span>. World Patent <span class="NLM_patent">WO0119829</span>, Mar 22, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=G.+C.+Hirst&author=D.+Calderwood&author=N.+Wishart&author=P.+Rafferty&author=K.+Ritter&author=L.+D.+Arnold&author=M.+M.+Friedman&title=Pyrazolopyrimidines+as+Therapeutic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHirst%26aufirst%3DG.%2BC.%26atitle%3DPyrazolopyrimidines%2520as%2520Therapeutic%2520Agents%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderwood, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamens, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munschauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafferty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnofsky, S. E.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Lck I</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2167</span>– <span class="NLM_lpage">2170</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(00)00441-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1016%2FS0960-894X%2800%2900441-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=11012021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFKksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2167-2170&author=L.+D.+Arnoldauthor=D.+J.+Calderwoodauthor=R.+W.+Dixonauthor=D.+N.+Johnstonauthor=J.+S.+Kamensauthor=R.+Munschauerauthor=P.+Raffertyauthor=S.+E.+Ratnofsky&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+Containing+an+Extended+5-Substituent+as+Potent+and+Selective+Inhibitors+of+Lck+I&doi=10.1016%2FS0960-894X%2800%2900441-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I</span></div><div class="casAuthors">Arnold, L. D.; Calderwood, D. J.; Dixon, R. W.; Johnston, D. N.; Kamens, J. S.; Munschauer, R.; Rafferty, P.; Ratnofsky, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2167-2170</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Pyrrolo[2,3-d]pyrimidines contg. a 5-(4-phenoxyphenyl) substituent are potent and selective inhibitors of lck in vitro; some compds. are selective for lck over src.  Data are shown for two compds. demonstrating that they are potent and selective inhibitors of IL2 prodn. in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUbxHkjKto7Vg90H21EOLACvtfcHk0lidpghiYwwvWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFKksbg%253D&md5=74f53acc0bcae20393a59e1113156d67</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900441-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900441-8%26sid%3Dliteratum%253Aachs%26aulast%3DArnold%26aufirst%3DL.%2BD.%26aulast%3DCalderwood%26aufirst%3DD.%2BJ.%26aulast%3DDixon%26aufirst%3DR.%2BW.%26aulast%3DJohnston%26aufirst%3DD.%2BN.%26aulast%3DKamens%26aufirst%3DJ.%2BS.%26aulast%3DMunschauer%26aufirst%3DR.%26aulast%3DRafferty%26aufirst%3DP.%26aulast%3DRatnofsky%26aufirst%3DS.%2BE.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520Containing%2520an%2520Extended%25205-Substituent%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Lck%2520I%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2167%26epage%3D2170%26doi%3D10.1016%2FS0960-894X%2800%2900441-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geierstanger, B. H.</span></span> <span> </span><span class="NLM_article-title">Verification of a Designed Intramolecular Hydrogen Bond in a Drug Scaffold by Nuclear Magnetic Resonance Spectroscopy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5875</span>– <span class="NLM_lpage">5877</span>, <span class="refDoi"> DOI: 10.1021/jm700983a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm700983a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5875-5877&author=A.+Jansmaauthor=Q.+Zhangauthor=B.+Liauthor=Q.+Dingauthor=T.+Unoauthor=B.+Bursulayaauthor=Y.+Liuauthor=P.+Furetauthor=N.+S.+Grayauthor=B.+H.+Geierstanger&title=Verification+of+a+Designed+Intramolecular+Hydrogen+Bond+in+a+Drug+Scaffold+by+Nuclear+Magnetic+Resonance+Spectroscopy&doi=10.1021%2Fjm700983a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Verification of a Designed Intramolecular Hydrogen Bond in a Drug Scaffold by Nuclear Magnetic Resonance Spectroscopy</span></div><div class="casAuthors">Jansma, Ariane; Zhang, Qiong; Li, Bing; Ding, Qiang; Uno, Tetsuo; Bursulaya, Badry; Liu, Yi; Furet, Pascal; Gray, Nathanael S.; Geierstanger, Bernhard H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5875-5877</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2D 1H-15N HMBC NMR acquired at natural abundance and DMSO titrn. monitored by 1D 1H NMR verified the existence of an intramol. hydrogen bond that was designed to mimic the pyrimidinone ring of a class of kinase inhibitors.  A scalar coupling across the hydrogen bond was detected in org. and aq. solvent, suggesting a simple and general approach for testing the propensity of intramol. hydrogen bonds to stabilize pseudo-rings in drug scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzLJyCMZPJ17Vg90H21EOLACvtfcHk0lidpghiYwwvWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitrjM&md5=3b5662c258471320fc367eb9bc4f1c10</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm700983a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm700983a%26sid%3Dliteratum%253Aachs%26aulast%3DJansma%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGeierstanger%26aufirst%3DB.%2BH.%26atitle%3DVerification%2520of%2520a%2520Designed%2520Intramolecular%2520Hydrogen%2520Bond%2520in%2520a%2520Drug%2520Scaffold%2520by%2520Nuclear%2520Magnetic%2520Resonance%2520Spectroscopy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5875%26epage%3D5877%26doi%3D10.1021%2Fjm700983a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. W.</span>; <span class="NLM_string-name">Guo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase Inhibitors and Uses thereof</span>. US Patent <span class="NLM_patent">US2015005277</span>, Jan 1, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+W.+Wang&author=Y.+H.+Guo&title=Protein+Kinase+Inhibitors+and+Uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%2BW.%26atitle%3DProtein%2520Kinase%2520Inhibitors%2520and%2520Uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of Human Bruton’s Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for Tec Family Kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&author=D.+J.+Marcotteauthor=Y.+T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+Human+Bruton%E2%80%99s+Tyrosine+Kinase+in+Active+and+Inactive+Conformations+Suggest+a+Mechanism+of+Activation+for+Tec+Family+Kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0lidpghiYwwvWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520Human%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Active%2520and%2520Inactive%2520Conformations%2520Suggest%2520a%2520Mechanism%2520of%2520Activation%2520for%2520Tec%2520Family%2520Kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, V.
H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattachar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchingham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zocharski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surendran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoner, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span> <span> </span><span class="NLM_article-title">The Road Map to Oral Bioavailability: an Industrial Perspective</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1517/17425255.2.4.591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1517%2F17425255.2.4.591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=16859407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=591-608&author=V.%0AH.+Thomasauthor=S.+Bhattacharauthor=L.+Hitchinghamauthor=P.+Zocharskiauthor=M.+Naathauthor=N.+Surendranauthor=C.+L.+Stonerauthor=A.+El-Kattan&title=The+Road+Map+to+Oral+Bioavailability%3A+an+Industrial+Perspective&doi=10.1517%2F17425255.2.4.591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The road map to oral bioavailability: an industrial perspective</span></div><div class="casAuthors">Thomas, V. Hayden; Bhattachar, Shobha; Hitchingham, Linda; Zocharski, Philip; Naath, Maryanne; Surendran, Narayanan; Stoner, Chad L.; El-Kattan, Ayman</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-608</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Optimization of oral bioavailability is a continuing challenge for the pharmaceutical and biotechnol. industries.  The no. of potential drug candidates requiring in vivo evaluation has significantly increased with the advent of combinatorial chem.  In addn., drug discovery programs are increasingly forced into more lipophilic and lower soly. chem. space.  To aid in the use of in vitro and in silico tools as well as reduce the no. of in vivo studies required, a team-based discussion tool is proposed that provides a road map' to guide the selection of profiling assays that should be considered when optimizing oral bioavailability.  This road map divides the factors that contribute to poor oral bioavailability into two interrelated categories: absorption and metab.  This road map provides an interface for cross discipline discussions and a systematic approach to the experimentation that drives the drug discovery process towards a common goal - acceptable oral bioavailability using minimal resources in an acceptable time frame.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7_zZKacXE7Vg90H21EOLACvtfcHk0lgkipR93QmTkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1ahsLs%253D&md5=79cf4cea1b89914bd3a8826b5d7360f9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1517%2F17425255.2.4.591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2.4.591%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DV.%2BH.%26aulast%3DBhattachar%26aufirst%3DS.%26aulast%3DHitchingham%26aufirst%3DL.%26aulast%3DZocharski%26aufirst%3DP.%26aulast%3DNaath%26aufirst%3DM.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DStoner%26aufirst%3DC.%2BL.%26aulast%3DEl-Kattan%26aufirst%3DA.%26atitle%3DThe%2520Road%2520Map%2520to%2520Oral%2520Bioavailability%253A%2520an%2520Industrial%2520Perspective%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2006%26volume%3D2%26spage%3D591%26epage%3D608%26doi%3D10.1517%2F17425255.2.4.591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cull, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnasingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschbaum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span> <span> </span><span class="NLM_article-title">Twice Daily Dosing with the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=642&author=C.+S.+Tamauthor=S.+Opatauthor=G.+Cullauthor=J.+Trotmanauthor=D.+Gottliebauthor=D.+Simpsonauthor=P.+Marltonauthor=M.+A.+Andersonauthor=M.+Kuauthor=D.+Ritchieauthor=S.+Ratnasingamauthor=B.+Augustsonauthor=M.+Kirschbaumauthor=L.+Wangauthor=L.+Xueauthor=J.+X.+Yangauthor=E.+Hedrickauthor=J.+F.+Seymourauthor=A.+W.+Roberts&title=Twice+Daily+Dosing+with+the+Highly+Specific+BTK+Inhibitor%2C+BGB-3111%2C+Achieves+Complete+and+Continuous+BTK+Occupancy+in+Lymph+Nodes%2C+and+is+Associated+with+Durable+Responses+in+Patients+%28pts%29+with+Chronic+Lymphocytic+Leukemia+%28CLL%29%2FSmall+Lymphocytic+Lymphoma+%28SLL%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DOpat%26aufirst%3DS.%26aulast%3DCull%26aufirst%3DG.%26aulast%3DTrotman%26aufirst%3DJ.%26aulast%3DGottlieb%26aufirst%3DD.%26aulast%3DSimpson%26aufirst%3DD.%26aulast%3DMarlton%26aufirst%3DP.%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DKu%26aufirst%3DM.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DRatnasingam%26aufirst%3DS.%26aulast%3DAugustson%26aufirst%3DB.%26aulast%3DKirschbaum%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%2BX.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26atitle%3DTwice%2520Daily%2520Dosing%2520with%2520the%2520Highly%2520Specific%2520BTK%2520Inhibitor%252C%2520BGB-3111%252C%2520Achieves%2520Complete%2520and%2520Continuous%2520BTK%2520Occupancy%2520in%2520Lymph%2520Nodes%252C%2520and%2520is%2520Associated%2520with%2520Durable%2520Responses%2520in%2520Patients%2520%2528pts%2529%2520with%2520Chronic%2520Lymphocytic%2520Leukemia%2520%2528CLL%2529%252FSmall%2520Lymphocytic%2520Lymphoma%2520%2528SLL%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B-cell Activation and is Efficacious in Models of Autoimmune Disease and B-cell Malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+Tyrosine+Kinase+Inhibitor+PCI-32765+Blocks+B-cell+Activation+and+is+Efficacious+in+Models+of+Autoimmune+Disease+and+B-cell+Malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lgkipR93QmTkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520PCI-32765%2520Blocks%2520B-cell%2520Activation%2520and%2520is%2520Efficacious%2520in%2520Models%2520of%2520Autoimmune%2520Disease%2520and%2520B-cell%2520Malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">Xds</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Xds&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0litbzMpvZLbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXds%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser Crystallographic Software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+Crystallographic+Software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0litbzMpvZLbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520Crystallographic%2520Software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustyakimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span> <span> </span><span class="NLM_article-title">Towards Automated Crystallographic Structure Refinement with Phenix. Refine</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1107/S0907444912001308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0907444912001308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=22505256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=352-367&author=P.+V.+Afonineauthor=R.+W.+Grosse-Kunstleveauthor=N.+Echolsauthor=J.+J.+Headdauthor=N.+W.+Moriartyauthor=M.+Mustyakimovauthor=T.+C.+Terwilligerauthor=A.+Urzhumtsevauthor=P.+H.+Zwartauthor=P.+D.+Adams&title=Towards+Automated+Crystallographic+Structure+Refinement+with+Phenix.+Refine&doi=10.1107%2FS0907444912001308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Towards automated crystallographic structure refinement with phenix.refine</span></div><div class="casAuthors">Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Echols, Nathaniel; Headd, Jeffrey J.; Moriarty, Nigel W.; Mustyakimov, Marat; Terwilliger, Thomas C.; Urzhumtsev, Alexandre; Zwart, Peter H.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">352-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phenix.refine is a program within the PHENIX package that supports crystallog. structure refinement against exptl. data with a wide range of upper resoln. limits using a large repertoire of model parameterizations.  It has several automation features and is also highly flexible.  Several hundred parameters enable extensive customizations for complex use cases.  Multiple user-defined refinement strategies can be applied to specific parts of the model in a single refinement run.  An intuitive graphical user interface is available to guide novice users and to assist advanced users in managing refinement projects.  X-ray or neutron diffraction data can be used sep. or jointly in refinement. phenix.refine is tightly integrated into the PHENIX suite, where it serves as a crit. component in automated model building, final structure refinement, structure validation and deposition to the wwPDB.  This paper presents an overview of the major phenix.refine features, with extensive literature refs. for readers interested in more detailed discussions of the methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhn9QwIEkTbVg90H21EOLACvtfcHk0litbzMpvZLbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D&md5=1cc7da2cea396f1a75646ea709140cf1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1107%2FS0907444912001308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444912001308%26sid%3Dliteratum%253Aachs%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DMustyakimov%26aufirst%3DM.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DTowards%2520Automated%2520Crystallographic%2520Structure%2520Refinement%2520with%2520Phenix.%2520Refine%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D68%26spage%3D352%26epage%3D367%26doi%3D10.1107%2FS0907444912001308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Coot: Model-Building Tools for Molecular Graphics</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-Building+Tools+for+Molecular+Graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljXrrVhIbld2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-Building%2520Tools%2520for%2520Molecular%2520Graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN','PDB','3GEN'); return false;">PDB: 3GEN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M','PDB','6J6M'); return false;">PDB: 6J6M</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5P9J','PDB','5P9J'); return false;">PDB: 5P9J</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i78"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00687">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_63867"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00687">10.1021/acs.jmedchem.9b00687</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Biochemical and cellular assay data for <b>I</b>-<b>2</b> and <b>I</b>-<b>3</b>; evaluation of the BTK occupancy capability of studied compounds in mouse; fast dilution and protein precipitation experiment for <b>13</b>/<b>16</b>/<b>31a</b>; serine mutant assay for <b>13</b> and <b>16</b>; biochemical data for <b>20</b>-<b>int</b> and <b>21</b>-<b>int</b>; In vitro data of <b>20a</b>, <b>23a</b>, <b>25a</b>, and <b>29a</b>; second-order rate constants (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) for <b>31a</b>, <b>31b</b>, and ibrutinib; cellular toxicity evaluation of <b>31a</b>; cocrystal of <b>31a</b> with BTK; single crystal structure determination; kinase panel screen; experimental data for two probes (<b>P</b>-<b>1</b> and <b>P</b>-<b>2</b>) and intermediates (<b>37a</b>, <b>37c</b>, <b>38a</b>, <b>39a</b>, <b>39c</b>, <b>41</b>, <b>42</b>, <b>44a</b>, <b>45a</b>, <b>48b</b>, <b>49a</b>, <b>49b</b>, <b>57</b>, <b>68</b>, <b>71</b>, <b>73</b>, <b>76</b>, <b>78</b>, <b>81</b>, <b>82</b>, <b>87</b>, <b>89</b>, <b>90</b>, <b>91b</b>, <b>92a</b>–<b>c</b>); PK conditions (PK study in rats, plasma protein binding, microsome intrinsic clearance, and cytochrome P450 inhibition) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings list (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_002.csv">CSV</a>)</p></li><li><p class="inline">Crystallographic information file for <b>BGB-3111</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_003.cif">CIF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_001.pdf">jm9b00687_si_001.pdf (2.39 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_002.csv">jm9b00687_si_002.csv (9.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00687/suppl_file/jm9b00687_si_003.cif">jm9b00687_si_003.cif (423.29 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The crystallographic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6J6M">6J6M</a> for BTK-BGB-3111)</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00687%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-17%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00687" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993b132b662367","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
